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Antibiotic resistance, particularly amongst Gram-negative bacteria, has emerged as a 
major global health concern. Working synergistically with the permeability barrier 
created by the cell envelope, multidrug efflux pumps contribute significantly to the 
intrinsic resistance of Gram-negative bacteria to clinically relevant drugs. The 
majority of bacterial multidrug efflux pumps are multi-component assemblies, within 
which the interaction interfaces may represent potential inhibitor binding sites. The 
Escherichia coli AcrA-TolC interactions and the functional roles of sub-domains of 
these proteins have been assessed using computationally directed mutants with a 
combination of in vivo and in vitro approaches.  
Results reported here indicate that regions both at the tip of and halfway up the TolC 
coiled-coil domain are involved in determining the compatibility of AcrA with TolC. 
On the other side of the interaction, both the tip region and the helices of the AcrA 
hairpin are essential for normal function. The hairpin tip is required to maintain the 
permeability barrier, while the helices are necessary for a stable AcrA-TolC 
interaction. 
Based on these results, I present a dynamic model of tripartite complex assembly, in 
which initial bundling of AcrA and TolC coiled-coil domains opens the TolC channel. 
Transition to a tip-to-tip interaction drives channel closing and is required for 
complex disassembly in an energy-dependent manner. This model provides rationale 
for future development of complex-specific peptidomimetic efflux inhibitors that 
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CHAPTER 1: INTRODUCTION 
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Disclaimer: Parts of this Introduction, and figures therein, may appear in this or a revised 
form in either the textbook Bacterial Resistance to Antibiotics: From Molecules to 
Man (edited by B. Bonev, N.Brown and D. Turner) or in the review article Symmons et al., 
2015. 
This project investigates how the TolC outer membrane channel protein interacts 
with its partner proteins to produce an effective efflux pump that is known to have 
physiological, pharmaceutical, and biotechnological significance. Through 
understanding the assembly structure, it is likely to be possible to develop drugs to 
prevent efflux action and therefore decrease antimicrobial resistance, and to 
develop new biotechnological systems to improve yields of certain products. In 2012, 
two of the top ten causes of death globally can be directly attributed to bacterial 
infection, according to World Health Organisation (WHO) statistics (World Health 
Organisation, 2014), and in a further four of the remaining eight causes, bacterial 
infections are likely to be a major contributing factor to the death. This project will 
focus on the assembly of a multidrug efflux complex, AcrAB-TolC, given its 
importance in societal and clinical context with increasing prevalence of drug 
resistant infections.  
1.1 Outer membranes exist to protect the cell by decreasing permeability 
It is easy to think only about how bacteria respond to changes that we as humans 
impose upon them, be they in a clinical or laboratory setting, and to forget that most 
interactions involving bacteria occur without any intentional manipulation on our 
part. The natural environments in which bacteria are found drove their evolution, and 
forced them to develop an intrinsic resistance to toxic substances. Perhaps the most 
notable structure hypothesised to have developed as a result of antibiotic-mediated 
selection pressure is the outer membrane (Gupta, 2011), a defining feature of 
Gram-negative bacteria. This hypothesis postulates that development of an outer 
membrane structure occurred primarily to form an additional permeability barrier 
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against the influx of toxic substances, including antibiotics, and thus enabled survival 
of early didermic bacteria in hostile environments – particularly following the 
evolution of antibiotic-producing bacteria.  
Several outer membrane structures have been found in nature, as analysed by 
Sutcliffe (2010). These structures can consist of combinations of fatty acids (including 
mycolic acids, phospholipids, polyacylglycerol and other fatty acids; Bansal-Mutalik & 
Nikaido, 2014), lipopolysaccharide (which is discussed below) and sugars, or be 
proteinaceous (Huber et al., 1986; Olabarria et al., 1996) . Regardless of composition, 
each of these structures protect the cell from environmental factors. Components of 
the inter-membrane space – the periplasm of Gram-negative bacteria – are also 
protected by the outer membrane permeability barrier.  Given that some essential 
processes such as cell wall synthesis take place outside the cytoplasmic membrane, 
protection of such components is vital to survival in hostile environments. 
Perhaps the most widely-known outer membrane is that of the Gram-negative 
bacteria. This membrane is an asymmetric bilayer (Kamio & Nikaido, 1976), of which 
the inner leaflet consists of glycerophospholipids, enriched in 
phosphatidylethanolamine and saturated fatty acids compared with the inner 
membrane. The outer leaflet, formed of lipopolysaccharide (LPS), provides the main 
permeability barrier of this membrane. LPS varies by both species and strain, 
affecting a range of biological processes and membrane fluidity (Rottem & Leive, 
1977). Variation is seen throughout the LPS molecule (Wilkinson, 1996; Delcour, 
2009), but characteristic variations include those within the length of the O-antigen 
(which extends outside the cell) and the acylation of Lipid A. Representative 
structures of both LPS and the outer membrane are shown in Figure 1:1. 
Lipid A consists of a disaccharide of hexosamines. Each of the hexosamines is 
acylated by amide and ester bonds at their 2- and 3- positions, respectively, providing 
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the minimum of tetra-acylation seen naturally. A maximum of eight acyl chains have 
been observed in natural LPS – ester bonds can be made between the 3-hydroxy 
position of one fatty acid and the carboxylic acid of another, forming an acyloxyacyl 
moiety that can be attached to the dihexosamine at each of the four positions. The 
fatty acids found in LPS are often, though not always, saturated, and thus pack closer 
together for a greater combined hydrophobicity. This is one of the main factors 
contributing to the decreased fluidity and permeability of the outer membrane 
compared to the inner membrane. The acyl chains, which interact at a hydrophobic 
interface with the fatty acids of the inner leaflet glycerophospholipids in the middle 
of the outer membrane, to form the bilayer required of a membrane, are usually 
between ten and sixteen carbon atoms long, but chains as long as 22 carbon atoms 
have been reported in LPS (Heine et al., 2003). The hexosamines of Lipid A are 
phosphorylated, increasing hydrophilicity of the backbone region at the external face 
of the membrane, providing negative charge and decreasing permeability to 
hydrophobic substances that would otherwise cross the hydrophobic fatty-acid 
portion of the membrane. 
The core oligosaccharide of LPS is attached to the free 6-hydroxy position of the 
hexosamine. The core region consists of a series of 1-5` linked other sugars, which 
vary by species – in enteric bacteria, this is usually a series of three heptose sugars 
followed by up to six other sugars. Strains with shorter core regions are more 
susceptible to lipophilic drugs (Delcour, 2009), thus the LPS core region has a role in 
preventing access of drugs to the cellular target. Variability of this core region, in 
terms of length, composition and branching, is great, and will not be discussed 
further.  
On the outside of the cell is the O-antigen, which can vary from lacking entirely (in 
“rough-type” cells) to as many as 50 subunits each consisting of up to eight sugar 
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units (Caroff & Karibian, 2003). The number of different sugars, modifications and 
interlinking compounds (such as organic acids) that can make up each subunit, 
combined with the possible variations in number of sugars per subunit, provides 
huge scope for variation in O-antigen structure between different serotypes. This 
variation determines the immunogenicity of the outer membrane, but is not 
generally regarded as significant in decreasing permeability of the membrane to 
drugs, despite evidence that permeation of the outer membrane by macrolides is 







Figure 1:1 – Structure of the Gram-negative outer membrane.  
Representative chemical structure of an LPS molecule (left), excluding detail of the 
O-antigen, and a full atomic model of a section of outer membrane from Salmonella 
Typhimurium (right; courtesy of J.C.Gumbart). Many modifications are possible to the 
LPS molecule, including additional acylation, acylation with different chain lengths, 
incorporation of extra or alternative sugar subunits, and further phosphorylation. 
The full atomic model shows a single O-antigen chain (pink) and the acyl chains (grey) 
in space-fill, while the core (yellow) and all other LPS molecules are shown in line 
format only. A trimer of OmpD is shown in ribbon format with each monomer in a 
different colour. Clearing of O-antigen above the porin can be seen. The true density 
of packing of LPS molecules is greater than visualised here, due to the use of lines 




1.2 Transmembrane substance translocation  
The permeability barrier provided by LPS prevents toxic substances and nutrients 
from easily crossing the outer membrane. Gram-negative bacteria have outer 
membrane porins to allow uptake of nutrients. Porins are proteins which form a 
β-barrel through the outer membrane, introducing a water-filled pore through the 
otherwise highly hydrophobic membrane (Cowan et al., 1992). Between the strands 
that form the barrel are loops of various sizes, some incorporating short helices. 
These loops act as a filter, allowing some selectivity of solute transport. Some of the 
porins are therefore cation- or anion-specific, others are sugar-specific, while others 
do not show solute specificity and are regarded as general porins. General porins 
tend to have a wider accessible opening than specific porins, and can be a route of 
entry for many drugs (Danilchanka et al., 2015). Increased expression of porins can 
lead to increased sensitivity of a strain to antibiotics (Krishnamoorthy et al., 2016). 
Conversely, loss or down-regulation of porins is associated with drug resistance. The 
low expression levels of open general porins in Pseudomonas spp. and Acinetobacter 
spp. is attributable for their increased drug tolerance compared to E. coli (Delcour, 
2009). Size, number and specificity of the porins contribute greatly in determining 
how resistant or susceptible a cell will be to antibiotics, but changes in the porin 
profile are relatively slow in the context of responding to an environmental change. 
For a quicker response, porins can be closed by ligand binding under certain 
conditions, and cannot be thought of as constitutively open holes in the membrane. 
Not all drugs can fit through these porins, due to either their size or charge. 
Macrolides, for example, are thought to access the cell by permeating the lipid 
bilayer itself rather than utilising a protein as route of entry (Tsujimoto et al., 1999; 
Delcour, 2009). Vancomycin is a large drug which cannot pass through the porins or 
the outer membrane bilayer, ironically gaining entry to the Gram-negative bacterium 
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through a drug efflux channel protein, which is gated at the periplasmic end, 
occluded except for during efflux events.  
Channel proteins have also evolved to form essential parts of multidrug efflux 
pumps, which actively remove toxic substances from within the cell. The combination 
of an influx barrier with efflux pumps improves the survival of Gram negative 
bacteria in the presence of toxic substances, including antibiotics, quite considerably 
(Piddock, 2006; Nikaido, 2009); over-expression of or even a point mutation (such as 
G288D in AcrB, which causes resistance to fluoroquinolones) in these efflux pumps 
can cause clinically significant multidrug resistance and change the drug 
susceptibility profile of the strain (Webber et al., 2005; Tavio et al., 2014; Blair et al., 
2015; Kinana et al., 2016). 
1.3 Removal of substances from cell interior 
Transmembrane pump proteins are present and common throughout all kingdoms of 
life, and can be responsible for either active uptake of such substances as nutrients 
and vitamins, or for active efflux of unwanted (toxic) substances (Saier et al., 2014). 
Bacterial drug efflux pumps, which are grouped into six families based primarily upon 
common architectures (Piddock, 2006; Hassan et al., 2015), can increase tolerance to 
a wide variety of substances. To pump against the chemical concentration gradient, 
these pumps all require an energy source – one of the families, the ATP-binding 
cassette (ABC) family uses ATP hydrolysis (Kobayashi et al., 2001; Lu & Zgurskaya, 
2012), while the remaining five families utilise an electrochemical gradient across the 
cytoplasmic membrane (Thanassi et al., 1997; Law et al., 2008; Hassan et al., 2013; 
Ogawa et al., 2015; Dastvan et al., 2016; Gayen et al., 2016). This thesis will consider 
only assembly of the resistance-nodulation-cell division (RND) family of transporters, 
though members of other families that utilise the same outer membrane channel 
protein will be also be used for comparison.  
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Transmembrane pump proteins are present and common throughout all kingdoms of 
life, and can be responsible for either active uptake of things such as nutrients and 
vitamins, or for active efflux of unwanted (toxic) substances (Saier et al., 2014). Of 
particular interest in the context of multidrug resistance are the drug efflux pumps, 
which are grouped into six families, based primarily upon common architectures. 
Models of the common architecture are shown in Figure 1:2. 
1.3.1 ABC transporters 
Of these families, one uses substrate hydrolysis to provide translocation energy 
directly – the proteins utilise ATP, and are thus nominated ATP-binding cassette 
(ABC) transporters. Multidrug efflux ABC transporters like MacB (macrolide efflux 
pump) are dimeric, with each monomer consisting of a four-helix transmembrane 
domain, a cytoplasmic nucleotide binding domain and a mixed α/β periplasmic 
domain. The periplasmic domain interacts with partner proteins, while the nucleotide 
binding domain binds and hydrolyses nucleotides (primarily ATP). The 
transmembrane helices are predicted to bind the substrate and undergo a 
conformational change both upon binding of the substrate and upon hydrolysis of 
ATP. Such conformational changes move the substrate across the inner membrane 
within the binding cleft formed by the helices. The mechanism of ABC multidrug 
transporters is predicted based upon that of ABC transporters with other roles.  
1.3.2 MFS transporters 
All of the other five families utilise ion gradients for symport or antiport, or transport 
only one substrate by assisted diffusion. The largest family of transporters is the 
major facilitator superfamily (MFS), which contains examples of all three of these 
transport types, indicating that although a single superfamily has common 
architecture and a common mechanism for the transport action, the directionality of 
and energy source for the transport event may vary. The common mechanism in MFS 
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transporters is the use of a rocker-switch type movement of a single binding site, 
which alternates to which side of the membrane the binding pocket is open (Law et 
al., 2008). Crystal structures are available for members of this superfamily of 
transporters, which show the proteins to be formed almost entirely of a bundle of 
transmembrane helices, with virtually no periplasmic or cytoplasmic domains except 
for any protrusion of the transmembrane helices and their interconnecting loops. 
Most proteins in this family contain either 12 or 14 transmembrane helices; these 
helices account for 240 out of 394 residues in the EmrD multidrug efflux pump from 
E. coli, though these pumps are usually slightly larger, up to 600 amino acids long. 
The EmrD crystal structure indicates a dimeric structure (Yin et al., 2006), although 
this may be a crystallographic artefact. Within each MFS protein monomer is a narrow 
pore, which has been identified as the route through which the substrate 
translocates. This pore is open to only one side of the protein at a time, for binding or 
release of the substrate. The rocker-switch motion rearranges the helices around the 
active site, temporarily occluding the protein lumen during the translocation process, 
until the pore re-opens at the other side of the protein. In the case of antiport-driven 
pumps, this process will then reverse with the binding of the antiporting substrate. 
1.3.3 SMR transporters 
The smallest proteins currently identified as multidrug transporters are the so-called 
small multidrug resistance (SMR) family of proteins, which fall under the category of 
drug/metabolite transporter superfamily. SMR proteins have greater limitations to 
their range of substrates than the other families of transporters, as they have only 
been found to transport lipophilic compounds, including quaternary ammonium 
compounds and cationic dyes (Bay et al., 2008). While they have a limited substrate 
range, single proteins within this family are capable of transporting several 
structurally distinct substrates, and are therefore legitimately classified as multidrug 
transporters. All members of this family for which the transport type is known 
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function by drug/proton antiport. SMR transporters are encoded both 
chromosomally and on mobile genetic elements (plasmids and integrons). Similarly to 
MFS transporters, SMR proteins contain virtually no cytoplasmic or periplasmic 
regions. The functional oligomeric state of SMR proteins is unclear, as the 
multimerisation state determined experimentally is dependent upon the conditions 
used in the investigation (Bay et al., 2010). There have been several mechanisms of 
pump activity proposed over the years, but more recent studies are converging 
towards a similar rocker-switch type mechanism as in MFS transporters, but in SMR 
transporters both the binding pocket and pore form between dimers (Dastvan et al., 
2016; Gayen et al., 2016). 
1.3.4 MATE transporters 
Multidrug and toxic compound extrusion (MATE) efflux pumps consist of three sub-
types: cluster 2 proteins are eukaryotic, clusters 1 and 3 include bacterial and 
archaeal proteins whereby cluster 1 proteins (of the NorM-type) follow the same 
phylogenetic patterns as the organisms from which they originate while cluster 3 
proteins (of the DinF-type) follow no such pattern. MATE transporters utilise 
electrochemical potential, antiporting protons, Na+, or K+. One example protein 
(KetM from Klebsiella pneumoniae) has been found to be energised by any one of 
protons, Na+, K+ or Li+, and to pump several structurally-related compounds (Ogawa 
et al., 2015). Proteins within the MATE family have been shown to pump a variety of 
substrates of unrelated structure (Kuroda & Tsuchiya, 2009). Though they are 
therefore recognised as multidrug transporters, MATE proteins seemingly contribute 
little to the overall intrinsic resistance of bacteria to toxic compounds. Crystal 
structures of MATE transporters from different organisms are available, showing 
different binding states (He et al., 2010; Lu et al., 2013a; Lu et al., 2013b; Lu, 2016). 
These show the protein to form 12 transmembrane helices, which undergo major 
conformational changes upon substrate binding. Uniquely among antiporters, MATE 
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proteins have been shown bound to both substrate and cation simultaneously, 
although the binding of the cation causes such a significant conformational change as 
to force release of the substrate and enable continuation of the cycle. MATE proteins 
of the NorM family have also shown for the first time that Na+ - π bonding can occur 
in membrane proteins, thus indicating that selectivity for Na+ as an energy source is 
dependent on the presence of an aromatic residue at the cation-binding position. The 
drug and cation binding sites in the NorM family of MATE transporters are separated 
by a helix – the two moieties interact neither with each other nor with the same 
binding pocket of the protein. The DinF family functions by a very different 
mechanism: competition between protonation and substrate binding causes release 
of the separate moieties, from the same binding site (Lu, 2016). The NorM-type and 
DinF-type sub-families of MATE transporters are therefore clearly distinct, despite 
the structural similarity.  
1.3.5 PACE transporters 
The most recently discovered family of multidrug efflux pumps is the proteobacterial 
antimicrobial compound efflux (PACE) family. The nomenclature here may require 
re-defining, as this family of pumps is not limited to the proteobacteria, nor do all 
proteobacteria encode any (Hassan et al., 2015b). The natural substrates for this 
family of proteins have not yet been determined, as they have only so far been found 
to pump synthetic biocides (Hassan et al., 2015a). The only factor apparently common 
to the identified substrates is the presence of at least one aromatic ring. At the time 






Figure 1:2 - Models or crystal structures of an example from each class of MDR 
transporter. 
Each is displayed to the same scale to give a representation of the relative sizes of 
each transporter class. The inner membrane (IM) has been drawn at a position of best 
fit for each protein. Monomers within a protein are coloured separately. As 
stoichiometry is not known for PACE or MATE transporters, they are here 
represented as monomers. ABC: a homology model of MacB from E. coli. MFS: EmrD 
crystal structure, 2GFP. SMR: EmrE crystal structure, 3B61. PACE: homology model 
for AceI protein from Acinetobacter baumannii, generated by I-TASSER (Yang et al., 





1.3.6 RND transporters 
Of the pumps present in Gram negative bacteria, RND multidrug transporters show 
the greatest contribution to multidrug resistance (Sulavik et al., 2001).  The extent of 
this is such that in wild-type cells, they can mask efflux activities of some other 
pumps and study of these other pumps might require their overexpression , or use of 
a strain in which major RND pumps have been disrupted (Tikhonova et al., 2007). Such 
observations may raise issues regarding the classification of pumps contributing so 
little to natural efflux – are these pumps really drug efflux pumps? There are two 
main ideas regarding this: the first is that they are not naturally drug efflux pumps, 
but they normally do something different and fulfil a drug efflux role in a facultative 
manner (Lu & Zgurskaya, 2013), which is apparent only in artificial laboratory 
conditions.  The other is that most minor efflux pumps contribute to multidrug 
resistance via the activity of a major RND efflux pump, with multiple transporters 
moving substances from the cytoplasm to the periplasm, from where the RND 
transporter collects them for removal to the extracellular space (Tal & Schuldiner, 
2009). 
Efflux pumps are capable of increasing a cell’s tolerance to a substance by decreasing 
the intracellular concentration of that substance. Such activity is necessary not only 
for chemicals with an origin outside the cell, but also for toxic waste substances 
produced by the cell (Blanco et al., 2016). Unlike mechanisms of modifying or 
degrading antibiotics, efflux activity does not detoxify the environment; it only 
detoxifies the cell. The drug therefore remains in the environment and, as the pump 
acts against the concentration gradient, the drug is constantly diffusing into the cell. 
The permeability barrier of the OM therefore acts synergistically with efflux pumps 





Figure 1:3 - Crystal structure of RND transporter AcrB. 
The crystal structure of AcrB (1IWG) is shown in both ribbon and transparent format 
with each protomer in a unique colour. The inner membrane is not drawn, though the 
twelve helices of the trans-membrane domain of each protomer span the membrane.   
 
Given the significant contribution of RND transporters to MDR, these pumps have 
been extensively studied, and the mechanisms of translocation are reasonably well 
understood (Seeger et al., 2008; Eicher et al., 2012; Eicher et al., 2014; Zuo et al., 
2015; Oswald et al., 2016; Schuster et al., 2016). Crystal structures of the prototypical 
RND drug transporter from E. coli, AcrB, show the homotrimeric protein to go 
through a cycle of conformations, with each protomer in a different conformation 
and binding state (Seeger et al., 2006). By cycling through conformations, the pump 
undergoes a peristaltic action, to effectively squeeze the substrate through multiple 
binding pockets towards an external pore (Seeger et al., 2008). These conformational 
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changes are driven by proton motive force; a network of charged and polar residues 
in the transmembrane region of the protein relay the proton and trigger the 
conformational changes. The charge network is very well conserved in homologues 
of AcrB – in particular, two aspartic acid residues in the transmembrane helices (D407 
and D408 of AcrB) essential for AcrB activity appear to be absolutely conserved in all 
RND multidrug efflux pumps from alpha-, beta-, gamma-, delta-, and epsilon-
proteobacteria. A major requirement for efflux activity of a substance is that it must 
be capable of occupying the binding pockets only with low affinity – anything with 
high affinity will bind to the protein instead of passing through it, resulting in an 
inhibitive effect, as is the case with phenylalanine-arginine-β-naphthylamide (PAβN) 
and the pyranopyridines (Vargiu et al., 2014). Otherwise, the RND multidrug 
transporters are relatively non-selective, capable of exporting a multitude of 
compounds (Pos, 2009), with a wide range of physical characteristics – the only 
selectivity requirements seem to be that the compound must be lipophilic and 
capable of physically fitting through the different binding pockets, tunnels, and outer 
membrane channel.  
RND pump proteins can fulfil multiple functions. These can include export of multiple 
and unrelated toxic substances, transport of outer membrane lipid components 
(Varela et al., 2012; Yang et al., 2014), or export of quorum sensing molecules 
(Aendekerk et al., 2005). The role in transport of outer membrane lipids in the 
Corynebacterineae is an example of how an RND pump can contribute to multidrug 
resistance without directly extruding the drugs (Yang et al., 2014). Examples of 
substrates, inhibitors and a non-substrate of the MDR RND transporters of interest 
to this project are shown in Figure 1:4, including examples of linear and cyclic, large 
and small toxic compounds. Given the variety of substrates, it is perhaps not 
surprising that single substitution mutations mapping to the binding pockets can 
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affect how effectively the pump will transport any given substance (Blair et al., 2015), 
and can have significant impact on clinical outcome.  
 
 
Figure 1:4 - Substrates, inhibitors, and a non-substrate of common RND multi-
drug transporters. 
Great variation in size, shape and hydrophobicity can be seen between different 
substrates. PAβN and pyranopyridines are competitive inhibitors of the pumps, 
although PAβN is also a poor substrate. Vancomycin is not an efflux substrate, but 





1.4 Moving a substrate beyond the cell envelope 
All of the inner membrane transport proteins have a transmembrane domain to 
facilitate substrate transport across the inner membrane. However, they do not span 
the entire Gram-negative cell envelope on their own, and would therefore not 
remove the drug past the main permeability barrier of the outer membrane. For 
many toxic substances, their removal from the cytoplasm would be sufficient to 
prevent their action, as any drug which acts at the level of DNA, RNA, protein 
synthesis or on any other cytoplasmic function would be removed from its location of 
activity. It does however seem to be an inefficient mechanism of drug removal, as the 
energy is being used to overcome only a lesser permeability barrier, and the drug will 
likely re-enter the cytoplasm relatively quickly.  
In Gram-negative bacteria, the ABC, RND and some major facilitator superfamily 
(MFS) multidrug transporters form part of tripartite complexes capable of spanning 
the entire cell envelope, and thus transport their substrates to the external 
environment. Tripartite assemblies consist of the inner membrane transporter 
protein, an outer membrane channel protein, and a membrane fusion protein (MFP; 
may elsewhere be called periplasmic adaptor protein) which links the pump and 
channel proteins to ensure a continuous conduit from the inner membrane to the 
extracellular environment. Some complexes may have an additional small protein 
that is non-essential for efflux activity. These small proteins are currently poorly 
understood, but affect the efflux profile of the pump (Hobbs et al., 2012). Analysis of 
the genetic context of acrZ suggests that the small protein may naturally form part 
of a different complex, as the gene forms part of the modABC gene cluster, which 
encodes a molybdate ABC-transporter complex. For drug efflux to be detectable in 
vivo, all of the transporter, MFP and channel protein must be expressed, and there 
must be an energy source. Such activity can be derived through several approaches, 
including assays to determine minimum inhibitory concentration (MIC), fluorescent 
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substrate accumulation rate and removal of fluorescent substrate from pre-loaded 
cells (Blair & Piddock, 2016).  
1.5 Tripartite complexes 
1.5.1 Outer membrane channels 
As stated above, tripartite complexes consist of the transporter, an outer membrane 
channel protein, and a membrane fusion protein – Figure 1:8 shows the components 
in an exploded format after each component has been introduced. The channel 
protein is perhaps the most straightforward of the three proteins, as it essentially 
must form a conduit that is wide enough to allow passage of the pumped antibiotics. 
Members of this family form homotrimers. The prototypical member of this family of 
proteins, TolC from E. coli, is the main focus of this thesis.  
The first reports of the tolC gene identified gene loci in which mutation or disruption 
caused tolerance to colicin in a conditional manner (temperature-dependent), hence 
the name (Nagel de Zwaig & Luria, 1969). At this same time, it was also observed that 
these mutants were more susceptible to deoxycholate (Nagel de Zwaig & Luria, 
1967). It was therefore proposed that the tolC gene must in some way be required 
for normal cell envelope structure. It was later found that tolC mutants are deficient 
in expression of one of the major outer membrane proteins (OMPs), OmpF (Morona 
& Reeves, 1982) - an observation that seems to have been largely overlooked since 
the finding that TolC is itself an OMP (Morona et al., 1983). As an OMP, TolC not 
surprisingly contains a signal sequence that is cleaved as the protein matures 
(Hackett et al., 1983).  
Following the observation that TolC is an OMP, its requirement in the secretion of 
haemolysin was shown (Wandersman & Delepelaire, 1990), demonstrating for the 
first time that it is part of secretion pump assemblies - although this was not directly 
concluded by the authors, who only stated that TolC may allow interaction of the 
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other pump components with the outer membrane (OM). Conductivity experiments 
showed that TolC is a channel protein (Benz et al., 1993), providing further evidence 
for its direct role as part of a pump assembly. TolC was then shown to also be 
required for activity of AcrAB and does not affect expression of AcrA (Fralick, 1996), 
again suggesting a role for TolC as the export channel component of a pump 
complex. This finding also explained the early observations that strains in which tolC 
is disrupted are more susceptible to deoxycholate, as acrB mutants display the same 
phenotype (Ma et al., 1995; Lacroix et al., 1996). 
As with most outer membrane proteins, these channels contain a β-barrel domain, 
which spans the outer membrane and acts as an exit pore (Koronakis et al., 2000). 
Each protomer within the homotrimer contributes four β-strands to a 12-stranded 
barrel. While the β-barrel is sufficient for insertion into the outer membrane, one 
OMC (OprM) from Pseudomonas aeruginosa is known to be lipidated at its N-terminal 
cysteine residue, and the crystal structure suggests that this lipid moiety inserts to 
the outer, not the inner, membrane (Monlezun et al., 2015). Despite forming a 
β-barrel for insertion into the outer membrane, TolC expressed without a signal 
sequence folds and forms trimers in the cytoplasm, with the β-barrel not inserted to 
a membrane (Masi et al., 2009). In TolC, the internal pore diameter is approximately 
20 Å at the membrane; this extends at an almost continuous diameter (fluctuating to 
as wide as 26 Å, but retaining a minimum diameter of 20 Å) approximately 60 Å into 
the periplasm, at which point it begins to narrow to a diameter of less than 4 Å, 
closing the channel at the periplasmic end. The overall length of the channel is 
approximately 140 Å, of which 40 Å consists of the outer membrane β-barrel, and the 
remaining 100 Å is an α-helical barrel-type assembly extending into the periplasm 
from the outer membrane. The structure of TolC is shown in Figure 1:5. The occlusion 
at the periplasmic end prevents the channel from simply acting as a large porin, and 
21 
 
occurs due to the twisting of α-helical coiled coils, of which the lower portion of the 
periplasmic domain is formed (Figure 1:6). 
At the very tip of the coiled coils, there is a network of charged and polar residues, 
which interact to form a “gate” that must be opened before any efflux activity is 
possible (Andersen et al., 2002a; Andersen et al., 2002b). Mutational analysis shows 
that disruption of this network results in a channel which is constitutively open 
(Bavro et al., 2008; Pei et al., 2011). A second “gate” is present a few helical turns up 
the inside of the coiled coils, which can consist of either a pair of rings of aspartate 
residues, or one acidic and one hydrophobic ring (Andersen et al., 2002c; Vediyappan 
et al., 2006). Opening of the wild-type channel requires its interaction with a MFP – 
though some channel proteins form part of several efflux complexes within a single 
species: in Salmonella enterica, at least seven transporter/MFP pairs utilise one 
channel protein, TolC (Horiyama et al., 2010).  
These proteins also contain a mixed α-helical/β-stranded “equatorial domain” that 
forms a ring around the simple tube approximately halfway along the periplasmic 
portion. While parts of the equatorial domain are essential for TolC function 
(Yamanaka et al., 2001; Yamanaka et al., 2002; Yamanaka et al., 2004; Yamanaka et al., 
2007), exactly what the domain does or why it is present remain unclear. This domain 
is formed from both the N- and C-termini, plus a 34 amino acid sequence in the 
middle of the mature protein. A structural repeat is visible in TolC, leading to the 
suggestion that a gene duplication event took place (Koronakis et al., 2000), in which 
the second “copy” would start within the equatorial domain. The extent to which the 
sequence is also repeated within the structural repeat is assessed in Chapter 3.2, 





Figure 1:5 - Structure of outer membrane channel proteins. 
Crystal structures of TolC (left; 1EK9) and OprM (right; 4Y1K) are shown in both 
ribbon and transparent surface representation with each protomer in a unique 
colour. The N-terminal cysteine residue and palmitoyl group of a single protomer of 







Figure 1:6 - The TolC channel is occluded at the periplasmic tip. 
Viewed from a section through the equatorial region towards the periplasmic tip of 
TolC, the protein becomes occluded towards the periplasmic end, with clear 
constriction visible from the surface which, when properly ion-coordinated, is too 
narrow even to allow passage of water. The two aspartate rings (D371 and D374) are 






1.5.2 Membrane fusion proteins 
Membrane fusion proteins consist of several domains, as they must interact 
specifically with both their cognate transporter and channel proteins. Of particular 
interest to this thesis is AcrA, the cognate MFP of the main MDR efflux pump AcrB. 
The presence and size of certain domains within MFPs are determined by the type of 
transporter with which they function (Symmons et al., 2015). Separating the domains 
are flexible regions that appear to act like hinges (Mikolosko et al., 2006); such 
flexibility must be considered during any docking modelling. 
Most MFPs have a hairpin (helix-turn-helix) structure to contact the channel protein – 
for ease of nomenclature, the loop of the helix-turn-helix, and one complete helical 
turn each side of it, is referred to as the hairpin tip. The length of the hairpin, 
determined in helical turns, is dependent mainly upon how large a periplasmic 
domain the transporter possesses (Symmons et al., 2015). It thus follows that MFPs 
that function with RND transporters, which have large periplasmic domains, require 
relatively short hairpins, while those that function with an MFS transporter require 
much longer hairpins as they must bridge a substantial gap between the transporter 
and channel proteins. Somewhat illogically, at eight helical turns (approximately 58 
Å), the hairpin of AcrA is longer than that of MexA (Akama et al., 2004; Higgins et al., 
2004a; Mikolosko et al., 2006), its homologue from Pseudomonas aeruginosa, even 
though P. aeruginosa has a wider periplasmic space than E. coli (Matias et al., 2003). 
One example of an MFP lacking the hairpin domain entirely, instead having a loop, 
has been found from the spirochete, Borrelia burgdorferi (Greene et al., 2013). 
Although homology modelling suggests that the cognate channel protein, BesC, 
lacks some of the interactions that maintain its normal closed state (Bunikis et al., 
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2008), the implications of the lack of a hairpin domain, such as in BesA-BesC and 
possibly BesB-BesC interactions, have not been studied.  
All MFPs characterised to date contain both lipoyl and β-barrel domains. Both of 
these domains consist entirely of β-strands and connecting loops, and are required 
for normal function. Each of these domains can be cross-linked to the transporter 
protein, suggesting that one of the roles of these domains is to interact with the 
transporter component of the complex (Symmons et al., 2009). More direct evidence 
for this role within the β-barrel domain has been seen from adaptive mutagenesis, 
whereby a non-cognate transporter was utilised with the MFP and mutations tested 
for gain-of-function to determine which positions are required to determine 
specificity between two proteins (Krishnamoorthy et al., 2008).  
MFPs associated with transporters that have large periplasmic domains usually have 
a membrane-proximal domain. Via lipidation of an N-terminal cysteine residue (C25 in 
AcrA), this domain tethers the MFP to the inner membrane (Zgurskaya & Nikaido, 
1999). This same cysteine residue is also essential for normal signal sequence 
cleavage on AcrA (Kawabe et al., 2000). In MFPs associated with transporters lacking 
a large periplasmic domain, the lipidated membrane-proximal domain is not present; 
these proteins instead have a transmembrane helix for anchorage (Hinchliffe et al., 
2014). As with the lipoyl and β-barrel domains, membrane-proximal domains interact 
with the transporter proteins (Elkins & Nikaido, 2003; Ge et al., 2009). On the 
available crystal structure of AcrA (2F1M), the membrane-proximal domain is missing 
as it had been proteolytically removed prior to crystallisation. Without the 
membrane-proximal domain, the total length of the AcrA protein is approximately 
105 Å (Mikolosko et al., 2006), meaning it is capable of spanning around half of the 
total periplasmic distance of 180-235 Å (Matias et al., 2003). 
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The roles of the MFP appear to be complex. At the simplest level, these proteins 
interact with the other components of tripartite complexes to stabilise an IMT-OMC 
assembly (Tikhonova & Zgurskaya, 2004), although stabilisation can only be true in 
RND-type systems, where the IMT contains large periplasmic domains, otherwise the 
MFP bridges a gap between the transporter and channel proteins. In vitro studies 
have shown that the MFP is required for activation of the transporter protein, but 
only when a substrate is also present (Verchère et al., 2012). This activation of the 
transporter is independent of the outer membrane channel protein, as the activity 
can be seen in vitro even in the absence of a channel protein. In heavy metal RND-
type efflux systems, it has been shown that the substrate is passed from the MFP to 
the transporter (Bagai et al., 2008; De Angelis et al., 2010; Mealman et al., 2012), and 
an investigation of pump inhibitors suggest that this is also a possibility for some 
substrates of multidrug efflux complexes (Abdali et al., 2017). Constriction of the 
channel protein is relieved by the MFP, opening the channel ready for an efflux event 
(Janganan et al., 2011). Such opening of the channel protein is independent of either 
a substrate or the transporter protein, as shown by determination of susceptibility to 
vancomycin (a drug which is too large to efficiently traverse the outer membrane 
unless a wide channel such as TolC is available) for combinations of complex 





Figure 1:7 - Structure of MFPs. 
Top: The crystal structures of AcrA (2F1M, left) and the re-refined structure of MexA 
complete with the membrane-proximal domain (2V4D, right). Bottom: a homology 
model of the complete AcrA structure showing the protein coloured by sequence 
(left) and domains (right). The domains are uniquely coloured: yellow – membrane-





Figure 1:8 - Exploded view of tripartite complexes. 
Distances are not shown to scale, and the distances between proteins should not 
therefore be taken as representative of a model of interaction. Two transporters 
which function in association with TolC are shown: the RND transporter AcrB (1IWG) 
and ABC transporter MacB (manually generated homology model), as the 
physiologically relevant trimer and dimer, respectively. The OMC protein TolC (1EK9) 
is shown in the closed state of its physiological trimer. The MFPs MacA (3FPP) and 
AcrA (full-length homology model based on 2F1M ) are shown as monomers. The 
N-terminal lipidation of AcrA is not shown in either monomer, while the two 




1.5.3 Models of complete assembly 
There are two general and opposing models of how the complete tripartite complex 
assembles (Figure 1:1010). Both of these do of course place the transporter protein 
within the inner membrane and the channel protein with its β-barrel in the outer 
membrane. In the classical model of interaction, the first to be proposed, there is a 
bundling of helices between the MFP and channel proteins, which allows for direct 
interaction between the channel and large transporter proteins such as RND 
transporters (Symmons et al., 2009). One contributing factor for this model being the 
first proposed was that the top of the AcrB “TolC-docking domain” contains two 
β-hairpins per protomer (Figure 1:9), from which the interconnecting loops form a 
putative docking site that matches the diameter of the periplasmic tip of TolC 
(Koronakis et al., 2000; Murakami et al., 2002).  
 
Figure 1:9 - Putative TolC-interactive loops of AcrB. 
Each protomer of AcrB is shown in a unique colour, while the β-hairpins on all 
protomers are shown in brown. The diameter of the pore formed by the loops of 
these β-hairpins approximately matches that of the periplasmic tip of the static 




The later model, which was first proposed based upon crystal packing in structural 
studies (Yum et al., 2009), suggests interaction between the MFP and channel only at 
the tips of their respective coiled coil structures. This spaces the transporter and 
channel proteins apart by at least the length of the MFP hairpin (Xu et al., 2010). 
Henceforth, these models of assembly will be referred to as the “bundling” and 
“tip-to-tip” models, respectively. Research groups supporting either model argue 
that the other cannot be correct in light of available evidence for their preferred 
model (evidence for each model is presented in Sections 1.5.5 and 1.5.6 below). 
However, there is no logical reason why both cannot be correct but at different 















































































































































































1.5.4 Stoichiometry of complex assembly 
The stoichiometry of the complex is yet to be definitively determined, though the 
general consensus is that 3:6:3 transporter:MFP:channel is most likely in either 
model. Such consensus derives from multiple lines of evidence. Crystallographic 
studies show that MFPs often form dimers and some can form hexamers under 
crystallographic conditions (Akama et al., 2004; Mikolosko et al., 2006; Yum et al., 
2009). Genetic and functional analysis utilising AcrA-AcrA fusions shows that a forced 
dimer is functional (Xu et al., 2011a). Surface plasmon resonance studies show AcrA 
dimerisation to occur spontaneously upon lipidation, and that this increases affinity 
for AcrB (Tikhonova et al., 2011). A natural complex which requires two unique MFPs 
has been identified (Weeks et al., 2015). Electron microscopy images attempting to 
show the fully assembled complex directly show a 3:6:3 stoichiometry (Du et al., 
2014; Kim et al., 2015; Daury et al., 2016).  
Despite this, it has also been shown that the AcrAB-TolC complex in E. coli is capable 
of functioning with 3:3:3 stoichiometry, as AcrA-AcrB fusions remain functional 
without any other copy of acrA (Hayashi et al., 2016). 
1.5.5 Evidence supporting the tip-to-tip model 
A functional hexameric tube-like assembly of the MFP was first proposed upon 
solving of the MacA crystal structure (Yum et al., 2009). While this structure indicated 
that MacA has the same general modular configuration of other MFPs, the crystal 
packing generated a hexameric tube. As this tube, formed from the hairpin domains, 
was approximately the same diameter as the α-barrel of TolC, the authors 
hypothesised that the α-barrels of the oligomeric MacA and TolC assemblies may sit 
one atop the other to form a continuous channel. 
 Following the structure being solved, a new conserved motif was identified at the tip 
region of the MFP hairpin – the RLS motif – which was proposed to be common and 
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essential (Xu et al., 2010).When mapped to the crystal structure of AcrA (2F1M), the 
proposed RLS motif (RxxxLxxxxxxS, in which “x” is any amino acid) is shown to be 
located at the tip of the AcrA hairpin, with the arginine located on the N-terminal 
side of the loop turn, one helical turn down from the top of the hairpin, and facing 
away from the other helix. The leucine and serine positions are located at the ends of 
the loop turn, being the first and last amino acids not to form part of the helical 
structures. This RLS motif has been studied in various MFPs, with most of the 
mutations mapping to this motif published to date abolishing function and binding of 
MFP to OMF, summarised in Table 1:1.  
Table 1:1 - Published mutations of the RLS motif. 





R131A No No 
(Xu et al., 
2010) 
L135D No No 
S142D No No 
S142A Not tested Yes 
(Xu et al., 
2011b) 
AcrA 
L132C Not tested No 
(Xu et al., 
2011a) 
R128D Not tested No 
(Kim et al., 
2010) 
L132D Not tested No 
S139D Not tested No 
MdsA 
R135D No Yes 
(Song et al., 
2014) 
L139D No Yes 
S146D No Yes 
 
Chimaeric constructs of Actinobacillus actinomycetemcomitans (Aa) MacA on which 
the tip region was replaced by the tip regions of the TolC α-barrel have been 
analysed for structural formation with wild-type E. coli MacA by electron microscopy , 
and showed dumbbell-shaped structures with a central bulge (Xu et al., 2011b). 
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Similar studies, replacing the hairpin tip of E. coli MacA with that of MexA or AcrA and 
the hairpin tip of Aa MacA with the tip regions of the OprM or TolC α-barrel showed 
the same bulged dumbbell-shaped structures (Xu et al., 2011a; Xu et al., 2012). In all 
of these studies the bulges in the structures were modelled as an intermeshing of 
the tip regions of the two proteins, with the TolC aperture fully opened. 
Furthermore, positions that may interact were identified from the MexA-OprM 
docking model, with the authors proposing that R119, L123 and S130 of the MexA 
RLS motif interact with the OprM backbone carbonyl group, V201/V408, and S138 of 
OprM, respectively, and that additionally, MexA L122 makes hydrophobic contacts 
with OprM V199/T406 (Xu et al., 2012).  
The latest evidence supporting either model comes from electron microscopy images 
of complete complexes and the 3D reconstruction based thereupon. These should 
generate an image of the most stable configuration of the complex, which can 
therefore be interpreted as being the structure of the complete complex. However, 
in practice it is far more difficult to get such direct analysis of these complexes. To 
date, only one study using wild-type proteins has been published to show the entire 
complex assembly (Daury et al., 2016). Others have made use of highly engineered 
proteins that are likely to alter the complex assembly (Du et al., 2014; Kim et al., 
2015). It must also be remembered that all structural studies require isolation of the 
proteins, therefore the proteins are analysed in an unnatural environment, which 
may also affect the binding of the component proteins. Finally, these studies identify 
only a single state – the complex in its most stable configuration under the artificial 
conditions to which it is subjected – while the complex must be dynamic in the cell as 
it assembles and disassembles. Though the electron micrographs may therefore look 
convincing and conclusive, questions remain. All of these studies have identified a 
tip-to-tip type interaction, indicating that this model is almost certainly accurate 




1.5.6 Evidence supporting the bundling model 
Studies utilising more traditional biochemical and mutagenesis approaches conflict 
with the results from electron microscopy. Both cross-linking experiments and 
isothermal titration calorimetry show that the transporter and channel proteins are 
in close proximity and interact directly, which is entirely incompatible with the tip-to-
tip model (Touzé et al., 2004; Tamura et al., 2005; Tikhonova et al., 2011). Mutation to 
the β-hairpins on AcrB decreases efflux activity, while suppressor mutations appear 
to stabilise the entire complex or facilitate TolC opening (Weeks et al., 2014). From 
isothermal titration calorimetry, it is seen that transporter-channel binding is 
enhanced at mildly acidic pH, but hindered by drug binding, suggesting that the two 
proteins might not be in direct contact during the actual efflux event. Other 
cross-linking experiments have shown that positions along the entire length of the 
MFP hairpin can be cross-linked to the channel, and that positions high up the 
channel protein, as high as the equatorial domain, can be cross-linked to the MFP 
(Lobedanz et al., 2007).  
Mutagenesis studies both with cognate partners and generating gain-of-function 
mutants to function with non-cognate partners, show that positions along the entire 
MFP hairpin and throughout both the coiled-coil and equatorial domains of channel 
proteins are required for functionality (Yamanaka et al., 2004; Bokma et al., 2006; 
Vediyappan et al., 2006; Lee et al., 2012). Again, these results are incompatible with 
the tip-to-tip model. Such evidence for the bundling model might indicate that in 
vivo, the conditions are more favourable for this model than for the tip-to-tip model, 
while the conditions used in vitro are usually less favourable. They also suggest that 
stretching and contracting of the assembly might occur during efflux, to switch 
between the two models.  
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1.5.7 Specificity of interactions 
Individual channel proteins are capable of functioning with a variety of transporter-
MFP pairs. As these interactions are selective and not random, this poses conflicting 
considerations at the interaction interface – the interface on different MFPs that 
share a channel must be very similar, while interfaces on MFPs that are not capable 
of functioning with those same channels must be quite different. For example, AcrA 
and MacA from E. coli both function with TolC (Fralick, 1996; Kobayashi et al., 2001), 
but do not function with OprM from P. aeruginosa (Stegmeier et al., 2006), while 
MexA from P. aeruginosa functions with OprM but not TolC (Bokma et al., 2006). It 
would therefore be expected that the interfaces presented by AcrA and MacA would 
be very similar while that presented by MexA would be quite different. In 
Pseudomonas aeruginosa, the requirement for specificity is exaggerated by the 
presence of multiple channel proteins and RND systems (Yoshihara et al., 2002), 
which are only partially cross-reactive despite their structural similarity (Maseda et 
al., 2000; Phan et al., 2015; Yonehara et al., 2016).  
Trying to fit these factors into the two models suggests that the bundling model is 
more likely than the tip-to-tip, given the relative sizes of their interfaces. Early 
evidence in support of the tip-to-tip model identified the RLS motif, which was 
hypothesised to be conserved in all MFPs as it represents the MFP-side of the 
interface. Opponents to the tip-to-tip model point out that such a conserved 
interface would break the rule regarding specificity of the interaction, as all MFPs 
with that interface should function with all of the channels that normally function 
with any MFP that contains it (Symmons et al., 2015). Later developments showed 
that this proposed motif is neither always present, nor always located at the tip of 
the MFP hairpin, even when comparing MFPs which pair with a common channel (Kim 
et al., 2016).  
37 
 
To further complicate the issue, it is necessary to separate the concepts of 
interaction and functionality. A combination of proteins that does not show activity 
in an assay may still form a complex, even if it is non-functional, as several studies 
have shown (Bokma et al., 2006; Stegmeier et al., 2006; Vediyappan et al., 2006). The 
proteins can therefore form a complex, but may be missing a crucial interaction 
required to enable efflux activity. As such, any study investigating the interaction 
interface must consider both the structural and functional aspects, in addition to how 
any potential interface would fit into the rules about functioning very specifically 
with a small variety of partners. 
 
1.5.8 Energy requirements within the complex 
To transport a substance against its concentration gradient, as is the case during 
antibiotic efflux, energy is required by the pump protein. As mentioned earlier, this 
energy is provided either by ATP hydrolysis, the proton motive force or another 
electrochemical gradient, dependent upon the pump type. The requirements for 
assembly of an MFP and channel protein was first shown in a type 1 secretion system, 
in which the substrate was required for assembly but ATPase activity was not 
(Thanabalu et al., 1998). If the same were true in multidrug transporters, then the 
transporter and MFP would be expected to assemble as an inner membrane complex, 
which would then engage the channel protein upon binding of the substrate, 
regardless of whether or not an energy source was present.  
In RND complexes, each component is capable of interacting with each of the others, 
even in the absence of either the third component or any substrate (Tikhonova et al., 
2011). While assembly of the full complex appears to be independent of the 
availability of an energy source, the in vitro affinity between MFP and channel protein 
is higher at mildly acidic pH, suggesting that the presence of the energy source will 
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likely stabilise the complex (Tikhonova et al., 2009). However, this effect is observed 
in the absence of the transporter protein or a substrate, so it is clearly not the case 
that transport activity stabilises the assembly. Therefore, the actual interactions 
between MFP and channel protein are stabilised by the decreased pH. Whether this is 
purely a pH-dependent effect on the protein interfaces or if it is related to the 
availability of an energy source remains to be seen – equivalent experiments 
investigating ABC systems may be required for this. The presence of ATP, and thus 
the presence of the energy source, stabilises the interaction between the MacB ABC 
transporter and its cognate MFP, MacA, suggesting that energy availability may 
increase complex stability (Lu & Zgurskaya, 2012). 
While some papers refer to MFPs transducing energy from the transporter to the 
channel protein to induce opening of the channel, it is well-documented that opening 
of the channel requires no such transduction of conformational information 
(Tikhonova & Zgurskaya, 2004; Janganan et al., 2013). Both TolC from E. coli and MtrE 
from Neisseria gonorrhoeae have been shown to open in the absence of a functional 
cognate transporter protein, indicating that transporter activity and channel opening 
are not linked. However, the same studies also show that an MFP must be present to 
induce channel opening, in an energy-independent manner. The channel must not be 
dilated prior to complex formation, as the channel in an open state is unable to 
efficiently bind either the MFP or transporter protein (Tikhonova & Zgurskaya, 2004). 
Consistent with this, the complete complex is unable to form from a channel-MFP 
pre-assembly – presumably because the MFP-bound channel is open (Tikhonova et al., 
2011), further supporting the notion that energy is not required for either complex 
assembly or channel opening.  
Use of an MtrE mutant which is hypersensitive to vancomycin when its cognate MFP 
(MtrC) is also present, shows that energy is required for dissociation of the complex 
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(Janganan et al., 2013). Cells expressing this MtrE mutant, MtrC, and the RND 
transporter MtrD are mildly sensitive to vancomycin, while those expressing an 
inactivated mutant of MtrD, in which the proton relay network is disrupted, are 
resistant. This is explained by the transporter plugging the end of the channel to 
prevent vancomycin influx – the inactive mutant always plugs the channel because 
the lack of energy transduction prevents complex dissociation. These experiments 
are explained visually in Figure 1:11.  
The energy requirement for dissociation of the complex has been shown directly by 
pull-down assays with wild-type and proton-relay-deficient RND transporters using 
an in vitro system. The OMF could only be pulled-down with the wild-type transporter 
in the absence of a proton gradient, while it always pulled-down with the inactive 
transporter, regardless of the proton gradient (Enguéné et al., 2015). Although the 
use of an outer membrane channel protein allows extrusion of the drug entirely out 
of the cell, the channel protein is not essential for transporter activity, as seen in vitro 
(Verchère et al., 2012). Each of the transporter, MFP, proton gradient and a substrate 
must be present, however, for maximum activity to be observed (Verchère et al., 
2014). 
Within RND multidrug efflux systems, energy is therefore required for substrate 
translocation and for complex dissociation. Energy is not required for complex 
assembly or channel opening, and the channel protein does not contribute to 





Figure 1:11 - Energy is required for disassembly but not opening of the OMC. 
This figure summarises the conclusions made by Janganan et al. (2013). Light blue - 
MtrD RND-pump; brown – MtrC MFP; green – MtrE outer membrane channel protein; 
dark blue – the large efflux-restricted drug vancomycin; green plus symbol – protons; 
red star – approximate position of mutation; crosses – transport is blocked. The wild-
type MtrCDE complex (A) does not allow penetration of vancomycin. Introduction of 
the E434K mutation in MtrE to the entire complex (B) causes a low increase in 
susceptibility to vancomycin, although the mutation does not cause the channel to 
become constitutively open (C). MtrCE only (D), lacking the pump component, shows 
low-level susceptibility, indicating that the pump component is not required for 
channel opening. MtrC-MtrE(E434K) causes much higher susceptibility to vancomycin 
(E), suggesting that the mutation prevents channel closing. An inactive mutant of 
MtrD blocks the periplasmic end of the channel to prevent vancomycin entry to the 
cell (F) even when the channel cannot close – combined with the information from 
panels B and E, this indicates that energy is required for disassembly of the complex 
and normal closure of the channel protein.  
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1.6 Efflux pump inhibitors 
Efforts to identify inhibitors of efflux pump activity have yielded mixed results. While 
compounds have been identified which achieve this function, not all are inhibitors of 
the pumps, their effect instead coming by removal of the energy source. An inhibitor 
commonly used in research studies, CCCP (Carbonyl cyanide m-chlorophenyl 
hydrazone) is a protonophore and thus causes inhibition by chelating the protons 
that would otherwise generate proton motive force - while this is an effective 
inhibitor for in vitro studies, it is not a specific inhibitor of efflux pumps and cannot 
be considered for combinatorial therapy in clinical practice (Coldham et al., 2010). 
There are, however, some substances that have been shown to competitively and 
non-competitively bind to RND transporters, such as another inhibitor commonly 
used in research studies, phenylalanine-arginine-β-naphthylamide (PAβN). PAβN has 
been shown to competitively inhibit RND transporters such as AcrB (Vargiu et al., 
2014), but given that it is a substrate of AcrB, it is only effective at relatively high 
concentrations. Some researchers also question whether or not the apparent 
decrease in efflux activity caused by PAβN is purely due to its pump inhibition, as it 
appears that PAβN may permeabilise the outer membrane (Lamers et al., 2013), thus 
increasing influx. As most studies indirectly measure the net movement of molecules, 
without separation of influx or efflux, the increased rate of influx would appear the 
same as a decrease in efflux activity in these experiments. 
 A new series of efflux pump inhibitors (the MBX series of pyranopyridine derivatives) 
has been identified which do not show any bactericidal or membrane permeabilising 
activity (Sjuts et al., 2016). The first of these compounds to be confirmed as a pump 
inhibitor has been co-crystallised with AcrB, identifying the exact binding position 
and the residues involved in the interaction. From the crystal structure, it was clear 
that a water-filled cavity between the inhibitor and AcrB binding pocket had formed. 
This information was used to develop new inhibitor compounds with improved 
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binding capacity, to fill the cavity - representing the first time that an efflux inhibitor 
has been successfully designed based upon information derived from a crystal 
structure of the pump in complex with an inhibitor. This series of inhibitors binds a 
hydrophobic pocket adjacent to the distal binding pocket, and locks the 
conformational state of the protein, thereby preventing the peristaltic action of the 
pump. This would seemingly require only a relatively minor mutation to arise in order 
for the inhibitor to be rendered ineffective, and therefore poses a threat to the 
potential clinical use of efflux pump inhibitors. It also remains to be seen whether or 
not mutations in or over-expression of alternative efflux pumps may occur to 
ultimately mask the effect of the inhibitor in a clinical setting, as the inhibitor may be 
revealed as highly selective for only certain transporters.  
Apart from inhibiting the translocation activity of the transporter component, 
addition of large radius multi-valent cations from the extracellular side has been 
shown to decrease the conductivity of TolC (Andersen et al., 2002c). Added cations 
form ion bridges with the aspartate ring located just inside the lumen at the 
periplasmic end of the protein. This has been shown both from conductance 
experiments comparing wild-type protein with mutants lacking the aspartate rings, 
and by resolving the structure of TolC crystals soaked with hexamine cobalt (Higgins 
et al., 2004b). 
 
1.7 Inhibiting complex assembly 
As an alternative to inhibiting the pump activity directly, it may be possible to instead 
target assembly of the complex, at the level of the protein-protein interactions. 
While there are several theoretical interfaces (transporter-MFP, transporter-channel, 
MFP-channel, MFP-MFP), finding exactly what these interfaces are remains a 
challenge. The efflux system is clearly a dynamic one – as discussed earlier, the 
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complex assembles and disassembles while the channel opens and closes and the 
transporter undergoes conformational changes to pump the substrate. Meanwhile, 
all of the approaches available, except for computational molecular dynamics 
simulations (Vargiu et al., 2014; Sjuts et al., 2016), are incapable of being interpreted 
in a time-resolved manner. While molecular dynamics are providing insights into each 
of the individual components of the systems, they become limited at the complexity 
of the entire assembly, as the number of possible outcomes increases with system 
complexity and a consensus therefore becomes less likely.  
Each of the theoretical interfaces may be targeted, but do any of them present a 
good candidate for inhibition? Perhaps the simplest interface to predict is that of the 
MFP homodimerisation face. From all available structural data, and from mapping of 
mutations in the MFP that compensate for inactivating mutations in channel 
proteins, the lipoyl domain of the MFP almost certainly contains at least some of the 
dimerisation interface. In the tip-to-tip model of interaction, the hairpin domain also 
forms a dimerisation interface – in the bundling model, this same interface would 
instead interact with the channel.  The largest and most complex of the potential 
interfaces is that between the transporter and MFP; the implication being that this is 
not a promising therapeutic target, as it would be most prone to mutation. The 
smallest of the possible interfaces lies between the transporter and channel, but the 
existence of such an interface is disputed, in spite of the body of evidence in support 
of a direct interaction between these two proteins. In a transporter-channel 
interface, the face on the channel would be the same as that in the tip-to-tip model 
interface between channel and MFP – suggesting that this could be a promising 
candidate for interruption, as it may affect multiple interfaces and stages of the 
pumping cycle, thus being most resilient to mutation.  
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Regardless of the interaction that is disrupted, questions regarding what type of 
inhibitor to use, and how to administer it, will remain. The obvious candidates as 
inhibitors would be small peptides that specifically bind with high affinity to the 
target, out-competing the native cognate binding partner as a competitive inhibitor. 
Administration of such an inhibitor would not be trivial – the whole reason for 
targeting a tripartite efflux pump is that it removes toxic substances to the outside 
of a permeability barrier; that permeability barrier will also prevent access of the 
inhibitor to its site of action. It is widely accepted that only very short peptide chains, 
no more than six amino acids long, can be taken up by Gram-negative cells. 
Biotinylation of peptides has proven to enable peptides up to 31 amino acids in 
length to enter the Gram-negative cell, making use of the biotin uptake system, 
though this has not yet been shown to localise the peptide to the periplasm (Walker 
& Altman, 2005). 
 
1.8 Project context: multidrug resistance 
Antibiotic resistance is a growing global concern, and has been labelled by WHO as 
one of the three greatest threats to global health (Piddock, 2012). In 2014, antibiotic 
resistance was also made a Research Council UK strategic funding priority area, due 
to the potential threat posed to human health. Antibiotic resistance was described 
even before the introduction of antibiotics as therapeutic agents - indeed Fleming 
himself identified that some bacteria were unaffected by penicillin, in the very same 
paper as he first described the antibiotic (Fleming, 1929). Since therapeutic use of 
antibiotics began, emergence of resistant clinical isolates has always closely followed 
introduction of the drug (see Figure 1 in Clatworthy et al. (2007) for a diagrammatic 
representation of this). This emergence of resistance causes us to require new 
classes of antibiotic, but is also partly responsible for the lack of recent progress in 
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bringing new classes of antibiotic to market (Coates et al., 2011; Piddock, 2012). 
Despite the difficulties in bringing new and effective classes of antibiotic to market, 
new antibacterial molecules are being developed, even of novel classes (O'Daniel et 
al., 2014), and it remains to be seen whether or not these will be introduced for 
therapeutic use. A system has been developed (the isolation chip, or iChip) to grow 
previously unculturable soil-borne bacteria (Nichols et al., 2010), recently leading to 
the identification of a new antibiotic to which the minimum inhibitory concentration 
(MIC) of Staphylococcus aureus did not increase over 25 days of serial passaging at 
sub-inhibitory concentrations (Ling et al., 2015). The iChip approach to growing 
previously unidentified bacterial species from soil may provide the means required to 
identify further new antibiotics, as more soil samples are tested with the system.  
Classical resistance mechanisms that were identified relatively early in the use of 
antibiotics relied upon inactivation or degradation of the drug by enzymatic action 
(Abraham & Chain, 1940; Kirby, 1944). Enzymatic action upon a drug affects only that 
drug or a family of chemically similar compounds. While this may cause a delay in 
successful treatment of an infection, treatment with a different class of antibiotic 
can usually circumvent the issue. Due to the inactivation of the drug, this enzymatic 
action has a detoxifying effect upon the environment local to the producer of the 
enzyme, thus allowing otherwise sensitive bacteria to survive in the same 
environment (Finkelshtein et al., 2015).  
Many antimicrobials are produced naturally, or are synthetic derivatives of a natural 
product. Those produced in nature must not kill the producing organism, and so the 
producer must have an anti-suicide system in place to resist the antibiotic. Clearly, if 
the organism that produced an antibiotic protected itself by enzymatically 
inactivating that antibiotic, then production of the antibiotic would have been a 
wasteful process, and resistance is therefore better achieved by alternative means.  
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Given that antibiotics generally bind a particular target and inhibit a particular 
process, having a “target” variant that enables the same process but to which the 
antibiotic cannot bind, is a useful way by which resistance can be achieved. Species of 
Pseudomonas, for example, which are common antibiotic-producers (Fuller et al., 
1971; Demain, 2009; Darabpour et al., 2010), are known to utilise this method 
(Yanagisawa & Kawakami, 2003). This mechanism of resistance provides very high 
intrinsic levels of resistance to a particular substance or class of substances.  Being a 
novel gene, this type of resistance can spread by gene transfer, particularly when 
these resistance genes are encoded on a plasmid or other mobile genetic element. 
Accumulation of genes that provide resistance to specific antibiotics can lead to 
multi-drug resistance (MDR), though as this is a cumulative process, it is slow 
(Nikaido, 2009). MDR can otherwise arise from prevention of the increase of 
intracellular drug concentrations, which can be a result of either decreased 
membrane permeability or increased drug efflux (Nikaido, 1994). These changes can 
arise within a strain by a single mutation, for example by mutation in a non-coding 
gene regulatory region which increases efflux pump expression or decreases porin 
expression (Ohneck et al., 2011; Fournier et al., 2013), and can therefore 
spontaneously increase resistance to a variety of drugs. 
All of the above may indicate that multidrug efflux pumps are a severe threat to 
humans. However, they may also prove to have uses beneficial for industrial 
processes. In a world moving away from fossil fuel use, biofuels are likely to become 
increasingly important. Engineering of AcrB has been shown to increase tolerance to 




1.9 Challenges in preventing multidrug resistance 
Put simply, we have become dependent upon antibiotics to support our population 
growth, and bacteria have become dependent upon their resistance mechanisms to 
survive our use of antibiotics. It is a variation of the Red Queen model of evolution, in 
which a species must continue to evolve purely to survive the evolution of its 
ecological neighbours, except that in this case, the “evolution” of human use of 
antibiotics is technological rather than genetic. The situation now appears to be one 
of the bacteria winning this arms race, as their natural evolution of resistance has 
outpaced our ability to find new and effective drugs (Fox, 1996). The non-specific 
nature of antibiotics also does not aid our cause. Our bodies naturally consist of more 
bacterial cells than human cells, of many different species and performing a variety 
of commensal tasks; antibacterial agents used to treat a bacterial infection do not 
only affect the pathogen in question, but most of the other bacteria present too, 
whether they are causing harm at the time or not. Our bodies also naturally produce 
antibacterial substances, such as bile salts, that encourage development of antibiotic 
resistance. There is evidence that dietary changes may also cause temporary 
increases in expression of multidrug efflux pumps (Fadli et al., 2014); if a mutation 
leads to a strain becoming pre-adapted, this may give the strain an advantage over 
others that must instead respond to the change. This causes directionality to the 
evolution of the entire microbiota (towards antibiotic resistant), and also provides 
clearances and new bacterially-naïve niches to open for colonisation by bacteria that 
were not previously a part of the microbiota, increasing the threat for subsequent 
infection.  
Multidrug efflux pumps are a major contributor to multidrug resistance, but some 
have other, possibly more ancient, functions that were discovered more recently 
than was their contribution to drug resistance (Poole, 2008). These functions may 
have once been, and possibly still are, the primary function of the pumps. Roles in 
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quorum sensing (Minagawa et al., 2012), biofilm formation (Baugh et al., 2012; Baugh 
et al., 2014), acid survival (Deininger et al., 2011), iron scavenging (Bleuel et al., 2005; 
Tatsumi & Wachi, 2008), and host colonisation (Lin et al., 2003), all mean that these 
multidrug efflux pumps may be essential outside the laboratory environment – 
despite knockout strains being perfectly viable in the laboratory. It is clear that efflux 
pumps are required for survival in the hostile environment of the host, and it appears 
that over-expression of the pumps, or mutation to alter their range of substrates, 
does not have the detrimental effect that would be required to prevent the spread 
of the multidrug resistance thus conferred. The spread of multidrug resistance is 
therefore difficult to prevent because the fitness cost to the bacteria of being 
multidrug resistant is insufficient for the absence of antibiotic challenge to select for 
the susceptible strains. In the case of single drug resistances encoded on mobile 
genetic elements, the maintenance of the additional genetic material and expression 
of the genes causes a great enough fitness cost that over time, the resistant 
population is outcompeted, in the absence of antibiotic challenge, by the susceptible 
population. The population dynamics are therefore different between single drug 
resistance and multidrug resistance, with multidrug resistance being the more 
difficult to stop.  
 
1.10 Gaps and conflicts within the literature, to be addressed 
Crystal structures are available for representative proteins of each component within 
the tripartite multidrug efflux pumps. Docking of these into EM-generated structures 
of the complete assembly indicates a different method of interaction compared to 
that suggested by other biochemical and mutagenic approaches. Both of these 
models have been shown only in a static format. If neither model of interaction can 
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be categorically disproved using the approaches that support the other model, can 
the two models be reconciled in a dynamic system?  
The available structures give little information as to the role of various regions of the 
MFP and OMC proteins. For example, the structures indicate that the OMC contains 
an equatorial domain around the outside of the channel, which has been shown to be 
essential for function, but what this domain does is unclear. Likewise, the MFP 
contains a hairpin structure which, when the cognate transporter has only a small 
periplasmic domain, makes sense to bridge the gap between the transporter and the 
channel, but why is this retained in RND-associated MFPs?  
As stated above, the tripartite models available to date are static. The system is 
known to associate and dissociate dynamically. If functional roles of the sub-domain 
regions of the MFP and OMC, and the interaction interfaces, can be determined, a 
dynamic model of interaction needs to be developed.   
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1.11 Aims and objectives 
The overall aim of this project is to develop a mechanistic understanding of the 
assembly of multidrug efflux complexes in Gram negative bacteria, particularly the 
assembly and disassembly at the MFP-OMC interface. This can be split into smaller 
aims: 
1. Identify the interfaces presented by partner proteins for functional 
interaction. 
2. Assign a role for positions within each interface with respect to the binding-
extrusion-disassembly process. 
3. Derive a dynamic model of complex assembly and disassembly. 
To progress towards these aims, this project has the following objectives: 
1. Make strains of E. coli suitable for analysing TolC and AcrA function in vivo, 
namely being a suitable knockout strain with a suitable expression plasmid. 
2. Generate a library of mutations in both tolC and acrA that might impact the 
interface between the TolC and AcrA proteins. 
3. Identify which mutations likely have an effect on efflux pump function by 
screening the mutations using in vivo functional assays. 
4. Confirm that the effects observed are due to functional effects and not due 
to low protein production or protein instability. 
5. Confirm that the effects observed are due to a difference in efflux activity 
and not due to other effects on general cellular function, using purified 
protein for in vitro assays. 
6. Identify whether pump deficiencies are due to loss of interaction, or whether 
a non-function complex forms, using in vitro assays. 
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2.1 Bacterial strains used in this study 
E. coli strains BW25113 (Datsenko & Wanner, 2000), the BL21-derivative C43(DE3) 
(Miroux & Walker, 1996), and the Keio collection strains (Baba et al., 2006) JW5503 
(here referred to as BW tolC::aph), JW0451 (BW acrB::aph) and JW0452 (BW 
acrA::aph) were provided by Dr Faye Morris in the laboratory of Professor Ian 
Henderson at University of Birmingham. Strains C43acrA::aph and C43acrB::aph were 
made by P1 transduction from the relevant Keio collection strains. Strain C43 
tolC::aph was made by homologous recombination with PCR products. Strains 
BWΔtolC, BWΔacrA, C43ΔacrA, C43ΔacrB and C43ΔtolC were made by curing of the 
aph cassette using pCP20, as described at the end of Section 2.7.1. 
Table 2:1 – List of strains used in this study, and their genotypes 
Strain Genotype Description Source 
MG1655 F-, lambda-, rph-1 A "wild-type" E. coli 
laboratory strain 
 
(Blattner et al., 1997) 
BW25113 F-,  
DE(araD-araB)567,  
lacZ4787(del)::rrnB-




A "wild-type" E. coli 
laboratory reference strain, 
the parental strain for the 
Keio library  
(Datsenko & Wanner, 
2000) 
BW acrA::aph As BW25113, 
additionally acrA 
BW25113 with the acrA 




(Baba et al., 2006) 
BW acrB::aph As BW25113, BW25113 with the acrB (Baba et al., 2006) 
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BW tolC::aph As BW25113, 
additionally tolC 
BW25113 with the tolC 




(Baba et al., 2006) 
BWΔtolC As BW tolC::aph, 
with aph gene 
replaced by Frt-
recognition scar 
BW tolC::aph with aph 
kanamycin marker removed 
by pCP20 
This study 
BWΔacrA As BW acrA::aph, 
with aph gene 
replaced by Frt-
recognition scar 
BW acrA::aph with aph 




(also referred to as 
C43) 
ompT, hsdSB (rB- 





differences to BL21 
strain) 
A laboratory strain of E. coli 
capable of expressing 
membrane proteins at 
higher levels than other 
strains, due to deficiency in 
the OmpT protease. 
Contains DE3 - the T7 
phage RNA polymerase 
under control of the Lac 
repressor. Differs from 
other strains developed for 
high expression by 
Miroux & Walker, 1996 
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unpublished mutations.  
 
C43 acrA::aph As C43, additionally 
acrA::aph 
C43 with the acrA gene 




C43 acrB::aph As C43, additionally 
acrB::aph 
C43 with the acrB gene 




C43 tolC::aph As C43, additionally 
tolC::aph 
C43 with the tolC gene 




C43 ΔacrA As C43 acrA::aph, 




C43 acrA::aph with aph 
kanamycin marker removed 
by pCP20 
This study 
C43 ΔacrB As C43 acrB::aph, 




C43 acrB::aph with aph 
kanamycin marker removed 
by pCP20 
This study 
C43 ΔtolC As C43 tolC::aph, 




C43 tolC::aph with aph 






2.2 Plasmids used in this study 
The plasmids pET26b and pKD46 were gifted by Dr Douglas Browning of University 
of Birmingham, and pCP20 was gifted by Dr Faye Morris. The vector pASK-IBA13plus 
was purchased from IBA-Lifesciences, and was converted to the vector of choice for 
the in vivo work in this study, pASK-RM, as described below. Plasmids 
pEX-K4-acrA(Δhelices) and pEX-K4-acrA(Δhairpin) were purchased from Eurogentec 
under the gene synthesis service. 
Plasmid pASK-RM was generated from pASK-IBA13plus by three rounds of site-
directed mutagenesis-type manipulation, as described in Section 2.5.7 (figures 
indicating the changes made are also in Section2.5.7 – Figures 3:1 to 3:4). The first 
round used the pASK-NdeI-F and pASK-NdeI-R primers, the second round used 
pASK-altNde-F and pASK-altNde-R primers, and the final round pASK-STOP-F and 
pASK-STOP-R primers. Incorporation of the required changes was tested by NdeI 
(New England Biolabs) digest, NdeI/XhoI (New England Biolabs) double digest or by 
sequencing using either the pASK-seq-F or pASK-seq-R primers. Digest reactions 
were set up according to manufacturer's instructions, and the digest incubations 
were 1 h at 37°C. Digests were resolved on 1% agarose stained with SYBRsafe 
(Invitrogen), against Hyperladder I (rebranded as 1 KB DNA ladder; Bioline), and 
visualised on a GelDoc system (Syngene).  
The plasmids pASK-acrAB and pASK-tolC were generated by restriction cloning 
(Sections 2.5.4and 2.5.5) of PCR products generated using the MG1655 chromosomal 
DNA as template (Sections 2.5.2 and 2.5.3) using primer pairs acrA-WT-F and 
acrB-WT-R or tolC-WT-F and tolC-WT-R. Mutant genes of tolC or acrA in the pASK-RM 
plasmid were generated by site-directed mutagenesis as described in Section 2.5.7 to 
generate pASK-tolC and pASK-acrAB variants, except for pASK-acrA(Δhelices) and 
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pASK-acrA(Δhairpin), which were generated by restriction cloning from 
pEX-K4-acrA(Δhelices) and pEX-K4-acrA(Δhairpin).  
Wild-type and mutant variants of tolC were cloned from pASK-RM to pET26b by 
restriction cloning directly from pASK-{gene} to generate pET26-tolC variants. Wild-
type and mutant variants of acrA were cloned by PCR amplification from the pASK-
{gene} plasmid using the acrA-WT-F and acrA-WT-R primer pair, and the PCR product 
ligated into the pET26b vector at the NdeI and XhoI sites to generate pET26-acrA 
variants. The pET26-acrB plasmid was generated via restriction cloning of PCR 
products generated by two rounds of PCR, first using the SL1344 strain as a template 
with the Salm-pWKS-F and Salm-pWKS-R primer pair, then using the resulting PCR 
product as template with the salm-acrB-F and salm-acrB-R primer pair – the product 
from this second PCR was used for restriction cloning into the pET26b vector.   
 
2.3 PCR primers 
Primers used in this study were obtained from Alta Bioscience (Abingdon Health, 
Birmingham, UK), Eurogentec (Liège, Belgium) or Thermo Fisher Scientific (Invitrogen 
or Life Technologies Limited, Paisley, UK). All primers were supplied de-salted by 
SePOP and stored as 100 mM in Tris-EDTA (TE) buffer at -20°C. For standard PCR 
reactions and mutagenesis, the primers were diluted to 10 mM with sterile distilled 
water (sdH2O; Gibco, Life Technologies) by ten-fold dilution, and this working stock 
was further diluted three-fold to 3.2 mM with dH2O for sequencing reactions. Each of 
the diluted stocks was stored at 4°C. Annealing temperatures for each primer pair 
were calculated using the IDTDNA OligoAnalyzer 3.1 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/), with parameters for 
primer, dNTP and divalent cation concentrations corrected for the relevant PCR 
systems. For a list of primer names and sequences used in this study, see Appendix 2. 
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2.4 Bacterial growth conditions 
Growth media were usually prepared from powders supplied by Oxoid, according to 
manufacturer’s instructions; when pre-mixed powders were not used, LB-broth (LBB) 
was prepared by dissolving 10 g tryptone, 5 g yeast extract and 5 g NaCl in 1 l of 
deionised water. For strains containing resistance markers, ampicillin or kanamycin 
were added to final concentrations of 100 μl.ml-1 or 50 μg.ml-1, respectively either to 
the cooled molten agar before pouring plates or to the broth before inoculation. For 
routine propagation of bacteria, cells were grown at 37°C overnight (12-16 h) on LB-
agar. When liquid cultures were required, cells were picked from colonies on agar 
plates into Universal bottles containing 5 ml LBB and incubated at 37°C overnight 
(12-16 h) with shaking at 180 rpm to provide aeration.  
2.5 Genetic manipulations 
2.5.1 Plasmid extraction 
For sequencing, plasmids were extracted using a Thermo Fisher GeneJET plasmid 
miniprep kit (product number K0503) as per manufacturer’s instructions, with elution 
from the column in 30 μl sdH2O. For routine laboratory use, isopropanol precipitation 
was used as described below. 
From overnight cultures, 3 ml culture was harvested by centrifugation at 21000 x g 
for 5 min at room temperature, and resuspended in 250 μl GTE (50mM glucose, 25 
mM Tris from pH8.0 stock, 10 mM EDTA). Cells were lysed by addition of 250 μl lysis 
buffer (1% SDS, 0.2 M NaOH), with gentle agitation by inversion of the tube, and 
incubated at room temperature for 5 minutes. Cell debris was precipitated by 
addition of 350 μl neutralisation buffer (3 M potassium, 5 M acetate), with gentle 
agitation by inversion of the tube and incubated on ice for 10 min before removal of 
the precipitate by centrifugation at 21000 x g at 4°C for 10 minutes. The supernatant 
was added to 600 μl isopropanol cooled to -20°C, mixed by inversion, and incubated 
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at -20°C for 30 minutes. The precipitated DNA was pelleted by centrifugation at 
21000 x g at 4°C for10 min, then the pellet washed with 200 μl 70% ethanol followed 
by 200 μl 100% ethanol. The ethanol was aspirated and any residual ethanol 
evaporated by incubating the open tubes at 65°C for 5 min, before the pellet was 
resuspended in 50 μl TE (10 mM Tris from pH8.0 stock, 0.1 mM EDTA). 
2.5.2 Chromosomal DNA extraction 
To extract chromosomal DNA, the same isopropanol precipitation approach was used 
as for plasmid extraction (Section 2.5.1), except that following addition of lysis 
buffer, the mixture was vortexed intensively for 1 min to shear the chromosome.  
2.5.3 PCR reactions 
Either the Q5 DNA-polymerase or MyTaq RedMix systems were used for PCR 
reactions, depending upon their purpose. For screening purposes, MyTaq RedMix was 
used, using 25 μl of the pre-mix, 1 μl of template, 2.5 μl of each primer from 10 mM 
stocks, and 19 μl sdH2O. For normal PCR reactions, template refers to the plasmid 
prep, while for “colony” PCR, a 1 ml culture was incubated under appropriate growth 
conditions for 2 h, cells harvested by centrifugation at 20000 x g for 5 min at room 
temperature, and the cells resuspended in 50 μl sterile water before boiling at 99°C 
for 30 min to form the template solution. For purposes where sequence fidelity is 
essential, such as cloning, Q5 polymerase was used. The Q5 reaction mix consisted of 
0.5 μl Q5 polymerase, 10 μl Q5 buffer, 10 μl Q5 GC enhancer, 1 μl template, 2.5 μl of 
each primer from 10 mM stocks and 23 μl Gibco sterile distilled water. The reaction 
cycles are set out in Table 2:2. 
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Table 2:2 - PCR reaction cycle conditions 
 Q5 MyTaq 
1x Initial denaturing 98°C, 5 min 95°C, 5 min 
30 cycles 
Denaturing 98°C, 30 s 95°C, 20 s 
Annealing 20 s, primer-specific  15 s, primer-specific  
Extension 72°C, 1 min per kb 68°C, 30 s per kb 
1x Final extension 72°C, 2 min + 1 min/kb 68°C, 2 min + 30 s/kb 
 
2.5.4 Restriction digest conditions 
Restriction enzymes were purchased from New England Biolabs. Digests were set up 
using 0.5 μl of each restriction enzyme required, plus 5 μl of the 10x CutSmart buffer, 
5 μl PCR product or 20 μl plasmid miniprep to be digested, and made up to 50 μl with 
Gibco sterile distilled water. To vectors being cut to receive an insert, 1 μl calf 
intestinal phosphatase was also added. The reaction was incubated at 37°C for 12-16 
hours. Following restriction digest, if the change in fragment size would be too small 
to detect by agarose gel electrophoresis, DNA was purified by PCR clean-up kit 
(Qiagen). Where possible, digested fragments were analysed by agarose gel 
electrophoresis and extracted from the gel using a gel extraction kit (Qiagen).   
2.5.5 Ligation conditions 
To ligate DNA fragments, 1 μl T4 DNA ligase (NEB), 4 μl 5x T4 DNA ligase buffer, 5 μl 
digested vector and 10 μl digested insert were mixed and incubated on a 
thermocycler at 16°C for 1 h, 14°C for 1 h, 12°C for 2 h, 10°C for 2 h, 8°C for 30 min, 
6°C for 30 min and 4°C on hold until removed from the thermocycler (8-10 h). 
Ligations were used directly in transformations, without clean-up. 
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2.5.6 DNA sequencing 
DNA samples for sequencing were prepared as described in Section 2.5.1, using a spin 
kit. Primers were diluted to 3.2 mM in Gibco sterile distilled water, and 1 μl of the 
diluted primer added to 2 μl purified DNA and 7 μl Gibco sterile distilled water. The 
mixture was sequenced by the Functional Genomics facility at University of 
Birmingham. 
2.5.7 Site-directed mutagenesis 
Mutations were incorporated by site-directed mutagenesis with QuikChange 
Lightning (Agilent Technologies) according to the manufacturer's instructions 
(revision D). Mutagenesis primers were designed through the Agilent Technologies 
web-based QuikChange Primer Design tool, optimised for the Lightning system. 
Plasmid preparations from BW25113 (WT) or MG1655 (WT) were used as templates 
for the mutagenesis PCR. Following mutagenic PCR, the template was digested by 
DpnI enzyme supplied with the mutagenesis kit as per the manufacturer's 
instructions with the exception of the incubation time being increased to 30 min. The 
mutagenesis product was used to transform BW25113 according to the TSS 
transformation approach (as described in Section 2.6.1); if no colonies were formed, 
the approach was repeated but the transformation was into XL-10 Gold cells, using a 
heat-shock approach as per supplier’s instructions.  
For mutagenesis that failed using the complementary primer (QuikChange) 
approach, a blunt-end ligation approach was used instead. New primers were ordered 
with the mutation at the 5’- end of one primer or, for larger mutations, the mutation 
split over the 5’- ends of both primers in the pair. These primers were diluted to 10 
mM in sdH2O and phosphorylated with T4 polynucleotide kinase (NEB) by mixing 5 μl 
each primer in the pair, 5 μl T4 polynucleotide kinase buffer, 4.5 μl 11 mM ATP, 0.5 μl 
T4 polynucleotide kinase enzyme and 30 μl sdH2O, and incubated at 37°C for 2 hours. 
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The phosphorylated primers were used in a Q5 PCR reaction to amplify the entire 
plasmid. The PCR product was purified using a PCR clean-up kit as per manufacturer’s 
instructions, and subsequently used in a self-ligation reaction (as described in Section 
2.5.5, but sdH2O replaced the insert). The ligation mixture was used directly in 
transformation of BW25113 cells using the TSS approach as described in Section 
2.6.1. 
Transformant colonies were picked into overnight cultures in selective LBB and 
incubated at 37°C (180 rpm) 12-16 h, plasmids extracted as described in Section 2.5.1 
and sequenced as described in Section 2.5.6. 
 
2.6 Preparation and transformation of competent cells  
2.6.1 Chemically competent cells 
Cells were made chemically competent using the single-step transformation and 
storage solution (TSS) approach, as published (Chung et al., 1989). Namely, cells were 
picked from a colony into 5 ml LBB and incubated at 37°C for 12-20 h with shaking at 
180 rpm. The overnight culture was diluted 1 in 1000 into 100 ml fresh LBB and 
incubated at 37°C with shaking at 180 rpm until OD600 was between 0.3 and 0.6, with 
OD readings beginning after 2 h incubation. The culture at OD600 0.3-0.6 was 
incubated on ice for 30 min before the cells were harvested by centrifugation of a 
total of 80 ml culture at 4000 xg at 4°C for 10 minutes. Cell pellets were resuspended 
in 8 ml total ice-cold TSS (LBB supplemented with 10% (w/v) PEG-4400, 5% (v/v) 
DMSO and 25 mM Mg2+ ions (provided by addition of solution containing 1.25 M 
MgSO4 and 1.25 M MgCl2)). Resuspended cells were aliquoted to 100 μl in cold 
microcentrifuge tubes and stored at -80°C until use.  
62 
 
Cells made chemically competent in TSS were transformed by addition of DNA, the 
volume of which was dependent upon the source of the DNA, and incubated on ice 
for 30 minutes. Recovery solution, termed TSR (for TSS-recovery) consisting of LBB 
supplemented with  20 mM glucose was added (900 μl) and the recovering cells 
incubated at 37°C, unless otherwise specified, for 1 hour. Following recovery, cells 
were harvested by centrifugation at 20000 xg for 5 min at room temperature, the 
supernatant decanted and the cells resuspended in the residual supernatant, all of 
which was subsequently spread onto selective LB-agar medium (supplemented with 
100 μg.ml-1ampicillin, 50 μg.ml-1 kanamycin or 50 μg.ml-1 chloramphenicol). 
Transformants were selected after overnight incubation at 37°C on selective 
medium.   
2.6.2 Electrocompetent cells 
Note: any incubation at 37°C was changed to 30°C for any strains harbouring the pCP20 
or pKD46 plasmids. 
Cells were picked from a colony into 5 ml LBB and incubated at 37°C for 12-20 h with 
shaking at 180 rpm. The overnight culture was diluted 1 in 1000 into 1 l fresh LBB and 
incubated at 37°C with shaking at 180 rpm until OD600 was between 0.3 and 0.4, with 
OD readings beginning after 2 h incubation. Once OD600 was between 0.3 and 0.4, the 
culture was transferred to ice and incubated on ice for 30 min before harvesting the 
cells by centrifugation at 4000 xg at 4°C for 20 minutes. The cell pellets were 
resuspended in a total of 200 ml ice-cold sterile water (Ultrapure water from an Elga 
water purifier was filter sterilised by passing through a membrane with pore size of 
0.22 μm – larger volumes in Stericup units (Corning); smaller volumes by Millex 
syringe filter (Merck Millipore)) and harvested again by centrifugation at 4000 xg at 
4°C for 20 minutes. The cell pellets were resuspended in a total of 100 ml ice-cold 
sterile water and harvested by centrifugation at 4000 xg at 4°C for 20 minutes. Cells 
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were resuspended in a total of 40 ml ice-cold 10% glycerol, harvested once more by 
centrifugation at 4000 xg at 4°C for 20 minutes and resuspended in a total of 1 ml ice-
cold 10% glycerol. Cells were then aliquoted to 100 μl in cold microcentrifuge tubes 
and stored at -80°C until use. 
Electro-competent cells were transformed by addition of 1-5 μl DNA added to the 
cells on ice, mixed gently by movement of the pipette tip within the cell suspension. 
The mixture was incubated on ice for 5 min before being transferred to an ice-cold 
electroporation cuvette with 1 mm electrode gap. The cells were then immediately 
subjected to a 1600 V electrical pulse, and 900 μl LBB added. The resulting solution 
was transferred to a microcentrifuge tube and incubated at 37°C for 1 h to recover. 
Following recovery, cells were harvested by centrifugation at 20000 xg for 5 min at 
room temperature, the supernatant decanted and the cells resuspended in the 
residual supernatant, all of which was subsequently spread onto selective LB-agar 
medium. Transformants were selected after overnight incubation at 37°C on 
selective medium.  
 
2.7 Chromosomal gene deletion 
2.7.1 P1 phage transduction 
Deletions of the acrA or acrB genes were made in the chromosome of E. coli strain 
C43(DE3) by P1 phage transduction, using the Keio collection knockout strains 
JW0452 and JW0451 as donors (Baba et al., 2006). The donor strain was grown as  
1 ml culture in Lennox broth supplemented with CaCl2 to a final concentration of  
2 mM, at 37°C (180 rpm) for 12-16 h in a Universal bottle. From this culture, 500 μl 
was removed and the culture replenished with the same volume of Lennox broth 
supplemented with CaCl2 to a final concentration of 2 mM, and the new culture 
incubated at 37°C (180 rpm) for 5 h. After 5 h incubation, 100 μl each of the culture 
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and of diluted P1 phage stock were added to soft agar overlay consisting of 1 ml 
Lennox agar and 2 ml Lennox broth at 45°C. The overlay with P1 phage and the donor 
bacterial strain was vortex-mixed before being poured over a Lennox agar plate 
supplemented with glucose to a final concentration of 0.2% and CaCl2 to a final 
concentration of 2 mM, and incubated at 37°C for 12-16 h. From plates displaying a 
plaque following this overnight incubation, the soft agar was harvested with 2 ml 
Lennox broth, and homogenised in 1 ml chloroform on ice in a pre-chilled glass 
homogeniser before being transferred to a 15 ml centrifuge tube and spun at  
4000 xg (4°C) for 15 min in a benchtop centrifuge. The supernatant, including the 
chloroform, was collected in Universal bottles and stored at 4°C as P1-{gene} stock. 
A culture of the recipient strain (1 ml in Lennox broth supplemented with CaCl2 to a 
final concentration of 2 mM) incubated for 12-16 h at 37°C (180 rpm) was transferred 
from a Universal bottle to conical flask containing 20 ml of the same medium and 
incubated at 37°C (180 rpm) for 5 h. The cells were then harvested by spinning 5 ml 
aliquots in 15 ml centrifuge tubes at 4000 xg for 3 min and the pellet resuspended in 
500 μl Lennox broth supplemented with CaCl2 to a final concentration of 2 mM. To 
these cells, 100 μl of the P1-{gene} stock and dilutions thereof (ten-fold in Lennox 
broth, to a final 1 in 100 by a second (serial) dilution) was added, and the cells plus 
phage incubated at 45°C for 20 min in a waterbath. The bacterial cells were then 
washed of phage by harvesting the cells by spinning at 4000 xg for 3 min and washed 
by resuspending in 4 ml phosphate buffered saline solution (PBS), repeated to a total 
of 3 washes. When washed three times, the cells were harvested again, resuspended 
in 2 ml Lennox broth, and incubated at 37°C for 1 h for cell recovery. The recovered 
cells were harvested by centrifugation at 4000 xg for 3 min and resuspended in  
200 μl PBS, all of which was spread onto plates of LB-agar supplemented with  
50 μg.ml-1 kanamycin. The plates were incubated at 37°C overnight (12-16 h) to select 
for transductant cells.  
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Colonies from transduction were screened by colony PCR using the seq-{gene}-upst 
and seq-{gene}-dnst primers with Q5 DNA Polymerase PCR, using an amplification 
step of 3 min to ensure adequate time for extension of the entire gene. The PCR 
products were resolved on 1% agarose gels stained with SYBRsafe and visualised on 
a GelDoc system (Syngene), against HyperLadder I. PCR products of the expected size 
were purified from the remainder of the PCR product using a PCR clean-up kit 
(Qiagen), and the PCR product sequenced (Functional Genomics Facility, University of 
Birmingham) using each of the up- and down-stream primers for the respective gene.  
Colonies for which sequencing had shown the aph (KanR) replacement of the target 
gene were made competent using the TSS method, and transformed with pCP20 
using a modified TSS approach in which the recovery step was increased to 80 min at 
room temperature (18-26°C) and the overnight incubation temperature was 30°C. 
Transformants were selected for on ampicillin. Colonies resistant to ampicillin were 
inoculated to non-selective LB-agar plates and incubated overnight (16-20 h) at 43°C. 
From this plate, colonies were picked with a pipette tip containing 1 ml LBB and 
expelled into microcentrifuge tubes, spun for 5 min at 15000 x g and the cell pellet 
resuspended in 10 μl LBB, of which 3 μl was spotted onto each of LB-agar, Kan and 
Amp plates, and incubated overnight (16-20 h) at 37°C, 37°C and 30°C respectively. 
Clones susceptible to kanamycin were retained with the chromosomal marker having 
been removed, and clones susceptible to both kanamycin and ampicillin were 
retained as having additionally been cured of the pCP20 plasmid. When pCP20 was 
retained in all colonies, the process was repeated with a colony from the latest LB-
agar plate being inoculated to fresh LB-agar and incubated at 43°C overnight. 
2.7.2 Homologous recombination of PCR products 
The strain C43ΔacrB tolC::aph was made essentially from a shortcut approach to the 
commonly used approach developed by Datsenko and Wanner (Datsenko & Wanner, 
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2000). Chromosomal DNA from BWtolC::aph was isolated as described in Section 
2.5.2, and the tolC::aph cassette amplified by PCR as described as in Section 2.5.3 
using Q5 and the tolC-upst-seq-f and tolC-dnst-seq-R primer pair, which anneal 430-
406 bp upstream of the tolC start site and 462-481 bp downstream of the tolC stop 
site, respectively. The PCR product was analysed by agarose gel electrophoresis and 
purified from the gel.  
Electrocompetent C43ΔacrB (DE3) cells were transformed with the recombination 
helper plasmid pKD46. Transformants were made electro-competent as described in 
Section 2.6.2, with the addition of 10 mM arabinose and 100 mg.ml-1 ampicillin to the 
1 l culture. Electro-competent C43ΔacrB (DE3) pKD46 cells were transformed with  
5 μl of the above PCR product, with overnight outgrowth at 42°C on LB-Kan agar 
plates to cure the cells of the pKD46 plasmid and select for tolC::aph recombinant 
cells. Candidates were screened by PCR using the tolC-upst-seq-F and tolC-dnst-seq-R 
primer pair to check for the tolC::aph mutation.  
C43ΔacrB tolC::aph (DE3) strains were cured of the aph marker by use of pCP20, as 
described in Section 2.7.1 above, but using an electro-competent approach rather 
than TSS.  
2.8 Minimum inhibitory concentration (MIC) assays 
All MIC assays were designed to comply with standards set out by the British Society 
of Antimicrobial Chemotherapy (BSAC), in accordance with the guidelines updated in 
2006 and made available online as the latest version in 2012 (Andrews, 2012).  
2.8.1 Liquid broth MIC 
Cells were picked from colonies into 5 ml selective LBB (supplemented with 
appropriate antibiotic to select for the plasmid) and incubated overnight (16-20 h) at 
37°C with shaking at 180 rpm. Subject antibiotics were diluted in Iso-sensitest broth 
(Oxoid) to a concentration quadruple the expected MIC of the wild-type control 
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strain, based on previous data from literature sources and within the laboratory 
group, and anhydrotetracycline added to appropriate concentration. To all wells in 
columns 2-12, 50 μl Iso-sensitest broth containing anhydrotetracycline at appropriate 
concentrations was added. To all wells in columns 1 and 2, 50 μl antibiotic in Iso-
sensitest broth was added. The antibiotic was diluted through columns 2-11 by serial 
dilution, transferring 50 μl from one column to the next and mixing by pipette. 
Following serial dilution, 50 μl of solution was removed from all wells in column 11, 
making the total volume 50 μl in all wells on the plate. Antibiotic was not diluted into 
column 12, which instead contained only Iso-sensitest broth to act as a positive 
growth control.  
Overnight cultures were diluted by two-step dilution to 1 in 2000 in sterile water. Of 
the diluted cultures, 50 μl was added to each well in a row on the 96-well plate (one 
row per strain). As a negative control, row H was not inoculated. The 96-well plate 
was covered with a corresponding lid, and then incubated at 37°C overnight (12-16 h) 
with no shaking. Following overnight incubation, the OD600 was measured on a 
Fluostar plate reader. 
2.8.2 Agar dilution MIC 
Cells were picked from colonies into 5 ml selective LBB (supplemented with 
appropriate antibiotic to select for the plasmid) and incubated overnight (16-20 h) at 
37°C with shaking at 180 rpm. Subject antibiotics were diluted to 10000, 1000, 100 
and 10 mg.ml-1 in appropriate solvent. Into labelled sterile plastic universal bottles, 
antibiotic solution was added at volumes appropriate for the final concentration of 
the antibiotic in the agar plates, before addition of agar. Iso-sensitest agar (Oxoid) 
was melted and allowed to cool to 50°C before addition of anhydrotetracycline to 
appropriate concentration. Agar supplemented with anhydrotetracycline was 
dispensed by Perifill to aliquot 20 ml into the universal bottles containing subject 
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antibiotic. Immediately upon dispensing of agar, the universal was swirled to mix the 
antibiotic and agar, and the agar poured to appropriately labelled petri dish.  
Overnight cultures were diluted 1 in 100 in sterile water and transferred to a multi-
point inoculator template tray. The plates were inoculated by multi-point inoculator 
and incubated at 37°C overnight (12-16 h). Levels of growth were recorded for each 
strain on each plate to determine the minimum antibiotic concentration at which the 
strain was inhibited, based upon visual perception of the colony density.  
2.8.3 Chequerboard assays 
Cells were picked from colonies into 5 ml selective LBB (supplemented with 
appropriate antibiotic to select for the plasmid) and incubated overnight (16-20 h) at 
37°C with shaking at 180 rpm. Fusidic acid was diluted to 2048 μg.ml-1 and, 
separately, anhydrotetracycline to 512 ng.ml-1 in Iso-sensitest broth. 
To columns 2-12 of a 96-well plate, 50 μl Iso-sensitest broth (with no supplements) 
was added. From the above fusidic acid stock, 50 μl was added to every well in the 
first two columns of the 96-well plate, and the second column used as the starting 
point for step-wise dilution through columns 3-11, transferring 50 μl from one 
column to the next, with mixing by pipette at each step. From column 11, 50 μl was 
then removed and discarded. From the above anhydrotetracycline stock, 50 μl was 
added to every well in the first row. Anhydrotetracycline was diluted by step-wise 
transfer of 50 μl from the first row through each subsequent row, to the seventh 
row, and 50 μl removed from the seventh row. The final concentrations in each 
column and row are shown in  Figure 2:1. 
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Figure 2:1 - Layout of chequerboard assays 
Each row (A-H) contains a different concentration of anhydrotetracycline, while each 
column (1-12) contains a different concentration of fusidic acid. The values indicate 





Following overnight growth, cultures were diluted 1 in 2000 in Iso-sensitest broth, by 
1 in 100 dilution followed by 1 in 20 dilution. To each well on the 96-well plate, 50 μl 
of this cell suspension was added. A corresponding 96-well plate lid was put over the 
plate, and the plate was then incubated at 37°C for 24 h without agitation. Following 
incubation, the plate was read on a Fluostar plate reader and OD600 values recorded.  
 
2.9 Growth kinetics 
To 100 ml Iso-sensitest broth, anhydrotetracycline was added to a final concentration 
of 2 ng.ml-1 and the test antibiotic to the final concentration as required. The mixture 
was then filter sterilised in a Stericup and stored at 4°C for a maximum of two days 
until use. 
Single colonies were inoculated into 2 ml LBB supplemented with 100 μg.ml-1 
ampicillin and 2 ng.ml-1 anhydrotetracycline, in Universal bottles and incubated at 
37°C with shaking at 200 rpm for 8 hours. Cells were harvested from 100 μl of these 
cultures by centrifugation (20000 x g for 5 min at room temperature), the 
supernatant removed by aspiration, and the cells resuspended in 1 ml Iso-sensitest 
broth supplemented with 2 ng.ml-1 anhydrotetracycline. Cells were kept on ice to 
prevent growth in the fresh medium whilst handling. To every well on a 96-well plate, 
190 μl Iso-sensitest broth supplemented with anhydrotetracycline (final 
concentration of 2 ng.ml-1) was added. From the cell suspensions, 10 μl was added to 
wells on the 96-well plate, and the positions recorded – the layout was such that the 
complete set of strains to be analysed were present thrice – in wells A1-C8, C9-F4 and 
F5-H12 – allowing two wells in each set to not be inoculated, as negative controls. 
This plate formed a template, from which the assay plates could be quickly 
inoculated by use of a multi-channel pipette. 
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Assay plates were set up from the pre-prepared broth stocks with test antibiotic and 
anhydrotetracycline already added. Three assay plates were set up in parallel. To 
every well in each of the three groups of wells (A1-C8, C9-F4 and F5-H12), 200 μl 
stock broth was added; broth containing different antibiotics was added to each of 
the groups, for example broth containing vancomycin to all wells in A1-C8, broth 
containing deoxycholic acid to all wells in C9-F4 and broth containing fusidic acid to 
all wells in F5-H12. Assay plates were inoculated by transfer of 2 μl from wells in the 
template plate to the same positions on the assay plate. Each plate was sealed with a 
Breathe-Easy membrane (Diversified Biotech), and placed in a Fluostar plate reader – 
one plate each into the three readers. 
Each of the Fluostar plate readers was set up with the same programme. Machines 
were pre-warmed to 37°C whilst plates were being prepared. The plates were 
incubated at 37°C throughout the assay, with orbital shaking at 200 rpm between 
read cycles. The OD600 was measured every 3 min for 8 h using 10 flashes per well per 
read.   
 
2.10 Dye efflux assays 
Efflux assays using Nile Red as the substrate were modified from previously 
published methods (Bohnert et al., 2010; Iyer et al., 2015). Cells were picked from 
colonies into5 ml LBB supplemented with 100 μg.ml-1 ampicillin, in Universal bottles 
and incubated at 37°C with shaking at 200 rpm for 12-16 hours. From the overnight 
culture, 5 μl was used to inoculate 5 ml fresh LBB supplemented with 100 μg.ml-1 
ampicillin and 2 ng.ml-1 anhydrotetracycline, and subsequently incubated at 37°C with 
shaking at 180 rpm for 2 h to allow cultures to reach late exponential phase. Cells 
were harvested from 1 ml of this culture by centrifugation at 21000 x g for 5 min at 
room temperature, while the OD600 was measured from a further 1 ml of culture. Cell 
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pellets were resuspended in phosphate buffered saline (PBS, prepared from tablets) 
in a volume equal to the OD600 of that culture (example: if the culture OD600 was 
0.625, then 625 μl PBS was used), to equalise cell density of each sample. Of the 
resuspended cells, 150 μl were added to a clean microfuge tube, to which 1.7 μl  
10 mM CCCP and 16 μl 50 μM Nile Red were subsequently added. The cells were 
incubated at room temperature for 1 h in this solution. Free Nile Red and CCCP were 
removed by harvesting of the cells (21000 x g for 5 min at room temperature), 
aspiration of the supernatant that contains the free Nile Red and CCCP, and 
subsequent resuspension of the cell pellet in 150 μl fresh PBS.  
To each well on a black-sided tissue-culture treated 96-well plate (4titude), 150 μl 
PBS was added. Pre-loaded cells (25 μl) were added to the wells and the plate 
transferred to a Fluostar plate reader, pre-heated to 37°C. The OD600 was measured 
as a single step, before changing to fluorescence mode. The fluorescence in each well 
was measured with excitation at 550 nm and emission at 640 nm with 27 s between 
readings in plate mode or 2 s between readings in well mode. This was measured for 
5 readings before injection of 25 μl 70 mM glucose by the automated injector on the 
Fluostar. Readings were continued for 25 readings post-injection.  
 
2.11 Flow cytometry 
Cells were picked from colonies into 5 ml LBB supplemented with 100 μg.ml-1 
ampicillin and incubated at 37°C for 12-16 h with shaking at 180 rpm. From the 
overnight culture, 50 μl was used to inoculate 5 ml fresh LBB supplemented with  
100 μg.ml-1 ampicillin and 2 ng.ml-1 anhydrotetracycline (except where specified). This 
culture was grown for 3 h to get cells in late exponential or early stationary phase, at 
which point 1 ml was used to measure OD600 and 200 μl of the culture was harvested 
by centrifugation at 21000 x g for 5 min at room temperature and the cell pellet 
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resuspended in 200 μl 1x HEPES-buffered saline (Alfa-Aesar). For cultures that had 
OD600 greater than 0.7, 10 μl of the cell suspension and 90 μl HEPES-buffered saline 
were added to 500 μl HEPES-buffered saline, while for cultures with OD600 less than 
0.7, 100 μl of the cell suspension was added. To this, 5 μl ethidium bromide stock 
solution (10 mM) and 10 μl Syto 84 (Thermo Fisher Scientific) solution (0.5 mM) were 
added, to form the cell suspensions used for flow cytometry. The cell suspension for 
use in flow cytometry was vortexed briefly (less than 3 s), incubated for a minimum 
of 5 min at room temperature. Immediately prior to loading to the Attune flow 
cytometer, samples were vortexed briefly again. 
 
2.12 Isolation of membranes and protein purification 
2.12.1 Cell growth and lysis 
For high level expression of membrane proteins, genes were cloned to the pET26b 
vector and the relevant C43 (DE3) knockout strains were transformed with the 
resultant plasmids. Cells were picked from colonies to 5 ml LBB supplemented with 
50 μg.ml-1 kanamycin, and incubated at 37°C with shaking at 200 rpm for 16-20 hours. 
The overnight culture was used to inoculate 1 l of 2YT broth supplemented with  
50 μg.ml-1 kanamycin and pre-warmed to 37°C, in 2.5 l conical flasks. This culture was 
then incubated at 37°C with shaking at 120 rpm for 2 h, from which point 1 ml 
samples were taken at appropriate time intervals to monitor growth. When the 
culture reached OD600 0.3 to 0.5, IPTG was added to a final concentration of 10 μM to 
induce protein expression. Incubation continued for a further 20 h post-induction at 
20°C and shaking at 120 rpm. Cells were harvested by centrifugation at 6000 x g for 
30 min at 4°C, resuspended in 30 ml Tris/ NaCl resuspension buffer (20 mM Tris 
pH8.0, 200 mM NaCl) and frozen at -80°C for at least 3 hours before lysis. Frozen cell 
suspensions were thawed with manual agitation at room temperature, and 
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transferred to incubate on ice when almost thoroughly thawed. Once thawed, cells 
were disrupted on a One Shot cell disruptor (CellD SARL, Roquemaure, France) at 
30000 PSI with at least three passes of each suspension on the machine, until it 
appeared from the consistency of the material that lysis was complete.  
2.12.2 Membrane isolation 
Cell debris was removed from the suspension of lysed cells by centrifugation at 
10000 x g for 30 min at 4°C. The membrane fraction was harvested by 
ultracentrifugation of the supernatant at 120,000 x g for 1 h at 4°C. Membranes were 
transferred from the ultracentrifuge tube to a glass homogeniser using a sterile 2 ml 
plastic inoculation loop. The membranes were then resuspended in 2 ml Tris/glycerol 
solution (20 mM Tris pH6.8, 10% glycerol) by homogenisation on ice.  
2.12.3 Membrane protein purification 
To the 2 ml homogenised membranes isolated in Section 2.12.2, stock solutions were 
added to make the volume up to 10 ml and convert the solution composition to that 
of the membrane solubilisation buffer in Table 2:3. To solubilise the membrane 
proteins, the homogenised membranes were incubated in this solution for 12-16 h at 
4°C on a carousel rotating at 10 rpm and set at approximately 45° from vertical. Any 
remaining insoluble parts were removed by centrifugation at 120,000 x g for 1 hour 
at 4°C and only the supernatant retained.  
Table 2:3 - Buffers used in membrane protein purification. 
 Solubilisation Equilibration Wash Elution 
Tris(pH8.0) 20 mM 20 mM 20 mM 20 mM 
NaCl 500 mM 0 0 0 
Glycerol 10% 10% 10% 10% 
Detergent 1% 0.01% 0.01% 0.01% 




To a gravity flow column, 2 ml of Ni-NTA saturated ethanol was added. The resin was 
washed with 10 ml ethanol (100%) and twice with 20 ml of Ultrapure water, before 
equilibration by two washes with 20 ml of the equilibration buffer in Table 2:3. Once 
the level of buffer had dropped to the top of the resin, the solubilised membrane 
was added. To ensure maximum binding, the flow-through of the solubilised 
membrane was re-applied to the resin and allowed to flow through a second time. 
The protein-bound resin was washed twice with 10 ml resin wash solution in Table 2:3 
and the proteins eluted in 10 ml resin elution buffer in Table 2:3.Purified proteins 
were concentrated by spinning at 4000 x g for 5 min through Amicon-15 concentrator 
cartridges (Merck Millipore; 30 kDa variant for AcrA, 100 kDa variant for AcrB or 
TolC), desalted by passing through a PD-10 desalting column and eluting in 3.5 ml 
resin elution buffer in Table 2:3, followed by concentrating as before.  Protein 
concentration was estimated by Nanodrop measurement, and the purified proteins 
stored at -20°C until use. 
 
2.13 SDS-PAGE, Coomassie staining and Western blots 
Polyacrylamide gels were cast manually using the recipes in Table 2:4. Protein or 
membrane samples were prepared for gel resolution by addition of a loading buffer 
to a final 1x concentration (10% glycerol, 50 mM Tris (pH6.8), 2% SDS, 0.01% 
bromophenol blue and 1% β-mercaptoethanol, modified slightly from that described 
by Laemmli, 1970). To avoid aggregation of proteins, samples were not boiled. 
Prepared samples were loaded to the wells of the gels and resolved with SDS running 
buffer (0.3% w/v Tris, 1.4% w/v glycine, 0.1% w/v SDS) with 40 V applied whilst the 
proteins moved through the stacking gel and 100 V applied for the resolution. Gels 
were run until the dye in the loading buffer was observed to be at the bottom edge 
of the gel. 
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Table 2:4 - Recipes for SDS-polyacrylamide gels. 
 Resolving gel Stacking gel 
Water 3.9 ml 2.7 ml 
Tris 2.5 ml (1.5 M, pH 8.0) 500 μl (1.0 M, pH 6.8) 
Protogel (National Diagnostics) 3.3 ml 670 μl 
10% SDS 100 μl 40 μl 
10% APS 100 μl 40 μl 
TEMED 5 μl 4 μl 
 
 Gels not being subjected to a Western blot were stained with Coomassie blue. Gels 
were rinsed briefly with Ultrapure water, then incubated in staining solution (0.1% 
w/v Coomassie Blue G-250, 40% methanol, 10% acetic acid), such the entire gel was 
submerged, at room temperature with gentle agitation on a 2D rocking plate for 12-
16 hours. The stain solution was removed, and the gel rinsed with tap water to 
remove any residual solution. To destain the gel, it was incubated in destain solution 
(20% methanol, 5% acetic acid) with gently agitation on a 2D rocking plate at room 
temperature. The destain solution was replaced after 15, 30, 45, 60 and 120 minutes, 
and every 60 minutes thereafter until the background staining of the gel was 
sufficiently removed. 
For Western blotting of the proteins of the gel-resolved proteins, a semi-dry 
approach was used on the iBlot transfer system. Using the sandwich prepared as per 
manufacturer’s instructions, with filter paper and membranes having been soaked in 
water, the proteins were transferred to nitrocellulose (TolC) or PVDF (AcrA) 
membranes, using 8 min transfer time. For all subsequent incubations and washes, 
the solution was gently agitated on a 2D rocker plate, unless stated otherwise. 
Membranes with the proteins bound were then blocked in a tris-buffered saline 
buffer with 10% (v/v) Tween-20 (TBS-T) and 5% (w/v) skimmed milk, by incubation for 
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2 h at room temperature. Membranes were washed 3 times for 5 min per wash in 
TBS-T, before incubation in 25 ml blocking buffer (TBS-T with 5% milk) with 1 μl 
α-AcrA or 1 μl α-TolC rabbit-raised polyclonal antibody solution (gifted to the 
laboratory of Laura Piddock by Helen Zgurskaya) added. Membranes were incubated 
with the antibodies at 4°C for 12-16 h with agitation on a 2D plate rocker, then 
incubated for 30 min at room temperature. The antibody/blocking solution was 
removed, and the membrane rinsed with Ultrapure water before washing thrice for 
15 min per wash in TBS-T buffer. Goat-raised anti-rabbit alkaline phosphatase 
conjugated secondary antibody was used for detection. From the supplier’s antibody 
solution, 0.5 μl was added to 50 ml blocking buffer, and the membrane was incubated 
in this solution for 1 h at room temperature. The membrane was then washed three 
times for 10 min per wash in TBS-T, followed by a wash for 5 min in TBS lacking 
Tween20. To develop the blot, 2 ml BCIP/NBT solution (Thermo Fisher Scientific) was 
run over the membrane, ensuring equal coverage, constantly moving it across the 
membrane by pipetting until coloured bands had sufficiently developed. 
 
2.14 Glycerol gradients 
Solutions of glycerol were prepared at 2% increments, at minimum concentration 
10% and maximum concentration 28%. Into 3.5 ml ultracentrifuge tube inserts 
(Beckman Coulter), 300 μl of the glycerol solutions were added in order of 
concentration, with highest concentration first, and with freezing at -80°C between 
each addition to form layers of different glycerol concentration. Once all of the 
layers had been formed, the tube was allowed to thaw. 
Proteins were mixed with biotinylated amphipol (BA-Pol) at a 5:1 BA-Pol:protein 
ratio, by weight, in Ultrapure water. Combinations of AcrA, AcrB and TolC were 
mixed, adding 40 μg of any AcrA variant, 50 μg of any TolC variant and 120 μg of 
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AcrB. The mixtures were then loaded onto the top of the glycerol gradient, taking 
care not to disturb the layers. Ultrapure water was added to balance the tubes for 
ultracentrifugation. The protein-loaded gradients were spun at 100000 x g at 4°C for 
12 h on a benchtop ultracentrifuge. The gradient was fractionated by transfer of the 
top 100 μl to a unique well on a 96-well plate, until the entire gradient had been 
transferred. Each fraction was then treated as a protein sample for resolution by 
SDS-PAGE as in Section 2.13. 
2.15 Computational analyses 
JANUS is a programme designed to determine positions in a protein sequence that 
make up part of the active site of an enzyme (Addington et al., 2013). While TolC is 
not an enzyme, and therefore does not have an active site as such, JANUS was used 
with the idea that the interface with MFPs might be considered as the functionally 
important part of the protein.  The programme calculates importance from a series 
of sequence alignments, each of which must be similar proteins that have a different 
substrate and each of which must be based upon a structural alignment. The 
conservation at each position for each alignment is used to determine whether or not 
a position is important for that family of proteins – if a position is variable in proteins 
that perform the same function with the same substrate, then that position is highly 
unlikely to be important for the function of the protein, although this is calculated 
based on similarity, not identity. Next, the positions are compared between 
alignments – if a position shows conservation in both sets of sequences, then it is not 
responsible for determining specificity, regardless of whether or not it is important 
for function. The positions that are conserved only within the respective alignments, 
but not when comparing the two sets of alignments, are potentially important for 
determining specificity, and the scores for these positions are therefore calculated 
based upon an algorithm taking into account differences in size, charge and 
hydrophobicity between the two alignments.  
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All full-length sequences available in the UniProt database matching {gene: tolC AND 
organism: coli}, {(gene: tolC OR oprM) AND organism: Pseudomonas}, {gene: tolC 
AND organism: Vibrio} and {(gene: tolC OR mtrE) AND organism: Neisseria} were 
aligned using Clustal Omega. This alignment was then separated into four smaller 
alignments, one for each of E. coli, Pseudomonas spp., Vibrio spp. and Neisseria spp., 
keeping the same alignment positions as generated by Clustal Omega. The E. coli 
alignment was used as input file 1, with each of the other files used individually as 
input file 2. The output files were analysed to determine likely importance of 
positions only at or below the equatorial domain, as positions closer to the outer 
membrane are unlikely to be involved in an interaction with the cognate MFP. 
Positions at which the side chain faces into the lumen were also disregarded from 
this analysis, as they are also unlikely to contact the MFP. 
Results from JANUS were used in conjunction with Consurf (Ashkenazy et al., 2010), 
an online server which automatically generates sequence alignments based on a 
single pdb code as the input, scores the conservation at each position, and maps the 
categorised conservation score to the input pdb file. Partial sequences and duplicate 
entries were excluded from the alignment using the manual selection feature. 
Positions that show limited variability were taken to be those with potential to 
determine specificity of interaction with the MFP. Those that have a very low 
conservation score (hypervariable positions) were assumed to be unimportant, while 
those that showed maximum conservation are likely to be required for structural 
reasons and so were not selected for use in this study. 
To assess co-evolution of positions between MFPs and OMCs, a selection of MFP 
sequences were aligned and, separately, their cognate OMC sequences were aligned. 
The hairpin sequences were extracted from the MFP alignment, and the coiled-coil 
domains extracted from the OMC alignment. These extracts were combined, such 
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that the MFP hairpin and its cognate OMC formed a single sequence in a new 
multiple sequence alignment. This new chimaeric alignment was used as the input for 
CAPS (Fares & McNally, 2006), which assesses co-evolution of positions within a 






CHAPTER 3: RESULTS – GENETIC 




3.1 Making a compatible derivative of pASK-IBA13(plus) 
To generate a plasmid from which genes of interest could be expressed in a 
titratable fashion, with no tag, and from which the gene could easily be transferred 
to the pET26 vector for high expression of His-tagged protein, the pASK-IBA13plus 
vector was modified. First, the NdeI restriction site within the coding sequence of the 
tetracycline repressor protein was removed by silent mutation by site-directed 
mutagenesis using the pASK-altNde-F and pASK-altNde-R primer pair. To screen for 
loss of this NdeI restriction site, purified plasmid was digested in a double digest with 
XhoI and NdeI, whereby successful mutagenesis would cause a single band to seen on 
an agarose gel following this digest, as in Figure 3:1, as the DNA would cut only at the 
XhoI site.  
The resultant plasmid, designated pASK-IBA-/NdeI was subjected to a second round 
of mutagenesis using the pASK-NdeI-F and pASK-NdeI-R primer pair, to introduce a 
new NdeI restriction site at the transcriptional start site under control of the 
tetracycline promoter (Figure 3:2). To screen for gain of this restriction site, purified 
plasmid was digested with NdeI only, to see linearisation of the plasmid on an 
agarose gel, as a result of NdeI activity at the new restriction site; plasmids that were 
not mutagenised failed to cut, resulting in multiple bands corresponding to varying 
extents of supercoiling of circular DNA. The single bands were extracted from the 
agarose gel and digested with XhoI (Figure 3:3), to confirm that the NdeI activity seen 
was indeed at the new restriction site, and not as a result of failure to remove the 
original site in pASK-IBA13plus. From this XhoI digest, the multiple cloning site (MCS) 
alone would be excised and thus no observable change seen in fragment size if the 
NdeI site was in the new position - if the NdeI site had been the original, then the 
XhoI digest would result in fragments of 2.1 and 1.1 Kb in size. This plasmid was 
designated pASK-altNdeI as it has an alternative NdeI site to the original vector.  
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To allow expression of proteins resembling the wild type as far as possible, the tail 
sequence between the XhoI and three-frame STOP positions must be curtailed. A 
new STOP codon was therefore introduced adjacent to the XhoI site, on the 3'- side 
of the restriction site on the coding strand. This was done by a third round of 
mutagenesis, using the pASK-STOP-F and pASK-STOP-R primer pair. The final plasmid 
here could only be confirmed by sequencing (trace shown in Figure 3:4). The purified 
plasmid was therefore sequenced by Functional Genomics Facility at University of 
Birmingham, using the pASK-seq-F primer, and the plasmid sequence shown to be as 
designed. The final plasmid was designated pASK-RM. The STOP site is in-frame with 
the coding sequence provided that the gene of interest is amplified such that the 
CTC of the XhoI site on the PCR primer is in-frame to encode leucine. 
This new plasmid, pASK-RM, is a new derivative of the commercially available vector 
pASK-IBA13(plus), with added benefits, including a new NdeI site at the 
transcriptional start site, placing the START site 9 bases downstream of the Shine-
Dalgarno sequence. This allows very simple design of PCR primers for amplification 
of genes of interest, as the NdeI site can be incorporated into the primers at the 
START position. There is also a new STOP site adjacent and downstream of the XhoI 
site, allowing only a two amino acid (LE) “scar” tail sequence to be added to proteins 
expressed from a gene cloned into the NdeI and XhoI sites, allowing for a near-
natural protein sequence to be expressed. This in turn allows for easy transfer of 
genes of interest by NdeI/XhoI restriction cloning between this vector, suitable for in 
vivo studies, and the pET26b vector which encodes a hexa-histidine tag adjacent to 
and downstream of the XhoI site, for protein overexpression and purification. Genes 





Figure 3:1 - Restriction digest after removal of NdeI site from pASK-IBA13(plus). 
Gel resolution image of XhoI/NdeI double digests of two candidate plasmids 
resulting from site-directed mutagenesis of pASK-IBA13 to remove the NdeI 
restriction site (product designated pASK-IBA-/NdeI), and of the pASK-IBA13 vector 
used as the template for mutagenesis. Silent mutation resulted in loss of the NdeI 
restriction site at position 2438 of the plasmid map. Double digestion therefore acts 
as a single digest, only cutting at the XhoI restriction site at position 271, and gives a 
single band of the linearised full vector length (approximately 3 Kb). The pASK-IBA13 







Figure 3:2 - Restriction map of NdeI and XhoI sites in pASK-IBA13(plus) and its 
new derivative.  
A restriction map of the NdeI and XhoI sites from the original commercial vector 
pASK-IBA13(plus) and the modified vector pASK-altNdeI. The original NdeI site was 
located within the gene encoding the tetracycline repressor (labelled b on the 
diagrams), and a silent mutation was therefore made. Images generated using the 
NEBcutter online tool (http://nc2.neb.com/NEBcutter2/) and edited using GNU image 






Figure 3:3 - Restriction digests of second pASK-IBA13(plus) derivative. 
Top: NdeI digest on candidate plasmids resulting from a site-directed mutagenesis 
approach to insert a new NdeI restriction site covering the start site within the 
multiple cloning region of pASK-IBA-/NdeI. Successful incorporation of the change 
introduces a unique restriction site, causing linearisation of the plasmid upon NdeI 
digestion. 
Bottom: XhoI digest on the gel-extracted NdeI digest of pASK-altNdeI candidates 7, 9 
and 10, to test that the linearisation seen is from the new NdeI site and not from 
retention of the original site present in pASK-IBA13. Were the original NdeI site 






Figure 3:4 - Sequencing trace of final pASK-RM vector. 
Sequencing trace as shown in Chromas from sequencing of the final pASK-RM 
plasmid using the pASK-seq-F primer, displaying the sequence at both the 5`- (upper 
trace) and 3`- (lower trace) ends of the MCS of the plasmid. Indicated by brackets are 
the restriction sites for NdeI (CATATG) and XhoI (CTCGAG), as well as the newly-
introduced STOP codon (TGA) adjacent to and downstream of the XhoI site. On the 
upper trace, the Chromas software has detected the true sequence through the 





3.2 The structural repeat of TolC 
The structure of the TolC protein shows a clear structural repeat within each 
protomer (shown in Figure 3:5). Each repeat begins with a helix contributing to the 
equatorial domain, followed by a helix forming the “upward” part of the upper 
α-helical barrel, then two anti-parallel β-strand with an interconnecting loop, 
followed by a long helix stretching from the β-barrel to the periplasmic end of the 
protein, in turn leading into a turn and another helix which completes the α-barrel 
structure, and ending with a component of the equatorial domain.  
To show the structural repeat and enable analysis of the sequence alignment of the 
two half-proteins, the C-terminal half was taken as beginning at the equivalent helix 
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(H5) as starts the N-terminal (H1) of the 1EK9 TolC protein structure. The entire 
sequence from H5 to the C-terminal end of the protein was extracted to a new object 
in PyMol, and aligned to the remaining N-terminal half of the protein. An overlay and 
sequence alignment (based upon the structural alignment) of the two half-protomers 
is shown in Figure 3:5. This structural repeat causes the formation of two non-
identical grooves for potential MFP binding, one intra-protomer and the other inter-
protomer. Given that it is generally accepted that six AcrA proteins bind each TolC 
trimer, it is logical that each groove might bind one copy of AcrA. Therefore, it is also 
logical that, if all six copies of the MFP are identical, the residues on TolC that are 
required for binding will be the same in each groove, and led to the hypothesis that 
essential residues will be conserved in the internal duplication. Therefore, the 
conserved positions were mapped onto the 1EK9 TolC structure (Figure 3:6) for use 






Figure 3:5 - The structural repeat within TolC. 
When split into the N- (blue) and C-terminal (red) halves as described in the text 
body, the TolC monomer shows a structural repeat (left), which is also clear from the 
topology alone (bottom). Sequence alignment of the two halves of the protein (right) 






Figure 3:6 - Mapping of positions conserved in the TolC structural repeat. 
Mapping of positions that are conserved (yellow) in both the N- and C-terminal halves 
of TolC. Each TolC protomer is shown in a unique colour (green, magenta or cyan), to 
differentiate the inter- and intra-protomer grooves. Only the equatorial domain and 




3.3 tolC mutations used in this study 
D121N - This mutation has previously been shown to adapt TolC to function with 
MexAB (Bokma et al., 2006), but the reason behind this adaptation, and any effect of 
this mutation on the AcrAB-TolC complex have not been shown . Position 121 is close 
to the equatorial domain, and may interact with R390, an interaction which, if broken 
by AcrA, would weaken the inter-helical interactions that hold TolC in its closed 
conformation. The objectives of this mutation are therefore to determine firstly if 
the gain-of-function with MexAB is caused by constitutive opening of the TolC 
channel, and secondly if the mutation has an unreported detrimental effect on 
AcrAB-TolC function.  
Q129L – Although this residue faces into the TolC lumen, it appears to interact with 
N381 on H8, which, upon initial stages of relaxation of the coiled coils, would be 
pulled towards the surface between H3 and H8. This would form a more hydrophilic 
environment at this position of the intra-protomer groove than what is presented in 
the closed structure. By mutation to leucine, the possible requirement for the 
conversion from a hydrophobic region to hydrophilic at this region will no longer be 
achieved upon realignment of the helices, and this may cause the interaction with 
AcrA to be less efficient. JANUS gives a high importance score (combined score of 
397 when compared to MtrE, VceC and OprM) for this position, suggesting that it is 
likely to be involved in determining selection of the MFP. 
N145L – Mutation to cysteine at this position cross-links quite poorly to AcrB, 
compared to mutation of other positions in the same turn between H3/H4 of TolC 
(Tamura et al., 2005). The poor cross-linking upon mutation of this position may be 
indicative that it is involved in the interaction with AcrB, and that the mutation 
causes sufficient loss of interaction that the proteins are no longer in close proximity 
often enough or long enough for efficient cross-linking to occur. The distances 
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between the three N145 positions within the TolC trimer also match well with the 
distances between the Q255 and D256 on the AcrB trimer, and superimposing the 
TolC tip to the β-hairpins of AcrB suggest that these positions may well interact, 
although this would rotate TolC by 60° about an axis perpendicular to the membrane 
compared to the previously proposed AcrB-TolC interaction (Bavro et al., 2008). This 
mutation is therefore hypothesised to disrupt the AcrB-TolC interaction, by removal 
of the hydrogen bonds between the two proteins.  
R158D – Mutation of this position to cysteine has been shown to be unable to cross-
link to AcrA even when the long cross-linking agent LC-SPDP (with a 15.7 Å linker 
arm) is used (Lobedanz et al., 2007). Other positions in the same region of the protein  
do enable cross-linking when mutated to cysteine, which may indicate that this 
particular mutation prevents the TolC-AcrA interaction from being stable enough for 
cross-linking to take place. This position may also be involved in hydrogen bonding 
with Q346 and S350, as part of the inter-protomer interaction, disruption of which by 
binding of AcrA could facilitate outward movement of helices, dilating the channel. 
Even if not involved in channel dilation, this region of the external face of TolC 
contains a particularly high local concentration of hydrophilic residues, and switching 
of charge on one of these could disrupt binding of a partner protein. This mutation is 
therefore expected to cause loss of efflux activity and possibly to also increase 
channel dilation. 
V198D – The reported gain of function with MexAB has not been entirely 
investigated - the reason for this gain of function, and any possible impact upon 
functionality with AcrAB are unknown (Bokma et al., 2006).  Located on the 
equatorial domain loop between the two structural repeats of TolC, this position 
would be a less obvious candidate for mutation were it not for the reported gain-of-
function with MexAB. However, the positions around this in the structure are D121, 
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Y125, K383 and R390. This hydrophobic residue may therefore be required for 
interaction with a hydrophobic residue on the tip of the AcrA hairpin, possibly moving 
away from this otherwise very hydrophilic environment. Such a movement would be 
possible, being on a loop around the outside of the α-barrel of TolC, and such 
movement would possibly cause other residues on the loop to pull the helices with 
the loop; this is where the sharpest change of angle of the coiled-coils is located, and 
this movement could therefore induce maximum channel opening. By introducing an 
acidic residue at this position, it may cause the channel to become unable to open 
efficiently upon interaction with AcrA, and may also prevent AcrA from accessing its 
most interpenetrating position. 
N332L – This residue is located on H7, at the equatorial domain. It forms part of a 
network of hydrophilic residues, including N173, D176, N177, E180 and R328, at an 
inter-protomer interface at the position where the α-barrel begins to twist to 
generate the closed conformation. Disruption of the interactions in this area by AcrA 
binding could therefore lead to channel opening. In other proteins, the equivalent 
position is alanine in MtrE and OprM, but asparagine in VceC. Given that VceAB is 
capable of functioning with TolC (Vediyappan et al., 2006), but neither MtrC nor 
MexA are capable of functioning with TolC without mutational adaptation, this 
position could be one of the determinants for MFP selection. There is also 
conservation of this residue in the N- and C-terminal pseudo-copies of the protein, 
supporting the notion that this position is essential for interaction with partner 
proteins. This mutation is hypothesised to decrease the stability of AcrA binding, and 
therefore to decrease efflux activity, although it could instead lead to a separation of 
the helices at this area and thereby cause instability of the TolC protein. 
N342A – Based on computational results, this position is hypervariable in OMCs from 
different species, but is well conserved within a species. Furthermore, the equivalent 
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position in the first half of the protein is glutamine, indicating good similarity even 
though there is not conservation at the identity level between the two halves of the 
protein. This indicates that the position could be essential for the interaction with 
partner proteins. The JANUS score at this position is a mid-range score ,as the 
combined score to each of the other proteins used in the comparison is 193 (ranked 
233 out of 428), suggesting that there may be limited requirement for mutation at 
this position to switch binding partners. In the equivalent position in the other 
proteins analysed by JANUS, MtrE (aspartate) and VceC (arginine) have opposite 
charges to each other, while OprM contains glutamine. AcrA and OprM are known to 
interact in a non-functional manner, thus suggesting that this position may be 
required for the interaction but not for the functionality of the two proteins. This 
mutation is therefore predicted to abolish AcrA-TolC interaction and therefore 
prevent normal function of the efflux assemblies.  
Y344F – Y344 appears to interact with T120 and N167, forming an inter-protomer 
interaction. However, in the 1EK9 crystal structure, the side chain is twisted around 
the helix, in such a way that movement of the helix during opening of the channel will 
force this interaction to break. Results from Consurf indicate that this position is 
quite well conserved (group 9; Figure 3:7), in a region which is otherwise largely 
poorly conserved but not hypervariable (groups 5 and 6). JANUS gives a mid-level 
score to this position (88 to MtrE and 97 to OprM), indicating that although possibly 
important in selection of the partner protein, it is not likely to be as important as 
other residues. The position is conserved in VceC (also tyrosine) but not in either 
MtrE or OprM (leucine and glutamine, respectively), and so may be involved in 
selection of the MFP once the channel has partially opened. Mutation of this position 
to phenylalanine will prevent any possible hydrogen bonds from forming, but the 
change is sufficiently conservative that it is unlikely to cause major disruption to the 




Figure 3:7 - Consurf output of conservation in OMC sequences. 
Using the 1EK9 structure as the query, the Consurf results are mapped directly onto 
the same structure, to a single protomer. In pale yellow are adjacent helices of the 
other protomers. Each position is coloured on a scale from blue through white to 
purple, with blue being hypervariable, white being semi-variable and purple being 
most conserved. Positions in green are those lacking sufficient data in the alignment 
to calculate a conservation score. The labelled positions were chosen for mutation in 




Q346L – Mutation of the equivalent position in MtrE (K397) has previously been 
shown to increase sensitivity to tetracycline, but not other antibiotics. The score 
from Consurf (group 9) indicates that this position is well conserved across many 
channel proteins, and manual analysis of multiple sequence alignments indicates that 
this is indeed the case, except for in OprJ, which is only known to function with 
MexCD, although MexCD-OprM is also functional when OprM is overexpressed. 
Glutamine at this position is conserved in VceC but not in MtrE or OprM (lysine and 
aspartic acid, respectively); the charged residues of MtrE and OprM, which are not 
capable of complementing TolC (or vice versa), suggests that this position may be 
partially responsible for the selective functionality, but not binding, of MFPs with 
TolC. The JANUS scores reflect this, giving a high score for the comparison with MtrE 
(192) and a medium score (78) for comparison with OprM. Analysis of the TolC 
structure indicates that this position interacts with R158 and D162, both of which are 
also highly conserved, in an inter-protomer interaction. Binding of the MFP may 
therefore disrupt this interaction, or, given the local structure and the twist-to-open 
mechanism of TolC, cause re-arrangement of the helices in order to maintain these 
inter-protomer interactions. Mutation to leucine will eliminate side-chain hydrogen 
bonding at this position, and is expected to switch MFP-OMC specificity, losing 
functionality with AcrA. 
S350F – Conflicting information has been published regarding this mutation, by a 
single research group. Thorough analysis of the mutant is needed to determine what 
effect the mutation actually has. This position is part of an inter-protomer hydrogen- 
and ionic-bonding network, and introduction of a bulky side chain such as 
phenylalanine could logically push the protomers apart, although it may simply cause 
the aromatic ring to block the interprotomer groove and prevent binding of the MFP. 
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Therefore, this mutation should cause loss of function either due to the loss of 
interaction with its partner proteins or due to a dramatic increase in drug influx 
through an open TolC channel. It is also necessary to clarify the literature and 
determine to what extent this mutation causes degradation or otherwise decreased 
proteins levels. Intriguingly, serine is conserved at this position in OpmH and OprJ, 
while an alanine residue is conserved at the equivalent positions in MdsC, OprM, 
OprN and MtrE. MdsA can function with either TolC or MdsC, while AcrA is only 
capable of functioning with TolC. Similarly, MexC functions with either OprJ or OprM, 
and MexJ functions with either OprM or OpmH dependent upon the substrate, while 
MexA is only capable of functioning with OprM. Together, this may indicate that the 
hydroxyl group may be required for full functionality with a subset of partners, while 
other partners can function irrespective of whether the hydroxyl group is present. 
Q352A/E – Despite being only 17 Å from the tip of TolC, mutation of this position to 
cysteine does not facilitate cross-linking to AcrA even when using a 15.7 Å linker arm 
(Lobedanz et al., 2007), although mutation of S124 facilitated cross-linking with a 
shorter linker arm. This may indicate that Q352 is essential for the binding of AcrA to 
TolC, and mutation prevents this interaction from being sufficiently stable to 
facilitate cross-linking. Consurf indicates that this position is quite variable between 
proteins, although manual analysis of sequence alignments shows that when 
glutamine is not conserved at this position, a charged residue is present - this could 
indicate some charge-specific interaction takes place in certain OMC-MFP pairs. 
Based upon the possible charge-specific interactions, JANUS scores this position 
highly (a combined score of 384), indicating that it may be required in selection of 
partner proteins. This position will be assessed by two mutations - the first, to 
alanine, will prevent any hydrogen bonding at this position between AcrA and TolC, 
while the second, to glutamic acid, will determine whether or not the introduction of 
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a charge at this position has any effect on the interaction without changing any other 
parameters such as side-chain length.  
Y362F/R367S (YFRS) – This double mutation is known to disrupt the hydrogen- and 
ionic-bonding network at the periplasmic tip of TolC, but to cause less dilation of the 
channel than does the YFRE mutation. The YFRE mutation has been shown to not 
only be more dilated than the wild-type protein, but also to be more susceptible to 
novobiocin (an efflux substrate) and to have lower binding affinity to both AcrA and 
AcrB. It is not known whether the YFRS mutation affects efflux activity or binding of 
partner proteins. The mutation is therefore included in this study to determine 
whether the partial opening of the channel, or the specific mutations, are responsible 
for the loss of activity and decreased partner protein binding propensity.  
D371V – TolC has two aspartate rings at the periplasmic end of its lumen, which act 
as ion-selective gates (Andersen et al., 2002c). This position has previously been 
mutated to alanine as part of a double mutation, along with D374A, which causes a 
loss of cation coordination, and subsequently causes greater permeability of the 
channel. Upon complete channel dilation, the outward movement of the H7/H8 
helical pair may bring D371 into contact with R143, to stabilise the open state. 
Mutation to introduce a hydrophobic residue at this position may therefore either 
cause channel dilation due to disruption of the cation co-ordinated aspartate rings 
and possible conflict between the mutated position and its neighbours (potentially 
decrease trimer stability), or cause the channel to become unable to open as the 
hydrophobic ring cannot be opened by the same interactions as can the negatively 
charged ring.  
D374V – As with the D371V mutant, above, this position forms an aspartate ring that 
acts as an ion-selective gate (Andersen et al., 2002c). Being a helical turn higher in the 
TolC lumen, this position is unlikely to form new interactions at the periplasmic tip 
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that would stabilise the open state. However, it is possible that the change from an 
acidic residue to a hydrophobic residue low in the TolC lumen may impact the 
movement of efflux substrates, and possibly influx of substances, through the 
channel. Similarly to the D371V mutation, the D374V mutation may cause instability 
of the TolC trimer, cause channel dilation due to electrostatic incompatibility of 
other residues in the local environment, or cause the channel to become unable to 
open due to a different disruption mechanism being required to open the 
hydrophobic gate compared to an acidic gate. The structure of VceC, which has the 
equivalent of D371/V374 (Federici et al., 2005), is stable and appears closed, 
indicating that trimer instability should not be an issue. 
K383D/E – The K383D mutation has previously been reported to cause increased 
sensitivity to novobiocin, but not to vancomycin, suggesting that the increase in 
novobiocin sensitivity is not caused by a substantial increase of influx through the 
TolC channel (Bavro et al., 2008). Charge reversal of the equivalent position in MtrE 
(E434) causes increased vancomycin sensitivity only in the presence of the MFP, 
indicating that the mutation itself does not cause constitutive opening of the 
channel. The mutation to aspartate is therefore included for more detailed analysis 
than previously reported, and to assess the impact of MFP binding in vitro, while the 
mutation to glutamate is included to determine whether the effect is caused only by 
the charge reversal or if the length of the side chain is also a factor. 
R390E(/N392T) – In both TolC and at the equivalent position in MtrE, mutation of 
this position to glutamate has been shown to increase vancomycin susceptibility 
(Bavro et al., 2008). This is possibly due to a rearrangement of the H7/H8 helical pair 
towards the loop of the equatorial domain, caused by loss of the positive charge 
repulsion between R390 and K201. Random mutagenesis of TolC has shown that the 
R390C mutation causes hypersensitivity to all tested drugs (efflux substrates and 
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vancomycin), suggesting that the apparent loss of function is probably at least in part 
due to increased influx of the efflux substrates through TolC, although decreased 
efflux activity may also contribute. The R390E mutation was therefore included to 
study in greater detail the effect of this mutation, particularly in a possible 
interaction with AcrA. During mutagenesis, the R390E/N392T double mutant was 
found to have spontaneously arisen on the transformation plate following 





Figure 3:8 - Map of TolC mutants used, outside of the channel. 
Positions mutated for use in this study (green) are mapped onto the 1EK9 TolC 
structure, to the protomer shown in blue. The view is from the periplasmic side of the 




Figure 3:9 - Map of TolC mutants used, inside the channel. 
Positions mutated for use in this study (green) are mapped onto the 1EK9 TolC 
structure, to the protomer shown in blue. The view is from inside the channel lumen. 
Shown in magenta are adjacent helices of the other two protomers. 1: R367. 2: D371. 




3.4 CAPS analysis 
Sequences for MFPs and their cognate OMCs were prepared as described in the 
methods and used as the input for the CAPS programme. CAPS assesses differences 
at each position within a multiple sequence alignment, and calculates the Pearson 
correlation coefficient of the changes at every pair of positions. The output from the 
program only indicates pairs of positions that it indicates as co-evolving; any 
positions that are not indicated to co-evolve are not shown in the output file. Only 
pairs of positions that are ranked as likely to co-evolve in which one of the pair is a 
position in the MFP and the other a partner in the OMC are of interest from this 
programme. Positions that were shown as co-evolving only with another position 
from the same protein were disregarded for this study. The positions that CAPS 
determined as co-evolving on both the MFP and OMC within the chimaeric multiple 
sequence alignment are shown in Table 3:1 and mapped to the relevant structures in 
Figure 3:10. Given that the positions appear unlikely to co-evolve due to evolutionary 
pressure driven by the positions interacting, the positions were viewed in the 
sequence alignment (Figure 3:11). From the high conservation at each of these 
positions, it appears unlikely that they are co-evolved, and more likely that they are 
simply conserved between the input sequences. 
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Table 3:1 - CAPS output for co-evolution analysis of AcrA and TolC residues 
The raw output from CAPS provides alignment positions, which have been 
manually replaced by extraction from the alignment. Positional numbers 
correspond to the annotation in the 2F1M and 1EK9 structures. 
Position 1 Position 2 Correlation 
AcrA-E88 TolC-Y362 0.845047 
AcrA-E88 TolC-T406 0.864794 
AcrA-D97 TolC-Y113 0.850882 
AcrA-D97 TolC-N220 0.862368 
AcrA-D97 TolC-T326 0.824756 
AcrA-D97 TolC-D356 0.836107 
AcrA-D97 TolC-Y362 0.914149 
AcrA-D97 TolC-T406 0.914355 
AcrA-S178 TolC-T326 0.834062 





Figure 3:10 - Map of positions on AcrA and TolC that "co-evolve" 
Positions identified by CAPS as co-evolving are highlighted in magenta on the 
structures of AcrA (cyan) and TolC (green). Each structure is shown as trimmed to 





Figure 3:11 - Sequence alignment of positions identified by CAPS as co-
evolving. 
The CAPS input file was edited to remove all positions not identified as co-
evolving. Positions left of the space are in MFPs, those to the right are in OMCs. 
From left to right, (AcrA-)E88, D97, S178, (TolC-) Y113, N220, T326, D356, Y362, 
T406. Those MFPs that have multiple cognate partners are shown with each 




3.5 acrA mutations used in this study 
Using information mainly from published literature, mutations were designed in acrA, 
as detailed in Table 3:2, which details the actual mutations made for each named 
mutation and the logic behind all acrA mutations made. A sequence alignment of the 
three major hairpin mutants, with the wild-type sequence, is shown in Figure 3:12. 
The mutation sites and the major alterations to the hairpin are shown on the AcrA 
structure in Figure 3:13.  
Table 3:2 - acrA mutations in this study. 
Nomination Mutation (2F1M numbering) Logic 
GS-tip Δ131-141::”GSGGSG” Replacement of the hairpin tip with a 
flexible linker sequence, leaving the 
helices as wild-type but removing 
sequence specificity at the tip. 
Δhelices Δ102-126/Δ143-170 Removal of the helical part of the 
hairpin, leaving the tip region intact. 
Δhairpin Δ101-175::BesA loop Removal of the entire hairpin, 
replacing it with the loop sequence 
from the hairpin-less BesA. 
S139G S139G Replacement of the serine from the 
published “RLS” motif with a non-
reactive and flexible residue. 
TVYF T104V/Y105F Putative manual docking models 
suggest that T104 may interact with 
TolC-R143, while in an alternative 
orientation, Y105 may interact with 
TolC-R367. Replacement by amino 
acids of similar structure but lacking 







Figure 3:12 - Sequence alignment of hairpin mutants used in this study. 
Only the hairpin sequences and the five positions either side of it are shown in this 
alignment. The alignment indicates the sequence differences between each of the 
mutations used in this study, compared to the wild-type sequence. The GS-tip mutant 
is identical to the wild-type sequence except at the hairpin tip region. The Δhelices 
mutation retains the sequence at the hairpin tip region, but the coding sequences for 
the helices of the hairpin have been removed. The BesA-loop sequence is as used for 
the Δhairpin mutant, in which the entire hairpin structure was replaced by the 




Figure 3:13 - Predicted structures of hairpin mutants and positions of point 
mutants on AcrA. 
Indicated in blue on the wild-type sequence are the positions mutated in point 
mutants. In red are the GS-tip mutated sequence, with serine sidechains shown, 
and the BesA-loop of the Δhairpin variant. In yellow is the wild-type AcrA tip 
sequence that has been brought closer  to the lipoyl domain by deletion of the 
hairpin helices (Δhelices) 
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3.6 The published MtrE structure is an unnatural protein 
In an attempt to enable testing of cross-reactivity of proteins from non-cognate 
systems, efforts were made to clone mtrE from a pET21-mtrE plasmid received from 
the laboratory of Dr Adrian Walmsley. Upon failing to generate a PCR product, the 
received plasmid was sequenced to check that the primers used were suitable. The 
3`- end of the gene in the plasmid had several mismatches to the cloning primer, 
including towards the 3`-end of the primer, meaning that the primer would fail to 
primer for elongation. To ensure the differences in sequence were silent, the 
received plasmid was sequenced using both the forward and reverse pET sequencing 
primers and the resulting DNA sequences translated using the translate tool on the 
expasy.org website. When analysing the translated sequences, it was noticed that 
the sequence for MtrE as presented in the 4MT0 crystal structure, which was stated 
as being the wild-type sequence (Lei et al., 2014),was split between reading frames 
when sequenced from either end (Figure 3:14 and Figure 3:15).  
To determine whether the sequence used to generate the MtrE structure was indeed 
the wild-type, the sequence used (FA136) was aligned to MtrE sequences from other 
species of Neisseria and to the translation of that from the FA19 wild-type reference 
strain (Abrams et al., 2015). The sequence alignment showed that the FA136 
sequence was a clear anomaly among these sequences (Figure 3:16), with the 
mismatch being the same as the part of the sequence that was highlighted in the 
translations. As this had initially been found from the translated sequences in each 
frame, the DNA sequences were aligned to find any frame-shift mutations (Figure 
3:17). The DNA sequence alignment indicated that the FA136 sequence contains a 
single base insertion (T) and a single base deletion (G).  
According to the authors of the 4MT0 MtrE structure, this protein is constitutively 
dilated, which is inconsistent with other information available about the MtrE protein 
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(Janganan et al., 2013). The structure was resolved from protein expressed from a 
synthesised gene, in which the alternative sequence had been specified. The 
sequence from the plasmid received for use in this thesis corresponded to FA19 
except for towards the end of the discernible sequence trace. In these regions of 
sequence traces, the confidence in the trace decreases, with an increased rate of mis-
called bases, insertions and deletions, as the signal intensity decreases towards the 
same as the background. The authors of the 4MT0 structure were informed of these 
details, and mtrE in FA136 was re-sequenced. From the new sequences, it appears 
that the forward and reverse sequences had previously been misaligned due to the 
issue of low signal intensity. This has led to the MtrE protein being re-crystallised, 





Figure 3:14 - Translation of pET21-mtrE forward sequencing. 
Output from the expasy.org “Translate Tool”, using the results from forward 
sequencing of pET21-mtrE as the input. Green boxes indicate where the sequence 
matches the N. gonorrhoeae FA19 reference sequence; the red box indicates where 
the sequence matches the N. gonorrhoeae FA136 sequence. Reading frame 2 Is 





Figure 3:15 - Translation of pET21-mtrE reverse sequencing.  
Output from the expasy.org “Translate Tool”, using the results from reverse 
sequencing of pET21-mtrE as the input. Green boxes indicate where the sequence 
matches the N. gonorrhoeae FA19 reference sequence; the red box indicates where 







Figure 3:16 - MtrE proteins sequence alignments. 
Protein sequence alignments of wild-type N. gonorrhoeae (NgonWT), N. meningitidis 









































































































































CHAPTER 4: RESULTS – PROBING THE 
INTERACTION FROM THE CHANNEL SIDE 
117 
 
4.1 Minimum inhibitory concentrations 
The use of MICs in the study of antibiotic resistance is well-established. When cells 
are exposed to a sequence of drug concentrations, the lowest concentration at which 
growth is inhibited by 80% compared to without drug is the MIC of that drug against 
that strain. As the tolC gene is located on a plasmid, and is under the control of the 
tetracycline repressor, it was necessary to determine a suitable concentration of 
inducer (anhydrotetracycline, a derivative of tetracycline that de-represses the tet 
promoter, but which does not have any antibacterial activity) to use for all in vivo 
studies. Liquid broth MICs were tested for the wild-type strain with empty vector, 
tolC  knockout strain with empty vector, and the complemented strain, at four 
concentrations of anhydrotetracycline, erythromycin and novobiocin. The results of 
this are shown in Table 4:1. At the highest concentration of anhydrotetracycline 
tested (200 ng.ml-1), the complemented strain has the same MIC values to both drugs 
as did the knockout. In the absence of inducer and with 2 ng.ml-1 anhydrotetracycline, 
the complemented strain appeared essentially as wild-type, being not more than one 
doubling dilution different. The wild-type strain seemed unaffected by the inducer, 
with the MIC to each drug remaining constant across all inducer concentrations. For 
future experiments, 20 ng.ml-1 anhydrotetracycline was used for induction on agar, 




Table 4:1 - Minimum inhibitory concentration (in μg.ml-1) of erythromycin and 
novobiocin in a range of inducer concentrations. 
[Inducer] / ng.ml-1 0 2 20 200 
Strain ERY NOV ERY NOV ERY NOV ERY NOV 
BW25113 pASK-RM 128 512 128 512 128 >512 128 512 
BWΔtolC pASK-RM 32 2 32 2 32 2 32 2 




Having made a library of tolC point mutants, the MIC for a variety of drugs was tested 
against the library using the agar dilution method, the results of which are shown in 
Table 4:2 and Table 4:3. Although it will act as additional inducer, tetracycline was 
included as a drug against which to assay. All of the drugs tested are reported 
substrates of AcrAB-TolC except for vancomycin. The BSAC recommended control 
species ATCC 25922 was included to ensure that the MICs conform to expected 
values, and therefore that the experiment is valid, although there are no recognised 
standard MIC values for acriflavine, deoxycholic acid, erythromycin, novobiocin or 
vancomycin. When tested on chloramphenicol, fusidic acid, nalidixic acid, rifampicin 
and tetracycline, the MIC for the standard control strain was within a single doubling 
dilution of each expected value, and therefore accepted as valid values. Ciprofloxacin 
was also tested, but for all strains the MIC was lower than any tested concentration.  
The MICs for all strains were essentially equal on rifampicin. On erythromycin, there 
was no clear difference between the knockout and complemented strains, although 
the N145L, D371V and R390E/N392T (RENT) mutations had lower MICs than did the 
knockout strain.  Only the mutants Y344F, Q352A and RENT showed a difference in 
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MIC to vancomycin greater than a single doubling dilution, although Q129L, N145L, 
R158D, V198D and K383D had an MIC half that of either the knockout or 
complemented strain. Despite the possible increase in gene expression from the 
plasmid, the MIC to tetracycline was within a single doubling dilution of the 
complemented strain for all mutants except Q129L, N145L, Y344F and RENT; 
however, the wild-type and knockout strains were different by two doubling 
dilutions, and therefore classified as different to each other but neither different 
from the complemented strain. Chloramphenicol, fusidic acid and novobiocin MICs 
were all decreased by the S350F, Y362F/R367S (YFRS) and D371V mutations, in 
addition to the knockout, but not by any of the other mutations. These same three 
mutations, plus K383D decreased the MIC of deoxycholic acid. It was also observed 
that deoxycholic acid caused an unusual sequence of phenotypes, whereby the size 
of the colony of all mutants not hyper-susceptible increased with increasing 
concentrations of the drug, up to the MIC, as shown in Figure 4:1. The extent of this 
unusual phenotype was such that at 4096 μg.ml-1, even hyper-susceptible strains – 
with the exception of the tolC knockout – showed a large colony. The same mutations 
that caused hypersensitivity to deoxycholic acid also caused hypersensitivity to 
nalidixic acid, as did the N145L mutation. The MIC to acriflavine was also decreased 
by this subset of mutations, plus the Q352E mutation. Of the mutations tested, 
D121N, R158D, V198D, N332L, N342A, Q346L, K383E and R390E displayed no 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this study, the complemented strain and all of the point mutants have the tolC 
gene under control of the tetracycline promoter. To determine how much inducer 
should be added to cultures for in vivo studies, liquid broth MIC was used to compare 
the wild-type, knockout and complemented strains. This does not confirm that the 
promoter activity is similar to that of the chromosomally-encoded tolC promoter of 
the wild-type strain, in the way that quantitative reverse-transcriptase PCR would, 
nor does it confirm that the amount of TolC protein is comparable between the two 
strains, as a quantitative Western blot would. It does, however, allow a basic 
approximation of how much inducer is required for comparable results between the 
wild-type and tolC complemented strains from in vivo assays. This small experiment 
was also vital for confirming that the inducer does not in itself have any effect on the 
strains used. The MICs of the wild-type strain with the empty vector, and the tolC 
knockout strain with the empty vector, remained constant for each of the inducer 
concentrations tested, suggesting that in the concentration range used, 
anhydrotetracycline does not have an antibacterial effect, does not affect tolC 
expression from the chromosome, and does not have a significant inhibitory effect 
on the AcrAB-TolC efflux pump. Given that the MICs of erythromycin and novobiocin 
against the complemented strain are decreased to those of the knockout strain at 
200 ng.ml-1 anhydrotetracycline, this level of induction probably causes OM 
permeability issues by overproduction of the TolC protein. IBA-Lifesciences, the 
suppliers of the pASK-IBA13plus vector, state on the plasmid data sheet that 200 
μg.l-1 (200 ng.ml-1) should be used for induction, but this is likely the recommendation 
for protein overproduction for purification purposes. From the results of this small 
experiment, it was decided that 2 ng.ml-1 anhydrotetracycline should be used for in 
vivo assays in broth, while 20 ng.ml-1 should be used in agar. As the differences 
between wild-type and mutant TolC proteins could be very small in any given assay, 
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overproduction of the protein may mask the differences, therefore a low 
concentration would be required in liquid broth assays; the increased concentration 
in agar should account for any differences in diffusion from agar to the cell compared 
to from solution into the cell.  
In one set of MIC agar plates, inducer was aliquoted to universal bottles before 
addition of the antibiotic stock solutions, rather than into the cooled molten agar. 
This caused all MIC values for all strains with plasmid-encoded tolC to be equal to the 
knockout, although the values for wild-type strain were normal (results not shown). 
As anhydrotetracycline is dissolved in methanol and only a very small volume was 
added to each bottle, it is likely that the solvent evaporated completely, resulting in 
an anhydrotetracycline residue on the bottom of the bottle. This residue may not 
have re-dissolved upon addition of either the test antibiotics or the molten agar, 
leading to an effective concentration of zero anhydrotetracycline in the final agar 
plates. Alternatively, the anhydrotetracycline may have become less stable, again 
resulting in an effective zero concentration of inducer in the agar. Such results differ 
from what was suggested in the liquid broth MICs to determine what concentration 
of inducer to use, but results from liquid broth MIC can differ when compared to 
those from agar MIC – this is apparent within these results, particularly when looking 
at erythromycin, which had a far lower MIC in agar to all three strains than it did in 
broth.  
Several mutations showed no significant (≥2 doubling dilutions) difference from the 
complemented strain with any of the antibiotics tested. These were D121N, R158D, 
V198D, N332L, N342A, Q346L, K383E and R390E. All of the other mutations showed 
a significant difference to at least one of the tested antibiotics. These results 
indicate that the effect of some of these mutations may be substrate-dependent. 
Table 4:4 summarises the overall findings from these MIC assays for each mutation, 
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relative to the complemented strain, while the effects of each mutation are mapped 
to the structure in Figure 4:2. For mutations made in the lumen of the TolC channel, 
then the substrate-specific effects could be explained by the substrate-accessible 
surface of TolC being less conducive to the passing of certain substances than other. 
This is particularly likely for the D374V mutation, as the three D374 residues form a 
selective ring low in the TolC lumen. Changing of the lumen surface may also explain 
why the substrate-specific effect is observed in the R390E/N392T but not the R390E 
single mutant, as N392 faces into the lumen while R390 faces out; the double mutant 
was a spontaneous mutation found when screening for R390E site-directed mutants, 
and was included in this study out of curiosity as to why it had arisen. Although Q129 
faces into the lumen, it is predicted to interact with N381 and Q384, and should 
remain hidden from the substrate by the side chains of these interaction partners, 
which protrude further into the lumen; disruption of these interactions by mutation 
could cause a re-alignment of these other side chains, altering the face of the lumen 
and possibly causing the observed substrate-dependent effect. Being sandwiched 
between N167 and E385, the side chain of Y344 also faces into the lumen, although 
as the interactions between these residues is most likely driven by electron 
delocalisation, the change to phenylalanine should have minimal impact on the 
physical properties of the lumen surface.  
The apparent substrate-specificity was unexpected for N145L, Q352E and K383D, 
given the hypothesis that these mutations may affect binding of TolC to its partner 
proteins. If binding is affected, then the effect should logically be apparent for all 
substrates of the efflux complex, not only a subset of them. Both Q352 and K383 
also show mutation-specific effects – Q352A causes susceptibility to vancomycin but 
not to any efflux substrates, while Q352E causes increased susceptibility to acridine 
but not any other efflux substrates or vancomycin; K383D causes increased 
susceptibility to a subset of efflux substrates, but K383E apparently has no effect.  
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Table 4:4 - Summary of MIC findings for tolC mutants. 
Mutation Effect with efflux substrates Effect shown by vancomycin 
ΔtolC Susceptible to most -- 
D121N -- -- 
Q129L Susceptible only to Tet -- 
N145L Substrate-specific susceptibility -- 
R158D -- -- 
V198D -- -- 
N332L -- -- 
N342A -- -- 
Y344F Susceptible only to Tet Susceptible to Vanc 
Q346L -- -- 
S350F As knockout -- 
Q352A -- Susceptible to Vanc 
Q352E Susceptible only to Acf -- 
YFRS As knockout -- 
D371V As knockout -- 
D374V Susceptible only to Acf -- 
K383D Substrate-specific susceptibility -- 
K383E -- -- 
R390E -- -- 
RENT Substrate-specific susceptibility Susceptible to Vanc 






Figure 4:2 - Summary of MIC results on TolC structure. 
Onto a single protomer of TolC (1EK9, light blue) are mapped the positions that were 
mutated, colour coded according to the effect of the mutation as determined by MIC 
assays. In magenta are the adjacent helices from the other protomers. Green: 
mutation has no effect (positions not labelled). Yellow: effect observed is dependent 
on the amino acid mutated to. Blue: mutation has a substrate-specific effect. Red: 




Vancomycin is not an efflux substrate, but is reported to traverse the OM by utilising 
open efflux channels such as TolC; the MIC results here therefore suggest that the 
Y334F and Q352A mutations, plus the R390E/N392T double mutation, cause the TolC 
channel to allow greater influx of vancomycin due to being more open. While the 
Y344F mutation was expected to impact inter-helical interactions N167 and E385 at 
the part of TolC where narrowing of the channel begins, it is not clear whether this 
effect is caused by this or a change in binding of the MFP. As the channel dilates, 
Y344 should become more accessible to the MFP, and could therefore become 
involved in the stabilisation of the open structure, as well as holding the channel 
closed when MFP is not bound. The Q352A mutation affects the external face of the 
TolC channel, and should not contribute to inter-helical bonding in the closed state. 
Therefore, this mutation is unlikely to cause channel dilation on its own – it is more 
likely that the observed effect is MFP-dependent, as seen in the case of the E434K 
mutation in MtrE. Both the R390E and YFRS mutations have previously been 
published as causing pore dilation, tested by vancomycin zones of inhibition for 
R390E and by conductance assays for YFRS. Neither of these mutations showed 
increased susceptibility to vancomycin by MIC assay in this study. Conductance 
assays, though useful in assessing how likely the channel is to dilate when a current is 
applied, do not give any information as to the opening or closing of a channel protein 
in vivo, particularly when the process is controlled by a partner protein. Perhaps the 
YFRE mutation, which has been shown in vivo to cause vancomycin hyper-
susceptibility, would have been a better choice of mutation for this study. Published 
susceptibility testing of the R390E mutation was done using basal expression from 
the pTrc99 vector, and therefore different expression levels may account for the 
difference in results between that study and this. The double mutation R390E/N392T 
has not previously been reported, but appears from this study to cause far greater 
susceptibility to vancomycin than does the R390E single mutation. Given that N392 
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faces into the lumen of TolC, and appears to provide only a very minor contribution 
to inter-helical interactions, this result cannot be explained from MIC assays alone.  
Unfortunately, as there are multiple MFPs that could potentially interact with TolC in 
any in vivo assay, determination of the MFP-dependency of the vancomycin 
susceptible phenotype of these mutations was not possible within the scope of this 
study. The laboratory of Dr Jessica Blair has made good progress towards creating a 
Salmonella strain in which the genes encoding all TolC-dependent MFPs have been 
removed from the chromosome, but such a strain has taken several years of step-
wise gene deletion and was not available during this study. 
Whilst MIC assays are an approved method of determining whether a strain is 
susceptible or resistant to a particular drug, they have some limitations. Firstly, the 
results can be interpreted differently by different people – as drug concentration 
increases, the colony may appear to fade, or may start to appear as many small 
colonies within the spotted area. The point at which growth is inhibited sufficiently 
for the MIC to be assigned is therefore not as clear as a simple “is there any growth or 
not?”. Secondly, they are end-point assays, and give no indication as to how colonies 
have grown to their observed size, nor can any extrapolation be made as to whether 
or not the drug has completely inhibited growth or merely slowed it such that an 
observation is made earlier in the growth curve of the colony. This could be 
particularly relevant to the D371V mutant, which showed a decreased MIC to most of 
the efflux substrates tested. This strain had already been observed to form visible 
colonies at a slower rate than any of the other colonies, and therefore it is unclear if 
the measured MIC is an accurate representation, or if the MIC values would be higher 
if the plates were allowed a longer incubation.   
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4.2 Growth kinetics 
To determine finer details of the effect the tolC mutations have upon antibiotic 
resistance than can be determined from MIC assays, the growth kinetics of each 
mutant were analysed. This was done on 96-well plates, with readings automatically 
taken every two and a half minutes by Fluostar plate readers. The concentrations of 
inducer and test drug to use were informed by MIC results, such that the test drugs 
are at sub-lethal concentration for the complemented strain, but sufficiently high 
concentration to show any increase in sensitivity caused by the mutations. In all 
cases, anhydrotetracycline was added to a final concentration of 2 ng.ml-1 to ensure 
adequate induction of tolC expression. 
As each plate was measured at a different time and on one of three different 
machines, there was considerable variation between replicates. Therefore to 
normalise the data, each growth curve was analysed to find the generation time and 
defined as a relative growth rate against the complemented strain in the same 
conditions on the same plate. From the semi-log plot of the raw data, linear sections 
of the growth curve were selected (examples shown in Figure 4:3), with the first and 
last data points of these selected portions used for the calculation of generation 
time. The calculation was done in Microsoft Excel, by (60 x log102 x (end time – start 
time)) / (log10 end OD600 – log10 start OD600), giving generation time in minutes. To 
complete the normalisation, the generation time of the complemented strain was 
divided by the generation time of each mutant, and then multiplied by 100 to express 
a relative growth rate as a percentage of that of the complemented strain. A p-value 
was then calculated for each strain against the complemented strain using Welch’s 
T-test, with a P-value of <0.05 deemed significantly different from the 
complemented strain. Stationary phase OD600 was also analysed, to compare with the 
information from MIC assays and to determine what effects are observable as a 




Figure 4:3 - Example growth curve indicating where growth rates are calculated. 
Growth rates were taken from the linear portion of semi-log plots of OD600 against 
time. Shown in green are the portions of example curves from which growth rates 
were calculated. For curves with high noise, such as the ΔtolC example, the most 





As rifampicin showed the same MIC to both the knockout and complemented strains, 
it was not used in growth kinetics assays. Erythromycin was not included in growth 
kinetics assays as the difference in MIC against the knockout and complemented 
strains was minimal and not deemed significant. Tetracycline showed only a minimal, 
insignificant difference in MIC against the knockout and complemented strains, and, 
as this would also likely affect expression of tolC from the plasmid, was also omitted 
from the growth kinetics assays.  
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Deoxycholic acid was used at a final concentration of 500 μg.ml-1, to avoid the 
complications of increased growth of all mutants at higher concentrations of this 
drug, seen in the MIC results. At this concentration, the knockout and three point 
mutants – S350F, YFRS and D371V, all grew to a lower OD600 in their stationary phase 
than did the wild-type or complemented strains (bold in Table 4:5). These strains also 
showed a clear decrease in growth rate compared to the complemented strain 
(Figure 4:4 and Table 4:5). Several point mutations showed a small effect on growth 
rate, without greatly impacting on the OD600 at stationary phase. These mutations 
were D121N, N332L, Y334F, K383D and R390E, which all had a negative impact on 
growth rate. Each of these show a p-value of <0.05 when tested against the 
complemented strain (bold in Table 4:5). The V198D mutation showed generally to 
increase the growth rate relative to the complemented strain, but Welch’s T-test 
determined this to be not significantly different (p-value = 0.059); however, the 
lowest value in this data range is below the 95% confidence interval (seen in Figure 
4:4). 
Assays were done using nalidixic acid as a test substrate, at 1 μg.ml-1 final 
concentration. In these conditions, the mutations S350F, YFRS and D371V all caused 
the OD600 at stationary phase to be significantly lower than reached by the 
complemented strain (bold in Table 4:6), although the same was not true of the 
knockout strain. Comparing relative growth rates, the knockout strain again showed 
no difference compared to the complemented strain, nor to BW25113 pASK-RM, 
indicating that the knockout is capable of growing as wild-type in these conditions. 
The YFRS, D371V and K383D mutations all caused growth rate to decrease 
significantly in these conditions (Figure 4:5), compared to the complemented strain 
(p-values shown in bold in Table 4:6). Although the p-values did not indicate the 
mutations S350F or D374V to significantly affect growth rate (p-values italicised in 
Table 4:6), manually scrutinising the data indicate that these mutations probably do 
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cause a significant change in growth rate, once outlier values are taken into account. 
The indicated average relative growth rate for the N145L mutant is higher than four 
out of five of the contributing data values, the other being above the 95% 
confidence interval; however, even if this outlying value were omitted, the p-value 
would still be 0.09, and thus still not classified as significant.  
In the presence of 1 μg.ml-1 chloramphenicol, the tolC knockout strain showed a 
significant difference in both stationary phase OD600 and relative growth rate, when 
compared to the complemented strain (Table 4:7 and Figure 4:6). The generation 
time of the complemented strain was also longer in these growth conditions than 
that of BW25113 pASK-RM, and longer than the generation time of the 
complemented strain in the absence of chloramphenicol. The point mutations S350F, 
YFRS, D371V and R390E showed the same phenotypes as the knockout strain, with 
very low OD600 at stationary phase and a very low relative growth rate. Although the 
D121N mutation did not cause the OD600 at stationary phase to decrease, it did cause 
a small but statistically significant decrease in relative growth rate. There are clear 
outliers for mutations V198D, N332L and D374V, which are outside the 95% 
confidence intervals; exclusion of these values would result in average relative 
growth rates of 61%, 76% and 70%, respectively, with p-values of 0.019, 0.048 and 
0.016, respectively, when tested against the complemented strain, compared to the 
p-values of 0.214, 0.551 and 0.449 when tested using the complete set of data 








































































































































































































Table 4:5 - Growth information of tolC mutants in the 




growth rate (%) ± SD 
P-value against tolC 
complement 
Stationary phase 
OD600 ± SD 
BW25113 pASK-RM 160 ± 36 0.020 1.00 ± 0.08 
BWΔtolC pASK-RM 36 ± 22 0.003 0.04 ± 0.03 
BWΔtolC pASK-tolC 100 ± 0 -- 0.99 ± 0.11 
D121N 81 ± 12 0.024 1.00 ± 0.07 
Q129L 104 ± 10 0.509 1.00 ± 0.08 
N145L 103 ± 17 0.675 0.97 ± 0.16 
R158D 94 ± 17 0.453 1.03 ± 0.09 
V198D 121 ± 18 0.059 0.94 ± 0.12 
N332L 84 ± 10 0.022 1.09 ± 0.09 
N342A 95 ± 16 0.488 1.01 ± 0.10 
Y344F 89 ± 8 0.033 1.06 ± 0.09 
Q346L 106 ± 19 0.501 1.04 ± 0.13 
S350F 43 ± 11 3 x 10-4 0.11 ± 0.06 
Q352A 98 ± 22 0.846 1.05 ± 0.17 
Q352E 98 ± 22 0.819 1.07 ± 0.12 
YFRS 40 ± 15 0.001 0.23 ± 0.12 
D371V 27 ± 8 2 x 10-5 0.08 ± 0.02 
D374V 91 ± 24 0.470 1.06 ± 0.09 
K383D 76 ± 15 0.023 1.06 ± 0.08 
K383E 103 ± 18 0.774 0.98 ± 0.10 
R390E 76 ± 8 0.002 1.01 ± 0.09 


































































































































































































Table 4:6 - Growth information of tolC mutants in the 




growth rate (%) ± SD 
P-value against tolC 
complement 
Stationary phase 
OD600 ± SD 
BW25113 pASK-RM 123 ± 33 0.197 0.98 ± 0.18 
BWΔtolC pASK-RM 103 ± 17 0.677 0.83 ± 0.01 
BWΔtolC pASK-tolC 100 ± 0 -- 0.89 ± 0.07 
D121N 89 ±  21 0.295 0.83 ± 0.07 
Q129L 101 ± 29 0.920 0.89 ± 0.04 
N145L 100 ± 30 0.989 0.92 ± 0.07 
R158D 82 ±  16 0.069 0.89 ± 0.08 
V198D 104 ± 34 0.826 0.82 ± 0.08 
N332L 134 ± 45 0.170 0.83 ± 0.08 
N342A 135 ± 44 0.155 0.85 ± 0.10 
Y344F 113 ± 25 0.305 0.85 ± 0.09 
Q346L 110 ± 37 0.564 0.87 ± 0.10 
S350F 57 ±  35 0.051 0.39 ± 0.28 
Q352A 89 ±  22 0.310 0.90 ± 0.09 
Q352E 116 ± 26 0.241 0.90 ± 0.08 
YFRS 45 ±  30 0.015 0.31 ± 0.32 
D371V 33 ±  20 0.002 0.08 ± 0.05 
D374V 82 ±  15 0.050 0.88 ± 0.08 
K383D 62 ±  23 0.022 0.94 ± 0.11 
K383E 103 ± 22 0.790 0.89 ± 0.14 
R390E 88 ±  32 0.446 0.75 ± 0.07 






































































































































































































Table 4:7 - Growth information of tolC mutants in the 




growth rate (%) ± SD 
P-value against tolC 
complement 
Stationary phase 
OD600 ± SD 
BW25113 pASK-RM 154 ± 59 0.105 0.68 ± 0.04 
BWΔtolC pASK-RM 29 ± 6 1 x 10-5 0.12 ± 0.04 
BWΔtolC pASK-tolC 100 ± 0 -- 0.47 ± 0.13 
D121N 79 ± 12 0.019 0.48 ± 0.23 
Q129L 119 ± 45 0.395 0.57 ± 0.10 
N145L 77 ± 21 0.985 0.47 ± 0.17 
R158D 84 ± 22 0.217 0.49 ± 0.21 
V198D 76 ± 36 0.214 0.41 ± 0.21 
N332L 89 ± 32 0.551 0.54 ± 0.07 
N342A 94 ± 32 0.735 0.55 ± 0.09 
Y344F 96 ± 35 0.846 0.51 ± 0.17 
Q346L 102 ± 29 0.835 0.57 ± 0.07 
S350F 22 ± 20 0.001 0.10 ± 0.07 
Q352A 102 ± 43 0.906 0.52 ± 0.09 
Q352E 100 ± 23 0.891 0.50 ± 0.20 
YFRS 15 ± 9 4 x 10-5 0.06 ± 0.05 
D371V 9±  5 3 x 10-6 0.05 ± 0.05 
D374V 85 ± 35 0.449 0.49 ± 0.12 
K383D 75 ± 22 0.060 0.36 ± 0.14 
K383E 111 ± 68 0.723 0.56 ± 0.16 
R390E 38 ± 10 2 x 10-4 0.18 ± 0.22 





































































































































































































Table 4:8 - Growth information of tolC mutants in the 
presence of 200 μg.ml-1 fusidic acid. 
 
Strain Average relative growth rate (%) ± SD 
P-value against tolC 
complement 
BW25113 pASK-RM 110 ± 15 0.360 
BWΔtolC pASK-RM 19 ± 10 2 x 10-5 
BWΔtolC pASK-tolC 101 ± 9 -- 
D121N 116 ± 25 0.304 
Q129L 92 ± 13 0.354 
N145L 117 ± 14 0.094 
R158D 95 ± 21 0.677 
V198D 92 ± 16 0.394 
N332L 104 ± 21 0.789 
N342A 92 ± 22 0.518 
Y344F 75 ± 17 0.049 
Q346L 88 ± 28 0.477 
S350F 34 ± 10 7 x 10-5 
Q352A 83 ± 37 0.418 
Q352E 105 ± 18 0.641 
D374V 100 ± 15 0.934 
K383D 105 ± 38 0.831 
K383E 101 ± 19 0.927 
R390E 93 ± 17 0.476 





When grown in the presence of 100 μg.ml-1 vancomycin, none of the mutations 
caused a change in the OD600 at stationary phase (Table 4:9). Only the D371V and 
K383D point mutations showed any statistically significant effect on the relative 
growth rate in vancomycin, although D374V appears to cause a minor increase in 
growth rate and R158D appears to cause a decrease in growth rate. Recalculation of 
the average relative growth rate of D374V with its clear outlier excluded gives a 
value of 105 ± 2, with a p-value of 0.009 against the complemented strain when 
recalculated. In the case of R158D, all of the individual relative growth rates from 
each plate is lower than that of the complemented strain, and the lowest of all of 
these (furthest from being the same as the complement, seen in Figure 4:8) is the 
outlier; recalculation of the average relative growth rate for R158D excluding the 






































































































































































































Table 4:9 - Growth information of tolC mutants in the 




growth rate (%) ± SD 
P-value against tolC 
complement 
Stationary phase 
OD600 ± SD 
BW25113 pASK-RM 90 ± 14 0.2065 0.73 ± 0.09 
BWΔtolC pASK-RM 109 ± 34 0.603 0.72 ± 0.06 
BWΔtolC pASK-tolC 100 ± 0 -- 0.66 ± 0.06 
D121N 85 ± 20 0.163 0.63 ± 0.08 
Q129L 92 ± 21 0.469 0.58 ± 0.09 
N145L 101 ± 13 0.877 0.62 ± 0.09 
R158D 81 ± 16 0.059 0.56 ± 0.15 
V198D 85 ± 23 0.225 0.60 ± 0.06 
N332L 80 ± 17 0.059 0.60 ± 0.04 
N342A 86 ± 20 0.184 0.61 ± 0.08 
Y344F 89 ± 20 0.287 0.61 ± 0.06 
Q346L 87 ± 13 0.095 0.61 ± 0.05 
S350F 118 ± 35 0.314 0.44 ± 0.29 
Q352A 86 ± 25 0.275 0.67 ± 0.06 
Q352E 88 ± 28 0.405 0.61 ± 0.08 
YFRS 84 ± 19 0.122 0.46 ± 0.28 
D371V 63 ± 26 0.033 0.57 ± 0.10 
D374V 100 ± 12 0.971 0.64 ± 0.06 
K383D 78 ± 10 0.009 0.65 ± 0.08 
K383E 89 ± 23 0.321 0.64 ± 0.08 
R390E 100 ± 13 0.973 0.70 ± 0.08 





Due to the limited information that can be ascertained from MIC assays, growth 
kinetics assays were used to find finer differences between mutants. The MIC results 
can best be related to the stationary phase OD600 values from the growth kinetics 
assays. The MIC for the tolC knockout strain showed increased susceptibility to 
deoxycholic acid, chloramphenicol, fusidic acid, nalidixic acid and novobiocin, while 
stationary phase OD600 values from growth kinetics indicate deficiencies in overall 
growth in deoxycholic acid, chloramphenicol, fusidic acid and novobiocin but not in 
nalidixic acid. This is despite the concentration of nalidixic acid used in the growth 
kinetics assays being higher than the MIC of the knockout strain to nalidixic acid 
when tested on agar. Similarly, the N145L and K383D mutations appeared 
susceptible to 1 μg.ml-1 nalidixic acid on agar, but the OD600 at stationary phase 
indicates that these mutations do not cause susceptibility.  Fusidic acid also shows 
discrepancy between the MIC data and stationary phase OD600 values, as both YFRS 
and D371V showed a decrease in MIC to this substance, but grew to similar OD600 as 
the complemented strain in liquid culture. According to stationary phase OD600 
values, vancomycin failed to inhibit growth of any of the mutants, although MIC data 
indicates that Y344F, Q352A and RENT mutants are more susceptible. This can at 
least in part be attributed to the difference in growth on agar compared to in liquid 
culture, as was apparent in the differences between erythromycin MIC values on agar 
compared to those in liquid broth when determining the concentration of 
anhydrotetracycline to use for induction. 
Despite the discrepancies between MIC results and stationary phase OD600 values, 
the main reason for using growth kinetics in this study was to determine if the 
mutations have any effect on how the bacteria reach any perceived endpoint. A 
summary of the growth rate relative to the tolC complemented strain is shown in 
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Table 4:10 and indicated on the protein structure in Figure 4:9. From the summary 
table, the substrate-specific effect seen in the MIC results is again very clear from 
relative growth rate results. All of the mutations N145L, R158D, V198D, N332L, 
Y344F, D374V, R390E and RENT show some substrate-specificity to their effect. Such 
results indicate the importance of testing a variety of efflux substrates in a study 
such as this, and not relying on a sole reporter, which may not reveal all mutations 
that have an impact on functionality. Meanwhile, the S350F, D371V and K383D 
mutations appear to impact growth rate in all of the tested substrates, and K383D 
additionally caused a decrease in the growth rate in the presence of vancomycin. At 
this point, it should be made clear that the results for the D371V mutant in growth 
kinetics are not comparable to any of the other mutants, the wild-type, knockout or 
complement, as the growth rate in broth lacking any antibiotic was also significantly 
decreased in this mutant relative to the other strains.  
Assessing how open the TolC channel is likely to be by use of vancomycin 
susceptibility suggests that three of the mutations (excluding D371V) cause the 
channel to be more open than the wild-type channel, while the D374V mutation 
probably decreases vancomycin influx through the channel. All three of the 
mutations which cause a decrease in growth rate in the presence of vancomycin also 
impact growth rate in the presence of efflux substrates: K383D causes a decrease in 
the presence of any of the efflux substrates, N332L causes a decrease in the 
presence of chloramphenicol or deoxycholic acid and R158D causes a decrease in the 
presence of nalidixic acid or novobiocin. On the 1EK9 structure of TolC, all of these 
three mutated positions are on the outside of the channel, with side chains facing 
out away from the protein, rather than facing an adjacent helix. Of these positions, 
R158 is closest to the periplasmic tip of TolC, on the third helical turn from the tip, 
and its only apparent binding partner within the TolC trimer is Q346, with which 
inter-protomeric hydrogen bonds could form. However, mutation of Q346 to leucine, 
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which cannot participate in hydrogen bonding, did not cause the same apparent 
vancomycin sensitivity. On the fifth helical turn from the tip, K383 is the next 
furthest of these mutated positions from the periplasmic tip. The effect at this 
position seems to be side-chain length-dependent, as mutation to the longer 
glutamic acid shows no effect in any of the tested substances, despite the same 
charge reversal being present in both mutations. An equivalent mutation to K383D 
has previously been reported on MtrE, on which the wild-type equivalent position is 
E434, mutation of which to lysine causes an MFP-dependent increase in vancomycin 
susceptibility. Furthest from the periplasmic tip, N332 is on the outside of the helical 
barrel but at the level of the equatorial domain, and possibly makes inter-protomeric 
hydrogen bonds with D176 and N177. Mutation to the hydrophobic leucine could 
therefore cause a reorganisation of side chains around this area, forcing a separation 
of the helices and therefore increasing the likelihood of channel opening.  
Overall, growth kinetics analysis has revealed that some mutations have an effect 
which could not be seen on MIC testing. Some of the statistically significant 
differences are a fairly small decrease in relative growth rate, with some mutants still 
growing at 80% of the rate of the wild-type complemented strain. However, there 
were some differences seen in the MIC assays that were not present in growth 
kinetics. Using a higher antibiotic concentration may have provided greater 
difference between mutations, but a compromise was required in order to permit 
maximal growth of the complemented strain while still potentially inhibiting growth 
of efflux-compromised mutants. Results may also have been more comparable had 
liquid broth MIC assays been used, though these are more suited to a large number 
of antibiotics being screened against a smaller number of strains.  
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Table 4:10 - Summary of growth rates relative to tolC-complemented strain. 
Up and down indicate that the growth rate is increased and decreased relative 
to the tolC complemented strain, respectively. A dash indicates no difference 
from the complemented strain. N/a indicates that the mutation was not tested 
with that particular antibiotic. Doc: deoxycholic acid. Nal: nalidixic acid. Cam: 
chloramphenicol. Nov: novobiocin. Fus: fusidic acid. Vanc: vancomycin 
Strain Doc Nal Cam Nov Fus Vanc 
BW25113 pASK-RM Up - - Up - - 
BWΔtolC pASK-RM Down - Down Down Down - 
D121N Down - Down Down - - 
Q129L - - - Down - - 
N145L - - - Down - - 
R158D - Down - Down - Down 
V198D - - Down - - - 
N332L Down - Down - - Down 
N342A - - - - - - 
Y344F Down - - Down Down - 
Q346L - - - - - - 
S350F Down Down Down Down Down - 
Q352A - - - - - - 
Q352E - - - - - - 
YFRS Down Down Down N/a N/a - 
D371V Down Down Down Down N/a Down 
D374V - Down Down Down - Up 
K383D Down Down Down Down - Down 
K383E - - - - - - 
R390E Down - Down N/a - - 





Figure 4:9 - Summary of growth kinetics results on TolC structure. 
Onto a single protomer of TolC (1EK9, light blue) are mapped the positions that 
were mutated, colour coded according to the effect of the mutation as 
determined by growth kinetics assays. In magenta are the adjacent helices from 
the other protomers. Green: mutation has no effect (positions not labelled). 
Yellow: effect observed is dependent on the amino acid mutated to. Blue: 
mutation has an antibiotic-specific effect. Red: mutation shows same phenotype 





4.3 Dye efflux assays 
To give a more direct assessment of pump activity than growth kinetics, cells were 
assessed for their capability to extrude the fluorescent dye, Nile Red, which 
fluoresces when in hydrophobic environments such as the membrane. Using the 
proton decoupling drug CCCP to inhibit RND-efflux activity, cells were pre-loaded 
with Nile Red, diluted in PBS and loaded to 96-well plates with black-sided wells. The 
OD600 was measured, to calculate units of fluorescence per unit of OD, and the 
fluorescence measured every 27 s (the minimum plate cycle time). After five 
readings, glucose was injected to the wells to re-energise the cells, and fluorescence 
measurements continued. Cells that had been killed by boiling were included as a 
negative control, which would give maximum fluorescence. All measurements were 
blank-corrected against a control well containing no cells. Each fluorescence 
measurement was divided by the OD600 measurement for the well, normalising the 
data to “fluorescence per unit OD600”. To account for the amount of variation in raw 
blank-corrected fluorescence readings between wells, the data were further 
normalised by dividing each OD-corrected value by the initial OD-corrected value for 
that well, to give a proportion of initial fluorescence. Example curves after all 
normalisation steps are shown in Figure 4:10. 
Injection of glucose is a slower step than the measurement of fluorescence, 
therefore there was a larger interval of 84 s between fluorescence readings 
immediately before and after glucose injection (marked as “Lag” on Figure 4:10). This 
gap between readings was too large to determine any efflux kinetics, as steady state 
had already been achieved by the time the first post-injection reading was 
completed. However, it was still possible to calculate the proportion decrease of 
fluorescence. As the raw blank-corrected readings were increasing and decrease 
randomly with noise, the average of five consecutive readings was used for 
calculation of the proportion loss, to account for this variation and prevent selection 
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of any particularly high or low values. Therefore, the equation used to calculate the 
proportion (as a percentage) decrease of fluorescence was 100 x (1 – (average of five 
normalised readings post-injection / average of five normalised readings pre-injection). 
The results from this calculation are shown in Figure 4:11, using n = 2 biological 
replicates. Negative values, indicating that fluorescence rose after injection of 
glucose, indicate that the dye was not being removed from a hydrophobic 
environment; the boiled cell negative control showed a small increase in 
fluorescence, as did the tolC knockout strain and the D371V mutant. As this 
experimental design was unable to provide any detail of efflux kinetics, it was not 
repeated with extra biological replicates, and therefore statistical analysis is of 
limited power. Despite this, the tolC knockout and both the V198D and D371V 
mutants had p-values <0.05 when Welch’s T-test was used to compare them to the 
complemented strain. The mutations N145L, R158D, N332L, N342A, S350F, K383D, 
R390E and RENT all have p-values <0.3 and all had higher retention of fluorescence. 
To attempt to measure kinetics of efflux using this technique, the Fluostar 
programme was modified to read in well-mode rather than plate mode. This change 
makes the machine complete the entire read and injection process for a single well 
before moving onto the next, rather than reading each well in turn once per cycle, 
thus eliminating the slow process of injecting each well in turn on the whole plate. 
Using this mode, none of the strains, including the wild-type strain, showed any 
efflux activity (results indicated in Figure 4:12). The absolute fluorescence readings 
also decreased markedly from the start of the plate to the end of the plate (from 
tens of thousands to only hundreds of fluorescence units). Dye efflux assays were 
therefore abandoned with n = 2 in plate mode and no information available from well 




Figure 4:10 - Fluorescence intensity change with time in dye efflux assay. 
Values have been corrected to account for OD600 differences in each well. Data is 
from a plate-mode assay. The fluorescence intensity has been calculated as a 
proportion of the starting intensity. Injection of glucose is marked by an arrow, and 








Figure 4:11 - Percentage of fluorescence lost by tolC mutants in a plate-mode 
dye efflux assay. 
Values have been corrected to account for OD600 differences in each well. The 
percentage of fluorescence lost refers to the relative fluorescence per unit OD600 
before and after injection of glucose when the assay was run in plate mode. Negative 
values indicate that post-injection, the fluorescence reading increased relative to 
pre-injection; a value of 100 would indicate complete loss of fluorescence. n  = 2 






Figure 4:12 - Proportion of fluorescence retained by tolC mutants in a well-mode 
dye efflux assay. 
Values have been corrected to account for OD600 differences in each well. The 
proportion of fluorescence retained refers to the relative fluorescence per unit OD600 
before and after injection of glucose. A value of 1 would indicate that the 
fluorescence is the same before and after injection; a value of 0 would indicate 




Growth kinetics and MIC assays utilised cellular growth to report on efflux activity, 
but do not give a direct measurement of efflux pump function. To provide a more 
direct measurement of pump function, fluorescent dye efflux assays were used. Nile 
Red was chosen as the dye because it fluoresces in hydrophobic environments, such 
as the cell membrane, and has been shown to be a good reporter of efflux activity. 
Other efflux substrate dyes that could be used include Hoechst H33342 and ethidium 
bromide, both of which also have excitation and emission wavelengths compatible 
with the Fluostar plate readers used. However, both H33342 and ethidium bromide 
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fluoresce when bound to nucleic acids, and therefore the observed loss of 
fluorescence is a result of dye separating from nucleic acid, rather than the actual 
efflux activity. Loss of Nile Red fluorescence, meanwhile, indicates removal of the 
dye from the membrane, which should be a direct result of AcrB activity, as this pump 
takes its substrates from the cytoplasmic membrane.   
This approach was used in an effort to determine some efflux kinetics for the 
different mutations. However, as efflux occurs rapidly upon re-energisation of the 
cells, only steady-state parameters (before and after efflux) could be assessed. 
Attempting to read in well-mode to eliminate the long delay between re-
energisation and the next measurement resulted in very little apparent efflux for any 
strain. In plate mode, the entire assay is completed in 15 minutes, whereas in well-
mode, each well is individually focused on for 5 min, which may increase settlement 
of cells and any precipitates, leading to inaccurate readings. It will also increase the 
amount of water lost through evaporation in wells read later than those read earlier, 
as the injector requires the plate to be uncovered for the duration of the assay. The 
difference in time taken to start readings for each well also means that the cells 
within each well are de-energised by CCCP for different durations, before addition of 
glucose to recover the cells. As Nile Red is a lipophilic dye, and fluoresces in 
hydrophobic environments, it is likely that background fluorescence will increase 
over time as more dye adheres to the plastic surface of the 96-well plate, as seen by 
Hoechst H33342 binding to both PTFE and quartz (Verchère et al., 2013). Some 
precipitation was also observed in the Nile Red stock solution a day after the assays 
were completed; it is possible that some small granules of precipitated Nile Red also 
stared to form in the assay wells, which would also increase background fluorescence 
over time and lead to varying degrees of light scattering from the solution, which 
may affect readings. As this approach was only able to provide information regarding 
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the steady state of each mutant, and at the population level, the technique was 
abandoned in favour of flow cytometry.  
Despite the above, some results were obtained from dye efflux assays – as Figure 
4:11 indicates, the D371V mutant appears to be as defective in dye efflux as is the 
tolC knockout strain. From the plate-mode data, Welch’s T-test comparing each 
mutation against the complemented strain indicates that the only other mutation 
which has a statistically significant effect (albeit from only two biological replicates) 
is V198D (p-value = 0.011), which showed a decrease in fluorescence intensity only 
about half that of the complemented strain. Meanwhile, more replicates would 
probably show N332L and N342A to also be statistically significantly different, as 
Welch’s T-test with n = 2 gave values of 0.076 and 0.087, respectively, for these 
mutations when compared against the complemented strain. In contradiction to the 
results from MIC and growth kinetics assays, the R390E/R392T double mutant may 
be capable of removing more Nile Red from the cell (67%) than can the 
complemented strain (56%), with a p-value of 0.060 when n = 2 and the mutant was 
compared against the complemented strain by Welch’s T-test. Although the MIC and 
growth kinetics assays suggest that the RENT mutant may be slightly defective in 
efflux activity, they also show a substrate-specific effect – it is therefore plausible 
that the slight increase in efflux activity shown by dye efflux assays is also substrate-
specific, and that the results with H33342 or ethidium bromide may be quite 





4.4 Flow cytometry 
Experiments in this section were designed by Dr Jessica Blair, who also assisted with 
initial running and interpretation of these experiments. 
All of the results so far have investigated the effect of the mutations at the 
population level. To assess what impact the mutations are having on individual cells, 
flow cytometry was used to measure ethidium bromide fluorescence on a cell by cell 
basis. To allow identification of cells within the mixture, cells were essentially 
counter-stained with Syto84, a DNA intercalating fluorophore which is not pumped 
out of E. coli cells. The Attune flow cytometer used for these experiments has two 
lasers, on yellow and blue channels, allowing excitation and measuring of emission at 
two distinct wavelengths in a single experiment. In this experimental setup, Syto84 
fluorescence was measured on the yellow laser channel, and ethidium bromide 
fluorescence measured on the blue laser channel. As is standard practice in flow 
cytometry experiments, forward scatter and side scatter were also measured, which 
report as first approximations on relative particle size and complexity, respectively. 
Any particle that is measured by the flow cytometer should therefore have relatively 
high forward scatter, side scatter and yellow laser channel fluorescence intensity.  
On the Attune software, graphs were selected to plot side scatter against forward 
scatter, and Syto84 fluorescence against forward scatter, as well as a histogram 
showing the frequency of occurrence of each value for Syto84 fluorescence (shown 
in Figure 4:13). A rough gate was positioned on the graph showing Syto84 
fluorescence and forward scatter, such that all particles measured within this gate 
would likely be cells, and was therefore named “cells”. The flow cytometer was then 
run, set to record a minimum of 150,000 events within this gate, ensuring sufficient 
cell count from the experiment. The gate was then altered for each sample in post-
processing, to select the data points that are most likely to be cells, and exclude any 
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that might, for example, show a disproportionately high Syto84 fluorescence given 
the forward scatter value, which would likely not be cellular. The plot of side scatter 
against forward scatter was used to aid the positioning of this gate, as it showed de-
selection of events as they were excluded from the gate, thus allowing events of low 
complexity to be excluded.  
The “cells” gate was then used as the selection for analysis by other charts. Numerical 
data in this section were taken from histogram plots showing the number of events 
with each value of ethidium bromide fluorescence. As seen in Figure 4:14, there were 
two distinct peaks on the histogram, one showing higher ethidium bromide 
fluorescence and the other lower. New gates were positioned to separate these 
peaks, allowing events in subsequent graphs to be coloured according to which of 
these sub-populations they belonged.  
It is feasible that larger cells might be capable of containing more ethidium bromide, 
as concentration equals amount of substance divided by volume; a cell of greater 
volume requires a greater amount of substance in order to reach the same internal 
concentration of that substance. Therefore, ethidium bromide fluorescence was 
plotted against forward scatter, to ensure that there was no correlation between 
perceived cell size and the intensity of ethidium bromide fluorescence. If ethidium 
bromide fluorescence intensity of the cell was a function of cell size, then this graph 
would show a continuous population with a shift from low fluorescence to high 
fluorescence with increasing forward scatter. However, as Figure 4:14 indicates, 
there are two distinct populations with broadly equally forward scatter (the 
populations have the same x-axis values) but different fluorescence intensities.  
Both Syto84 and ethidium bromide fluoresce when bound to nucleic acids. It is 
therefore not unreasonable that fluorescence resonance energy transfer may cause a 
shift in emission wavelengths of one or both of these fluorophores, when both are 
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bound. It may also be possible that binding of one either enhances or inhibits binding 
of the other. To ensure that there was no correlation between the two fluorescence 
readings, Syto84 fluorescence was plotted against ethidium bromide fluorescence, 
shown in Figure 4:14. As was the case when comparing ethidium bromide 
fluorescence with forward scatter, there were two distinct populations on this graph, 
both of which showed broadly equal Syto84 fluorescence (the populations have 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To compare mutations by flow cytometry, all cultures contained 2 ng.ml-1 
anhydrotetracycline. Three biological replicates were analysed for each mutation.  
Most cultures showed the same split population as described above, with a sub-
population showing high ethidium bromide fluorescence and another sub-population 
showing low ethidium bromide fluorescence, although some cultures did show only a 
single peak for ethidium bromide fluorescence, as displayed in Figure 4:15. For 
cultures showing only one peak, the gate boundary for high and low fluorescence 
intensity groups was set at the tail of the peak, where the count was less than five. 
This was also done on the single very broad peak that was present for the YFRS 
mutant. Given that the YFRS peak extended over the entire high fluorescence peak 
of the complemented strain, but only over a small portion of the low fluorescence 
peak, this broad peak was measured as the high fluorescence peak, with the low 
fluorescence gate set with the same rules as for the other histograms with only a 
single peak. On any histogram that showed a second peak, no matter how small, the 
gate boundary was set at the value with the minimum count between the two peaks. 
The results for each mutant are shown in Table 4:11. 
Considering the proportion of cells that appear in each peak (displayed in Figure 
4:16), the tolC knockout and point mutants S350F and YFRS showed almost 100% of 
cells to have high ethidium bromide fluorescence. The point mutations D371V and 
K383D both caused a change in the proportion of cells with high or low ethidium 
bromide fluorescence such that a higher proportion showed high fluorescence than 
in the wild-type or complemented strains, but a lesser proportion than in the 
knockout strain. A Bonferroni pairwise T-test gives p-values of 0.015, 4.7x10-6, 5.8x10-
6 and 5.4x10-6 for the complemented strain against D371V, the knockout strain, 
S350F and YFRS, respectively, while all other pairwise T-tests against the 
complemented strain gives 1.00 as the p-value. These same mutations showed p-
values <0.01 when compared against the complemented strain by Bonferroni 
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pairwise T-test of the total population x-mean ethidium bromide fluorescence 
intensity. The other mutations again had p-values against the complemented strain 
of 1.00 when tested by Bonferroni pairwise T-test. The whole population and each 
sub-population fluorescence intensities are displayed in Figure 4:17. 
In the lower fluorescence intensity sub-population for each strain, most of the strains 
appear to show similar fluorescence intensities. Only the D371V mutation showed a 
statistically significant difference when all values were analysed by Bonferroni 
pairwise T-test. In this case, the average fluorescence intensity of the sub-population 
increased from approximately 9000 units in the complemented strain to 
approximately 18000 units in the D371V point mutant. Similarly, Bonferroni pairwise 
T-test showed no significant difference between any of the mutants, except for 
D371V against each of the wild-type, knockout and complemented strains, and S350F 
against only the wild-type strain. The fluorescence intensity of the higher 
fluorescence sub-population was higher in both the S350F and D371V mutants than 






Figure 4:15 - Comparison of flow cytometry histograms for tolC mutants. 
Example histograms showing examples of distribution of ethidium bromide 
fluorescence in the population, compared to that of the ΔtolC and tolC 
complemented strains. Distribution can be predominantly low-intensity (WT), a single 
high-intensity population (S350F), a single population with wide range of intensities 




Table 4:11 - Data derived for tolC mutants from flow cytometry. 
































17.4 ± 2.9 89% 12.6 ± 0.6 11% 56.5 ± 3.1 
BWΔtolC 
pASK-RM 
75.9 ± 5.6 <1% 10.9 ± 5.8 >99% 76.0 ± 5.6 
BWΔtolC 
pASK-tolC 
22.7 ± 17.1 77% 8.8 ± 0.9 23% 66.6 ± 5.6 
D121N 22.3 ± 12.8 83% 9.7 ± 0.7 16% 88.4 ± 7.1 
N145L 11.3 ± 1.3 96% 8.5 ± 0.7 4% 88.9 ± 8.9 
Y344F 13.8 ± 3.5 93% 8.9 ± 1.1 7% 88.3 ± 7.1 
S350F 97.0 ± 23.2 1% 9.0 ± 1.4 99% 98.0 ± 23.9 
YFRS 65.2 ± 3.6 <1% 5.5 ± 3.3 >99% 65.6 ± 3.9 
D371V 73.5 ± 20.7 39% 18.0 ± 5.5 61% 110.6 ± 26.9 







Figure 4:16 - Proportion of cells in each sub-population seen in flow cytometry. 
The proportion of total cells that form the sub-populations with low (blue) and high 




























































































































































































Flow cytometry is a powerful approach for obtaining single-cell information from a 
population of cells. Although it is an established method for studying eukaryotic 
cells, it is less routinely used in the study of bacteria. Despite this the relatively 
limited application of flow cytometry in bacteriology, there have been some 
publications indicating the potential use for this technology, particularly in the field 
of multidrug resistance. Over 20 years ago, addition of metabolic inhibitors, including 
CCCP, to cells being analysed by flow cytometry showed an increase in ethidium 
bromide fluorescence, which was attributed to inhibition of AcrAB (Jernaes & Steen, 
1994). A little more recently, it has been used to show that exposure to 
chlorpromazine increases the accumulation of ethidium bromide in E. coli (Paixāo et 
al., 2009), presumably by a combination of restricting acrB expression and inhibiting 
multidrug efflux pumps (Bailey et al., 2008). Another study has shown how flow-
cytometry (and the associated fluorescence-activated cell sorting) can be used as a 
step towards finding mutations increasing efflux activity (Whitehead et al., 2011), in 
the case of this example by de-repression of acrEF. However, this thesis appears to 
be the first example of point mutations within bacterial tripartite efflux assemblies 
being analysed by flow cytometry, and therefore is the first time that flow cytometry 
has been used in the investigation of bacterial tripartite efflux pump assembly.  
The most striking aspect of the results obtained from flow cytometry is that the 
population of both the wild-type strain and most of the mutants tested is split into 
two distinct sub-populations. One sub-population displays low fluorescence intensity 
on the channel measuring ethidium bromide fluorescence, and the other displays 
high fluorescence intensity. The results can be interpreted as meaning that the sub-
population with low fluorescence displays higher efflux activity than that with high 
fluorescence. This heterogeneity of the population has previously been observed in a 
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strain expressing an OmpC:GFP fusion, to report on expression of ompC (Sanchez-
Romero & Casadesus, 2014); in that study, heterogeneity was observed in both GFP 
fluorescence intensity and ethidium bromide fluorescence, although one of the sub-
populations in that study apparently showed essentially zero ethidium bromide 
fluorescence, and it is unclear how cells were gated to eliminate non-cellular events 
from the data.  
As was done with MIC assays, the effect of anhydrotetracycline was analysed by using 
a series of concentrations in the growth medium. Flow cytometry results broadly 
correlate with those seen in the MIC assay, whereby no or very little inducer cause 
higher efflux activity than the higher concentrations of inducer. In the case of the 
tolC gene being under control of the tetracycline promoter, this effect could also be 
explained as an increased inducer concentration leads to greater overexpression of 
the TolC protein, which means there are more channels available for the dye (or, in 
MIC assays, antibiotic) to use to gain access to the periplasm. When 
anhydrotetracycline was added to cultures at a final concentration of 2 ng.ml-1, the 
wild-type and complemented strains appeared to be essentially the same as each 
other – the decreased fluorescence in the “efflux active” population of the 
complemented strain, and the decreased fluorescence in the “efflux deficient” 
population of the wild-type strain, are not statistically significant. Therefore,  
2 ng.ml-1 is a suitable concentration at which to use anhydrotetracycline for this 
study. Importantly, anhydrotetracycline does not appear to be an inhibitor of AcrB at 
this low concentration, as the fluorescence intensity of the “efflux active” peak is the 
same at 2 ng.ml-1 anhydrotetracycline as it is in the absence of it. However, the data 
suggest that at higher concentrations, anhydrotetracycline may have an inhibitory 
effect, as ANOVA analysis indicates a significant (though small) difference between 
the fluorescence intensities of the “efflux active” sub-population, whereby 20 or  
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200 ng.ml-1 anhydrotetracycline causes higher fluorescence than 0 or 2 ng.ml-1 
anhydrotetracycline.  
Given that the difference between mutants used in this study is the point mutation 
each has in its coding sequence, any defect in functionality was expected to manifest 
as an increase in fluorescence in the “efflux active” peak (upper part of Figure 4:18). 
However, this is not what was observed. Instead, the population fluorescence 
intensity was driven by a change in the proportion of the population that was efflux 
active or efflux deficient (lower part of Figure 4:18). This split population could 
possibly be explained in part by the unequal partitioning of AcrAB-TolC upon cell 
division (Bergmiller et al., 2017), whereby half of all newly-divided cells contain very 
little AcrAB-TolC, and so will form a temporarily efflux deficient sub-population.  Of 
the mutants tested, S350F appeared as knockout, with the population almost 
entirely efflux deficient, while D371V and K383D showed an increased proportion of 
efflux deficient cells compared to the complemented strain. These results are 
consistent with the other in vivo data as shown in Sections 4.1and 4.2, and the split 
population may help to explain the apparent discrepancy whereby a population is 
sufficiently impacted by a toxic efflux substrate to grow more slowly, yet still be 
capable of achieving wild-type levels of overall growth (for example, on MIC plates 
and the stationary phase OD600 readings in growth kinetics). Only the D371V mutant 
showed an increase in fluorescence intensity of the “efflux active” peak, suggesting 
that this mutation either decreases efflux efficiency of ethidium bromide by TolC-
dependent efflux systems, or that the dye can re-gain entry to cell more quickly in 
this mutant. Both the D371V and S350F mutants showed increased fluorescence in 
the “efflux deficient” peaks, compared to any of the wild-type, knockout or 
complemented strains. This indicates that these mutations either have a pleiotropic 
effect, or enable dye to gain entry to the cell more easily. In both of these mutants, it 
was noted that within the higher fluorescence peak, fluorescence intensity showed 
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some correlation with forward scatter, suggesting that larger cells showed more 
ethidium bromide fluorescence. Fortunately, the same was not true when 
considering any populations as a whole – overall, ethidium bromide fluorescence and 
forward scatter did not correlate.   
The only strain to show a single peak shifted towards higher fluorescence intensity, 
and which was also a broader peak, was the YFRS mutant. The network of hydrogen 
bonds which hold TolC closed when not bound to an MFP is disrupted in this mutant, 
causing the channel to be more prone to allowing influx of substances. The 
broadness of the peak for this mutant may be caused by a difference in tolC 
expression across the population, whereby efflux is occurring poorly in most cells, 
but those cells expressing more TolC allow more rapid influx of the dye back into the 
cell. Alternatively, the mutation may be preventing efficient division of cells, as the 
highest fluorescence readings were in the cells with highest forward scatter 
readings.  
Mutants D121N, N145L and Y344F did not show any differences compared to the 
complemented strain, despite being included in the flow cytometry assay due to 
other in vivo approaches showing each of them to cause substrate-specific effects. 
The lack of difference compared to the complemented strain be another example of 
any effect being susbtrate-specific, and it may therefore be the case that repeating 
flow cytometry experiments with another fluorescent efflux susbtrate may prove 
these mutations to impact efflux. A recent study used flow cytometry to show that 
deletion of tolC and addition of the proton decoupling agent CCCP cause an increase 
in the intracellular accumulation of trimethoprim (Phetsang et al., 2016), which is 
another fluorescent substrate of AcrAB-TolC. Alternatively, Nile Red could be used, 
as this was seen in dye efflux assays (Section 4.3) to be an effective reporter of 
AcrAB-TolC activity. However, when choosing an efflux substrate dye for use in flow 
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cytometry, the excitation and emission wavelengths of both the efflux substrate and 
the cellular marker dye (in this case, Syto84) must be considered in the context of the 
lasers available on the flow cytometer. The lasers available for this study had 
wavelengths of 488 nm and 561 nm, for excitation of the dyes. According to the 
product data provided by the supplier for Syto84, this dye has an excitation 
maximum of 567 nm, and thus must be used on the yellow (561 nm) laser. As Nile Red 
has an excitation maximum of approximately 550 nm, this would also require 
detection on the yellow laser channel. Therefore, Nile Red is not compatible with 
Syto84 for use on the Yellow/Blue Attune flow cytometer, and an alternative cellular 
marker would be required in order to use Nile Red.  
It would be very useful to assess membrane permeability by flow cytometry using a 
fluorescent conjugant of vancomycin, such as BODIPY-FL-vancomycin. Unfortunately, 
the BODIPY-FL fluorescent conjugant has an excitation maximum of 505 nm, and, 
given the narrow peak on the excitation spectrum for this molecule, it may therefore 
not excite particularly well with the 488 nm laser. It is also unclear what effect the 
conjugant moiety may have on movement of vancomycin through the TolC channel, 













Figure 4:18 - Expected and observed difference in fluorescence intensity with 
decreasing efflux activity. 
From left to right, efflux is depicted as decreasing, from efflux active (blue) through 
partially efflux active (green) to efflux deficient (red) populations. The top row 
indicates the expected effect of decreasing efflux efficiency, whereby the single 
peak was expected to move right as efflux activity decreased, as ethidium bromide 
fluorescence per cell increased. What actually happens is shown in the bottom row, 
whereby the “efflux active” peak drops in count and the “efflux deficient” peak gains 





4.5 Confirmation of the presence of TolC protein during in vivo analyses 
Given results from in vivo assays, it was necessary to confirm that mutant protein was 
present in cells grown in the conditions used. To achieve this, cells were grown in the 
same conditions as for the flow cytometry assays but scaled up to 500 ml to enable 
isolation of the membranes. Cells were harvested at stationary phase and lysed using 
an Emulsiflex C3 homogeniser. Membrane fractions were then harvested, solubilised 
and the relative total membrane protein concentration of each sample measured by 
Bradford assay. An equal amount of total membrane protein from each sample was 
then resolved by SDS-PAGE, and the proteins blotted by Western blot, probed using 
polyclonal α-TolC antibodies. Alkaline phosphatase-conjugated secondary antibody 
was then added, allowing the use of the chromogenic substrate NBT/BCIP for 
developing the blot. A photograph of the relevant part of the developed blot is 
shown in Figure 4:19. The blot indicated that the wild-type strain produced very little 
TolC protein compared to the tolC-complemented strain. Of the mutations that 
showed the greatest apparent effect on efflux activity, D121N, S350F, and YFRS 
showed comparable levels of TolC protein as the complemented strain. The K383D 
and R390E mutations showed slightly lower levels of TolC protein than the 
complemented strain, but more than the wild-type strain. The amount of D371V 
mutant TolC protein was substantially lower than amount of TolC in the 
complemented strain, but was comparable to the amount of TolC protein in the wild-
type strain. Multiple bands are visible for each strain, presumably one band 














































































Figure 4:19- Western blot confirming TolC protein is present during assays. 
Photograph of Western blot showing TolC protein (52 kDa) for mutants of tolC 
grown in the same conditions as in preparation for flow cytometry. Following SDS-
PAGE resolution of membrane preparations, proteins were transferred to 
nitrocellulose and probed with (rabbit-raised) α-TolC polyclonal antibody, followed 
by α-rabbit AP-conjugated secondary antibody. Chromogenic substrate NBT/BCIP 
was added to develop the blot. The sample volume loaded for SDS-PAGE was 
adjusted to load equal amounts of total membrane protein per sample. The 62 kDa 
marker band is visible. 
 
Discussion 
There are several possible reasons why a protein may lose functionality after 
mutagenesis. Whilst the aim of much of the mutagenesis in this study was to cause 
loss of function by preventing binding of TolC to its cognate MFPs, the assays used to 
assess functionality cannot determine why a certain mutation has the effect it does. 
To check that mutant protein is expressed and present in the membrane, membranes 
were purified from cultures of the mutation-bearing strains and analysed by Western 
blot with polyclonal α-TolC antibodies. All of the mutant TolC proteins were present 
in the membrane with at least as much abundance as in the wild-type strain, and 
therefore a lack of protein expression or aberrant localisation is the not the cause of 
loss of functionality. It is not known which part of TolC is recognised by the 
antibodies used in this study, but for correct recognition of the protein, it is likely 
that the protein must be folded at least mostly correctly. Protein misfolding is 
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therefore also unlikely as a cause of the differences in functionality, although it 
remains a possibility.  
Of the mutant proteins, lowest abundance was observed for D371V, which also had 
the greatest effect on phenotype. However, the relative protein abundance is not 
the sole cause of all the differences in phenotype, as the knockout strain grows well 
in normal laboratory conditions. As the band intensity is similar to that of the wild-
type strain BW25113 pASK-RM, it is also highly unlikely that the relative decrease in 
amount of TolC D371V compared to the complemented strain caused the increased 
susceptibility to antibiotics and decreased efflux of dyes. This mutation was 
predicted to have one definite effect, in replacing part of the gate that selectively 
excludes ions from passing through the periplasmic end of TolC, and a second 
possible effect of preventing binding of the MFP tip – or even possibly the top of the 
RND transporter – to the tip of TolC. Which of these actually happens cannot be 
determined from these in vivo assays alone, though use of in vitro protein-protein 
interaction analyses, such as the glycerol gradient approach used in Section 6.1 
would allow determination of whether or not TolC-D371V can interact, even if it 




CHAPTER 5: RESULTS – PROBING THE 
INTERACTION FROM THE MFP SIDE 
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5.1 Minimum inhibitory concentrations 
As with the process of investigating the MFP-OMC interaction from the side of the 
channel, minimum inhibitory concentration assays were used as an approved method 
of testing whether or not the mutations cause resistance or susceptibility to the 
library of tested antibiotics. The results from the tolC MIC results with differing 
concentrations of anhydrotetracycline were used to calibrate the acrA MIC 
experiments; anhydrotetracycline was added to a final concentration of 20 ng.ml-1 in 
the MIC agar. The same library of antibacterial compounds was screened for the acrA 
mutants as for the tolC mutants. The MICs of each antibiotic to each mutation is 
detailed in Table 5:1. None of acriflavine, chloramphenicol, nalidixic acid, rifampicin 
or tetracycline showed any difference between the knockout, complement or 
mutants. Deoxycholic acid showed no significant difference between the wild-type, 
knockout and complemented strains, but the GS-tip, Δhelices and Δhairpin mutations 
all caused a decrease in the MIC from 4 mg.ml-1 to 1 mg.ml-1, a difference of two 
doubling dilutions. The MIC of fusidic acid was lower against any strain expressing 
any variant of acrA from a plasmid than against the knockout strain, which in turn was 
lower than against the wild-type strain with empty vector. While the knockout and 
complemented strains showed no significant difference when challenged with 
erythromycin, both were significantly less tolerant to erythromycin than was the 
wild-type strain. The acrA mutant in which the AcrA hairpin helices were removed, 
leaving the tip intact, was less tolerant to erythromycin than the complemented 
strain, but the other mutants appeared the same as both the knockout and 
complemented strains. The MIC of novobiocin against the complemented strain was 
the same as against the wild-type strain; the MIC of novobiocin against the acrA 
knockout strain was significantly lower than against the complemented strain. The 
GS-tip, Δhelices and Δhairpin mutants were all as susceptible to novobiocin as was 



































































































































































































































































































































































































































































































































































































































































































As before, the antibiotic challenge with vancomycin is different to the challenge with 
other drugs used in this study, in that it is not an efflux substrate but rather utilises 
the OMC to gain access to the periplasm through the outer membrane. Vancomycin 
susceptibility was increased in the complemented strain compared to either the wild-
type or knockout strains, with a difference of two doubling dilutions. Both the GS-tip 
and Δhairpin mutants showed the same increased susceptibility to vancomycin as did 
the complemented strain. To determine the TolC-dependency of the increased 
vancomycin susceptibility caused by the GS-tip mutant, the MIC was also determined 
for the BWΔtolC pASK-acrA(GS-tip)B strain, and found to be 256 μg.ml-1, the same as 
the BWΔtolC pASK-RM strain. Each of the S139G, TVYF and Δhelices mutants had an 
MIC to vancomycin between those of the knockout and complemented strains, of a 
single doubling dilution difference compared to either, and therefore could not be 
classified as significantly differently to either. 
Of the efflux substrates, only deoxycholic acid and novobiocin showed MIC profiles 
as expected, based on the low MIC of the complemented strain in comparison to the 
wild-type and knockout strains. To assess whether this was due to the concentration 
of anhydrotetracycline used, the wild-type, acrA knockout and acrA complemented 
strains were tested in chequerboard assays. Chequerboard assays test for synergy or 
antagonism between two compounds by assessing growth at different 
concentrations of either and both substances. In this case, the concentration of 
anhydrotetracycline varied by row on a 96-well plate, and the concentration of fusidic 
acid varied by column on the same plate, essentially allowing comparison of the MIC 
of fusidic acid against the tested strains at a range of inducer concentrations. In the 
right-most column, fusidic acid was omitted, leaving only a range of 
anhydrotetracycline concentrations, while in the bottom row, anhydrotetracycline 
was omitted, testing the MIC of each strain to fusidic acid without inducer. To 
remove ambiguity regarding growth, or lack thereof, within any wells, the final OD600 
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was measured. Any OD600 less than 20% that of the maximum on the plate was 
interpreted as a lack of growth. Table 5:2 shows the OD readings and highlights wells 
which were recorded as having no growth in these assays. 
From the chequerboard assays, it is apparent that fusidic acid has the same MIC 
against the BW25113 pASK-RM strain regardless of the concentration of the inducer, 
up to 128 ng.ml-1 anhydrotetracycline, at which point the MIC appears to increase to a 
higher concentration than included in the assay. Although the MIC is lower against 
the knockout strain than the wild-type, the MIC is again unaffected by 
anhydrotetracycline concentration. The results for the BWΔacrA pASK-acrAB 
complemented strain however, were very different. In the complemented strain, it 
appears that there is some synergy between the two compounds, as the MIC to 
fusidic acid decreases as the concentration of anhydrotetracycline increases. The 
difference is noticeable between 16 and 32 ng.ml-1 anhydrotetracycline, at which 





Table 5:2 - Chequerboard assay results.  
OD600 values read from chequerboard assays of fusidic acid against 
anhydrotetracycline for the wild-type, ΔacrA and acrA-complemented strains. 
Highlighted in grey are values <20% of the maximum OD600 value. 
BW25113 
pASK-RM 
[Fusidic acid] / μg.ml-1 



















128 0.83 0.74 0.63 0.80 0.75 0.83 0.88 0.92 0.92 0.96 0.91 1.07 
64 0.17 1.13 0.68 0.80 0.90 0.77 0.84 0.88 0.87 0.88 0.80 0.87 
32 0.08 1.06 0.71 0.64 0.77 0.81 0.85 0.78 0.80 0.80 0.76 0.78 
16 0.13 1.09 0.76 0.65 0.85 1.03 1.10 0.96 1.03 1.02 0.96 0.87 
8 0.14 1.02 0.83 0.71 0.76 0.96 0.96 0.99 0.97 1.05 1.05 1.08 
4 0.12 1.13 0.93 0.75 0.90 1.08 1.14 1.08 1.23 1.19 0.93 1.05 
2 0.15 0.95 0.90 0.77 0.85 1.00 0.93 0.97 1.01 1.05 1.02 1.04 




[Fusidic acid] / μg.ml-1 



















128 0.05 0.08 0.14 0.17 0.21 0.23 0.36 0.47 0.59 0.83 1.07 1.33 
64 0.06 0.07 0.10 0.21 0.25 0.27 0.32 0.41 0.48 0.73 0.99 1.34 
32 0.03 0.04 0.09 0.17 0.25 0.34 0.41 0.46 0.53 0.65 1.14 1.35 
16 0.05 0.05 0.08 0.16 0.29 0.39 0.49 0.51 0.58 0.75 1.12 1.38 
8 0.07 0.04 0.07 0.15 0.29 0.40 0.50 0.49 0.55 0.70 1.17 1.42 
4 0.07 0.05 0.09 0.11 0.29 0.40 0.50 0.54 0.64 0.67 1.03 1.42 
2 0.05 0.06 0.08 0.12 0.29 0.36 0.44 0.54 0.66 0.60 1.10 1.43 




[Fusidic acid] / μg.ml-1 



















128 0.05 0.08 0.09 0.04 0.07 0.06 0.08 0.08 0.62 0.51 1.01 1.41 
64 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.07 0.09 0.70 0.88 1.32 
32 0.06 0.04 0.04 0.04 0.06 0.06 0.07 0.07 0.13 0.58 0.89 1.39 
16 0.08 0.07 0.08 0.24 0.38 0.67 0.14 0.07 0.45 0.74 0.89 1.41 
8 0.07 0.07 0.24 0.86 1.08 1.13 1.13 1.16 1.11 1.02 1.02 1.45 
4 0.07 0.07 0.44 1.10 1.19 1.13 1.14 1.21 1.21 1.17 1.16 1.45 
2 0.08 0.12 0.84 1.13 1.17 1.15 1.19 1.17 1.23 1.26 1.23 1.46 





As there was very little difference between the BWΔacrA pASK-RM and BWΔacrA 
pASK-acrAB strains, but significant difference between both of these strains and the 
BW25113 pASK-RM strain, it appears that MIC assays do not work particularly well 
when expressing acrAB from the pASK vector. For most of the antibiotics tested, the 
knockout and complemented strains appeared the same, and so the colonies that 
grew on the MIC plates were tested by colony PCR for both chromosomal and 
plasmid-borne copies of acrA, to ensure the genotype had been corrected assigned. 
The results from the colony PCR indicated that the genotype had been correctly 
assigned, therefore the reason for the complemented strain appearing knockout 
instead of wild-type for most antibiotics is unclear. One possibility is that the 
complemented strain overexpresses AcrA in the conditions used in this MIC assay, 
causing increased permeability of the cell envelope, which manifests as increased 
susceptibility to vancomycin, as seen in these MIC assays. Increased permeability of 
the cell envelope will cause increased susceptibility to most of the efflux substrates, 
as the rate of influx will increase to match, or even exceed, the rate of efflux, even 
with less pressure from the concentration gradient. Although several of the tested 
antibiotics (erythromycin, fusidic acid, novobiocin) are lipophilic and expected to 
cross the OM by diffusion through the bilayer rather than through porins, they 
appear to behave differently in the acrA-complemented strain. This difference may 
be explained by differences in how efficiently each drug crosses the bilayer, and how 
much more easily it can gain access through an open TolC channel. Alternatively, it 
may be that the shape of the OM changes around the TolC protein when AcrA is 
bound – either model of interaction of the entire complex must cause the inter-
membrane distance to change from its average value. The helical bundling model 
causes a compression while the tip-to-tip model causes an expansion. If we consider 
the density of the LPS molecule packing, and in particular consider the O-antigen, 
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then local curvature of the membrane must cause different relative densities of O-
antigen: membrane invagination could be expected to locally increase O-antigen 
density, while the tips of any protrusion could be expected to have lower O-antigen 
density. As stated in Section 1.1, the O-antigen is not generally considered important 
in the study of antibiotic resistance, even though permeation of the OM by 
macrolides is dependent upon the length of the O-antigen. It may therefore be a 
worthwhile experiment to repeat these experiments with a deep-rough mutant, to 
determine the effect of acrA deletion and (mild) over-expression in both strains. 
Although 20 ng.ml-1 anhydrotetracycline gave reasonable results in the MIC assays 
for tolC variants, it may not be a suitable concentration of inducer to use for acrA 
variants.  
The chequerboard assay of anhydrotetracycline concentration against fusidic acid 
concentration indicate that anhydrotetracycline does not in itself have any toxic 
effect at the concentrations used, based on results in the BWΔacrA pASK-RM strain. 
Results from the BW25513 pASK-RM wild-type strain also show that 
anhydrotetracycline has no inhibitory effect on AcrAB-TolC activity at the tested 
concentrations. Therefore, the synergy observed between anhydrotetracycline and 
fusidic acid against the acrA complemented strain must be a result of protein 
overexpression at higher inducer concentrations. However, the logical assumption to 
make would be that more AcrAB protein leads to an increased rate of efflux, and 
therefore logically the results would be expected to show antagonism of fusidic acid 
by anhydrotetracycline in the acrA complemented strain, not synergy. The above 
hypothesis of overproduction of AcrA leading to increased cell envelope permeability 
can also explain these results – as more AcrA is expressed, the cell envelope allows 
more rapid entry of fusidic acid, masking the effect of active efflux and therefore 
decreasing the MIC of fusidic acid at higher concentrations of inducer. This 
hypothesis could be tested by a chequerboard assay of anhydrotetracycline and 
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vancomycin, using the same three strains as in the fusidic acid chequerboard. If this 
hypothesis is correct, then the same pattern of results would be observed in the 
vancomycin chequerboard, whereby only in the complemented strain does increasing 
anhydrotetracycline have any effect, and that effect would be synergy.  
As the knockout and complemented strains behaved as expected only in the 
novobiocin MIC assay, it is difficult to determine much information about the 
mutants except for using the novobiocin and possibly vancomycin MIC data. The 
S139G and TVYF point mutants appear to behave as wild-type with respect to 
novobiocin efflux, but do not permeabilise the cell envelope to vancomycin in the 
same way as the complemented strain does. Each of the more extreme mutations, 
however, decrease the MIC to novobiocin considerably, to at least as low as the 
knockout strain. Of these, the GS-tip and Δhairpin mutants also permeabilise the cell 
envelope to vancomycin to the same extent as the complemented strain, while the 
Δhelices mutant does not. This effect is TolC-dependent, at least for the GS-tip 
mutant. Although highly speculative from MIC data alone, this may indicate that the 
hairpin tip is required to close but not to open TolC, and that the distance from the 
lipoyl domain of AcrA to the tip of TolC is insignificant in the closing of TolC, as the 
Δhelices mutant, which retains the hairpin tip but in much closer proximity to the 
lipoyl domain, does not display hypersusceptibility to vancomycin. The apparent loss 
of efflux activity against novobiocin for all of these mutants, however, suggests that 
the tip region is also essential for normal efflux activity, and that the helices are also 
essential for efflux activity, either for productive interaction with TolC, or for 




5.2 Growth kinetics 
To establish the wider effect of mutations and to determine greater detail about 
how the mutations affect growth, the mutations were tested in growth kinetics in 
the presence of sub-inhibitory concentrations of a variety of drugs. Gene expression 
from the tetracycline promoter was induced by addition of anhydrotetracycline to a 
final concentration of 2 ng.ml-1 in the iso-sensitest broth used for the assays.  
In the MIC assays, erythromycin and rifampicin showed no difference between the 
knockout and complemented strains for either tolC or acrA mutants, and were 
therefore not included in the library of drugs used in growth kinetics assays. 
Tetracycline showed too small a difference in MIC against the different strains to be 
included in the growth kinetics assays. In the presence of 1 μg.ml-1 acriflavine, none 
of the strains, including BW25113 pASK-RM, grew during the growth kinetics 
experiments, and the data were therefore not analysed and are not presented here.  
When challenged with 500 μg.ml-1 deoxycholic acid, the highest concentration at 
which the GS-tip, Δhelices and Δhairpin mutants grew in MIC assays, all of the acrA 
mutants achieved a similar OD600 at stationary phase as did both the knockout and 
complemented strains (shown in Table 5:3). However, the growth kinetics in 
achieving this OD600 were different between mutants. Both the Δhelices and Δhairpin 
mutants grew at a slightly decreased rate compared to the complemented strain 
(Figure 5:1and Table 5:3). Although this was only an approximately 20% decrease in 
relative growth rate, Welch’s T-test comparing these mutants with the 
complemented strain indicate that these mutants have a statistically significant 
effect when a 95% confidence limit is applied. None of the S139G, TVYF or GS-tip 
mutations caused any difference in growth rate or stationary phase OD600 in the 
presence of 500 μg.ml-1 deoxycholic acid.  
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Nalidixic acid showed a greater difference between the mutants and the 
complemented strain in growth kinetics than in MIC assays. Challenge with 1 μg.ml-1 
nalidixic acid caused each of the S139G, GS-tip, Δhelices and Δhairpin mutants to 
grow at decreased rate compared to the complemented strain (Figure 5:2 and Table 
5:4). Similarly to the case with deoxycholic acid, the difference in relative growth 
rates was not large, at 15-25%, but was statistically significant. Under this challenge, 
the wild-type, acrA knockout and acrA complemented strains all grew with similar 
kinetics to each other. None of the mutations caused any difference in the OD600 at 
stationary phase. The TVYF mutation also caused no difference in growth kinetics 




Figure 5:1 - Relative growth rates for acrA mutants in the presence of 500μg.ml-1 
deoxycholic acid. 
Values are given as a percentage of the BWΔacrA pASK-acrAB strain growth rate. 
Each x represents the value for an individual biological replicate. Lines indicate 




Table 5:3 - Growth rate information for acrA mutants in the 








OD600 ± SD 
BW25113 pASK-RM 124 ± 36 0.209 0.98 ± 0.10 
BWΔacrA pASK-RM 126 ± 28 0.107 0.96 ± 0.09 
BWΔacrA pASK-acrAB 100 ± 0 -- 0.93 ± 0.12 
S139G 87 ± 27 0.329 0.93 ± 0.05 
TVYF 103 ± 18 0.785 0.94 ± 0.10 
GS-tip 100 ± 25 0.986 0.84 ± 0.15 
Δhelices 80 ± 14 0.031 0.87 ± 0.10 







Figure 5:2 - Relative growth rates for acrA mutants in the presence of 1 μg.ml-1 
nalidixic acid. 
Values are given as a percentage of the BWΔacrA pASK-acrAB strain growth rate. 
Each x represents the value for an individual biological replicate. Lines indicate 





Table 5:4 - Growth rate information for acrA mutants in the 








OD600 ± SD 
BW25113 pASK-RM 97 ± 12 0.590 0.92 ± 0.12 
BWΔacrA pASK-RM 103 ± 8 0.439 0.98 ± 0.18 
BWΔacrA pASK-acrAB 100 ± 0 -- 0.83 ± 0.18 
S139G 85 ± 6 0.004 0.90 ± 0.15 
TVYF 101 ± 16 0.917 0.85 ± 0.14 
GS-tip 77 ± 19 0.049 0.91 ± 0.05 
Δhelices 77 ± 10 0.007 0.82 ± 0.09 
Δhairpin 74 ± 10 0.005 0.87 ± 0.11 
 
Although the MIC assay suggested no difference in chloramphenicol MIC against each 
of the acrA variants, and suggested that the MIC should be 0.5 μg.ml-1 to both the 
acrA knockout and the complemented strain, a final concentration of 1 μg.ml-1 was 
used for growth kinetics assays. In these conditions, the stationary phase OD600 was 
lower for the complemented strain than for the wild-type strain with empty vector, 
while this value was lower still for the acrA knockout strain and the GS-tip, Δhelices 
and Δhairpin mutants (Table 5:5). The S139G and TVYF mutations had no effect on 
stationary phase OD600 and these values were comparable to that of the 
complemented strain. The relative growth rates show that the S139G and TVYF 
mutations have no effect compared to the complemented strain, which in turn 
showed no difference compared to the wild-type strain (Table 5:5 and Figure 5:3). 
The relative growth rates reflect the stationary phase OD600 in so far as the GS-tip, 





Figure 5:3 - Relative growth rates for acrA mutants in the presence of 1 μg.ml-1 
chloramphenicol.  
Values are given as a percentage of the BWΔacrA pASK-acrAB strain growth rate. 
Each x represents the value for an individual biological replicate. Lines indicate 





Table 5:5 - Growth rate information for acrA mutants in the 








OD600 ± SD 
BW25113 pASK-RM 160 ± 80 0.173 0.68 ± 0.04 
BWΔacrA pASK-RM 28 ± 23 0.002 0.10 ± 0.07 
BWΔacrA pASK-acrAB 100 ± 0 -- 0.38 ± 0.19 
S139G 96 ± 33 0.803 0.40 ± 0.19 
TVYF 99 ± 31 0.936 0.49 ± 0.11 
GS-tip 21 ± 14 2.56x10-4 0.07 ± 0.04 
Δhelices 18 ± 8 2.53x10-5 0.07 ± 0.05 






To determine the effects of the acrA mutants on outer membrane permeability, 
growth kinetics assays were also done with the addition of vancomycin to 100 μg.ml-1 
final concentration. In these conditions, the stationary phase OD600 was the same for 
each of the wild-type, acrA knockout, acrA complement and all of the acrA mutants 
(Table 5:6). However, the kinetics in achieving this OD600 were different between the 
strains (Figure 5:4 and Table 5:6). It appears that the complemented strain grew 
faster than the wild-type in these conditions, although the difference is not 
statistically significant. The acrA knockout strain grew slower than the wild-type or 
complemented strains, and this difference was statistically significant. The TVYF 
mutant grew the same as the wild-type, and like the wild-type strain was not 
statistically significant compared to the complemented strain. The Δhelices mutant 
grew relatively slowly compared to the complemented strain, and slower than the 
wild-type and knockout strains, but these differences were not statistically 
significant when a 95% confidence limit is applied. Although the relative growth rate 
of the S139G and Δhairpin mutants appear similar to those of the wild-type and the 
TVYF mutant, which were not statistically significant, the variance in the data meant 
that the data for the S139G and Δhairpin mutants are statistically significantly 
different to the complemented strain when a 95% confidence limit is applied.  The 
GS-tip mutant grew very marginally slower than the S139G and Δhairpin mutants 
(though not significantly so), and was statistically significant to the complemented 
strain. Overall, it appears likely that the acrA complemented strain grows probably 
grows faster in the presence of 100 μg.ml-1 vancomycin and 2 ng.ml-1 
anhydrotetracycline than do the wild-type, acrA knockout or any of the acrA mutants 
that were tested. A Bonferroni pairwise T-test indicates that the p-value between any 
pair of strains is 1.00 for all combinations except the complemented strain and: the 




Figure 5:4 - Relative growth rates for acrA mutants in the presence of 100 μg.ml-1 
vancomycin. 
Values are given as a percentage of the BWΔacrA pASK-acrAB strain growth rate. 
Each x represents the value for an individual biological replicate. Lines indicate 






Table 5:6 - Growth rate information for acrA mutants in the 








OD600 ± SD 
BW25113 pASK-RM 84 ± 16 0.094 0.73 ± 0.09 
BWΔacrA pASK-RM 69 ± 8 0.001 0.70 ± 0.17 
BWΔacrA pASK-acrAB 100 ± 0 -- 0.70 ± 0.12 
S139G 86 ± 9 0.027 0.63 ± 0.07 
TVYF 84 ± 18 0.114 0.66 ± 0.13 
GS-tip 77 ± 10 0.007 0.68 ± 0.14 
Δhelices 74 ± 23 0.072 0.76 ± 0.06 
Δhairpin 81 ± 6 0.003 0.71 ± 0.05 
 
 
The wild-type, ΔacrA and acrA complemented strains, plus the GS-tip mutant, had 
been included in early preliminary growth kinetics assays, which were done before 
the full library of mutants was available. As the GS-tip mutant showed a distinct 
phenotype in these early preliminary experiments, the plasmid was transformed into 
the wild-type strain, and used in later preliminary experiments, in which the strains 
were grown in iso-sensitest broth supplemented with 128 μg.ml-1 novobiocin,  
2 ng.ml-1 anhydrotetracylcine and 100 μg.ml-1 ampicillin (relevant results are 
summarised in Table 5:7). This was done to test whether the GS-tip mutation was 
dominant or recessive compared to the chromosomally-encoded wild-type AcrA. 
Ampicillin was added in the preliminary experiments to ensure selection of plasmid-
harbouring bacteria, though it was removed from the protocol for the data-collection 




Table 5:7 - Relative growth rates of GS-tip mutants in the presence of 128 μg.ml-1 
novobiocin. 
Strain Average relative growth rate (%) ± SD 
BW25113 pASK-RM 117 ± 14 
BW25113 pASK-acrA(GS-tip)B 76 ± 19 
BWΔacrA pASK-RM 23 ± 16 
BWΔacrA pASK-acrAB 100 ± 6 




















0.006 -- 6.3 x 10-4 0.217 
BWΔacrA pASK-RM 6.5 x 10-7 6.3 x 10-4 -- 8.0 x 10-6 
BWΔacrA pASK-
acrAB 
0.989 0.217 8.0 x 10-6 -- 
BWΔacrA pASK-
acrA(GS-tip)B 




The results from this experiment show a clear difference between the wild-type, acrA 
knockout and acrA complemented strains. The wild-type strain grew faster than the 
complemented strain, which grew substantially quicker than the knockout strain. The 
strain encoding only the GS-tip variant of acrA grew at the same rate as the knockout 
strain. The strain with both the chromosomal wild-type copy of the gene and the 
plasmid-encoded GS-tip variant of the gene grew with approximately half the growth 
rate of the wild-type strain with empty vector, and approximately 70% the rate of the 
complemented strain. To determine statistical significance, a Bonferroni pairwise 
T-test was used, the output of which is shown in Table 5:8. The table indicates that 
the strain expressing both wild-type and GS-tip mutant AcrA is statistically 
significantly different to each of the other strains, being able to grow faster than 
either the knockout strain or the strain expressing only the GS-tip mutant form of 
AcrA, but slower than the wild-type or complemented strains. It also shows that the 
wild-type and complemented strains are not significantly different, and that the 
strains expressing no AcrA or only the GS-tip mutant AcrA are essentially the same as 
each other.  
Discussion 
To obtain finer detail about possible minor effects of mutation than can be 
ascertained from MIC assays alone, growth kinetics experiments were used to 
compare acrA mutations. Results are summarised inTable 5:9, and show a clear 
difference in the apparent phenotype when looking at relative growth rates or 
stationary phase OD600 values. At 500 μg.ml-1 in broth, deoxycholic acid does not 
appear to inhibit growth, based on stationary phase OD600 values, although it does 
cause a decrease in the relative maximum growth rates of the strains in which the 
AcrA hairpin has been removed, either entirely (Δhairpin) or by removal of only the 
helices (Δhelices) – this is not surprising, given that the lowest MIC value for any of 
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the acrA variants was double the concentration used in the growth kinetics assay. The 
same overall results are apparent with 1 μg.ml-1 nalidixic acid, additionally both the 
S139G point mutant and the GS-tip mutant are both also affected in the same way. 
The effect in nalidixic acid does not correlate quite so well with the MIC data, as 
nalidixic acid had an MIC value of 1 μg.ml-1 against all of these mutants. This 
discrepancy could be due to differences in growth on agar compared to in liquid 
broth, or could be an effect of the lower inducer concentration used in the growth 
kinetics assays.  
Stationary phase OD600 values and growth rates corresponded well in 
chloramphenicol and novobiocin, whereby mutants that grew slower achieved a 
lower OD600 at stationary phase. The results obtained in these growth kinetics assays 
do not match the results in MIC assays, but the difference between the acrA 
knockout and both the wild-type and complemented strains better matches the 
expected results.  Growth kinetics indicate some substrate-specific effect of the 
S139G mutation, as this mutation caused a decrease in growth rate in the presence of 
nalidixic acid but not deoxycholic acid or chloramphenicol. All of the mutations which 
affect the hairpin tip, including S139G and the acrA knockout (which by definition 
also lacks the hairpin tip) were more susceptible to vancomycin. The difference 
between vancomycin MIC results and the growth kinetics results can be potentially 
be explained by the difference in expression levels, and fit with the hypothesis set 
out in the MIC discussion (end of Section 5.1). At lower concentrations of 
anhydrotetracycline, less AcrA will be produced from the plasmid-encoded gene, and 
so fewer copies of AcrA are available to interact with TolC, causing fewer inactive 
AcrA-TolC complexes lacking a transporter protein to form. As energy is required for 
dissociation of the complex, AcrA-TolC bipartite complexes should theoretically 
remain bound, and probably – supported by the results here – have a dilated channel. 
The new hypothesis is therefore that AcrA or AcrB alone are capable of dilating the 
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TolC channel, and that the AcrA hairpin tip is required to close the channel. 
Meanwhile, the entire AcrA hairpin is required for active efflux function, hence the 
decreased growth rate of each of the GS-tip, Δhelices and Δhairpin mutants in (most 
of) the tested efflux substrates. By explaining how channel dilation is affected by 
expression of acrA, this hypothesis may also explain the difference between MIC 
assay results and the stationary phase OD600 values. As a higher inducer 
concentration was used in the MIC assays, more non-productive AcrA-TolC bipartite 
open complexes formed, allowing greater influx of the efflux substrates, as well as 
vancomycin, hence decreasing the MIC of these efflux substrates against all strains 
with plasmid-encoded acrA, regardless of efflux activity. This also explains why all 
mutants were capable of growing – even if some of them had decreased growth rate 
– at the apparent MIC of nalidixic acid against these mutants, when a lower inducer 




Table 5:9 – Summary of growth rate change relative to acrA-complemented 
strain. 
“Up” or “Down” indicates that the growth rate is increase or decreased relative to 
the acrA complemented strain. A dash indicates no difference from the 
complemented strain. N/a indicates that the mutation was not tested with that 
particular antibiotic. Changes in stationary phase OD600 are presented in the same 
way in brackets. 
Strain Doc Nal Cam Nov Vanc 
BW25113 pASK-RM - (-) - (-) - (Up) - (-) - (-) 




S139G - (-) Down (-) - (-) N/a Down (-) 
TVYF - (-) - (-) - (-) N/a - (-) 




Δhelices Down (-) Down (-) Down N/a - (-) 
Δhairpin Down (-) Down (-) Down N/a Down (-) 
 
5.3 Flow cytometry 
Experiments in this section were designed by Dr Jessica Blair, who also assisted with 
initial running and interpretation of these experiments. 
As with investigation of tolC mutants, the other in vivo approaches investigate the 
effect of mutations at the population level. Flow cytometry was used to measure 
ethidium bromide fluorescence on a cell by cell basis. Again, cells were counter-
stained with Syto84, and both blue and yellow laser channels were used, to measure 
ethidium bromide and Syto84 fluorescence, respectively. Forward and side scatter 
were also used to report on particle size and complexity. The same graphs as were 
used for gate placement in TolC flow cytometry experiments (Figure 4:13) were 
generated for each acrA mutant and used to position gates to select for cells.  
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The histograms showing cell counts for each value of ethidium bromide fluorescence 
showed two distinct peaks, as was seen in Figure 4:14 for the tolC mutants. The 
proportion of cells in each peak was comparable for the wild-type and complemented 
strains, with a clear majority of cells showing low ethidium bromide fluorescence 
(proportions of the population which contribute to either sub-population peak are 
visualised in Figure 5:5). Neither of the Δhairpin or Δhelices mutants showed any cells 
with low ethidium bromide fluorescence, and both showed a marginal, but not 
significant, increase in the fluorescence intensity of this peak compared to the 
complemented strain sub-population showing higher fluorescence intensity 
(fluorescence intensity for each peak and overall populations are shown in Figure 
5:6). Almost all acrA knockout cells and GS-tip mutant cells showed high ethidium 
bromide fluorescence, although there were some events counted with low 
fluorescence. It was noted that some of the events counted within the GS-tip mutant 
cells gate showed ethidium bromide fluorescence intensity of zero, which, given the 
low number of cells in the lower fluorescence sub-population peak for two of the 
three biological replicates for this mutant, would contribute to the x-mean value of 
this peak being lower than for other strains.  
In the sub-populations showing higher ethidium bromide fluorescence, the wild-type 
strain showed less fluorescence than the strains expressing either wild-type or 
mutant AcrA from the pASK plasmid. However, when a 95% confidence interval is 
applied, the difference in fluorescence intensities of these sub-populations is only 
significant between the wild-type strain and each of the Δhelices and Δhairpin 
mutants. 
When all parts of the results of this assay are combined, all of the GS-tip, Δhelices and 
Δhairpin mutants appear essentially as knockout, while the complemented strain 
appears essentially as wild-type.  
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Table 5:10 - Summary of information from flow cytometry on acrA variants. 
Values given are average ± standard deviation. * - value significantly increased by 


































17.4 ± 2.9 89% 12.6 ± 0.6 11% 56.5 ± 3.1 
BWΔacrA 
pASK-RM 
80.2 ± 11.1 0.6% 14.1 ± 1.4 99% 80.6 ± 10.9 
BWΔacrA 
pASK-acrA 
26.6 ± 11.0 82% 11.6 ± 1.2 18% 86.6 ± 19.7 
GS-tip 69.1 ± 13.3 2%* 7.4 ± 3.3 98% 70.0 ± 12.3 
Δhelices 100.6 ± 7.4 0% - 100% 100.6 ± 7.4 





Figure 5:5 - Proportion of cells showing high- or low-level ethidium bromide 
accumulation. 
The proportion of cells shown by flow cytometry to contribute to the lower (blue) 
or higher (red) ethidium bromide accumulating sub-populations. Error bars 





Figure 5:6 - Ethidium bromide fluorescence in acrA mutants as determined by 
flow cytometry. 
The average ethidium bromide fluorescence intensity (± standard deviation) for 
the whole population (green), low fluorescence intensity sub-population (blue) 
and high fluorescence intensity sub-population (red). Each of the Δhelices and 





Flow cytometry enables greater detail to be ascertained regarding a bacterial culture 
as a whole. Notably, the wild-type and acrA complemented strains show clearly split 
populations, with 80-90% of cells showing low ethidium bromide fluorescence and 
the remainder showing high fluorescence. This reflects the results seen in the 
equivalent experiment using tolC variants (Section 4.4), and similar observations have 
been reported for other proteins when fluorescence protein fusions have been 
206 
 
expressed. As was the case with in the tolC experiment, differences in total 
population fluorescence intensities are driven by the proportion of cells in one sub-
population or the other; there does not appear to be any partial decrease in 
fluorescence intensity for any of the mutants. The two sub-populations can be 
assigned as “efflux active” for the low fluorescence peak and “efflux deficient” for 
the high fluorescence peak, as this fits with the expected increase in fluorescence of 
the acrA knockout strain and subsequent recovery in the complemented strain. The 
knockout strain has a very small sub-population that appears to be efflux active, 
which could be a result of up-regulation of acrE to compensate for loss of acrA – 
deletion of both genes is known to increase susceptibility to ethidium bromide 
(Smith & Blair, 2014), and therefore should a sub-population respond to the loss of 
one gene by up-regulation of the other, the phenotype should be at least partially 
rescued.  
Although not deemed significant, the difference in the “efflux deficient” 
fluorescence intensity for the wild-type strain compared to either the acrA knockout 
or complemented strains could indicate that there is some pleiotropic effect of the 
chromosomal mutation. As the wild-type strain contains the same empty vector as 
the knockout strain, the difference cannot be caused by pleiotropic effect of the 
plasmid backbone. As the differences in fluorescence intensities of the 
sub-populations of the mutants were not statistically significant from those of the 
complemented strain, it appears that the only scientifically sound conclusions that 
can be drawn from this experiment are that firstly, nearly all cells in the knockout, 
GS-tip, Δhelices and Δhairpin mutants are efflux deficient, and secondly, the relative 
proportion of cells that are “efflux active” or “efflux deficient” determine the overall 
fluorescence intensity of the population. The results from this experiment are not 
incompatible with the hypotheses formed from results in Section 5.1 or Section 5.2, 
although neither do they directly support those hypotheses. It is unfortunate that 
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BODIPY-FL-vancomycin, a fluorescent conjugant of the influx-limited vancomycin 
drug, is not compatible with the specific design of this experiment, as this would help 
to obtain data that would test the hypotheses formed from Sections 5.1 and 5.2.  
As far as the hypothesis that the GS-tip mutation causes a dominant effect over the 
wild-type AcrA, the data in this experiment suggest that this is probably not the case, 
although it remains a possibility. The proportion of cells in the lower fluorescence 
peak is essentially zero in both the GS-tip and knockout strains (values of 0.2%, 0.2% 
and 7.7% in the GS-tip against 0.2%, 0.5% and 1.1% in the knockout). It is not possible 
from this experiment to ascertain the reason behind the high ethidium bromide 
accumulation in the GS-tip mutant – it appears to certainly be efflux deficient, but 
this could be due to either loss of interaction with TolC or the formation of a non-
productive interaction with TolC.    
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5.4 Confirmation of AcrA presence during in vivo analyses 
To confirm that differences in in vivo assays are not due to differences in protein 
expression, the presence of AcrA protein from each acrA mutant was analysed by 
Western blot. Each of the strains were grown in 500 ml cultures of the same 
composition as used when growing cultures for flow cytometry. Membranes were 
harvested from these cultures, and a Bradford assay used to determine total 
membrane protein concentration in each sample. The results from the Bradford 
assays were used to enable volume adjustment when loading samples for SDS-PAGE, 
ensuring that an equal amount of total membrane protein was loaded for each 
sample. Following SDS-PAGE resolution of the proteins within the samples, the 
proteins were transferred to a PVDF membrane and probed with polyclonal α-AcrA 
antibodies. Alkaline phosphatase-conjugated secondary antibodies were used, and 
the blots developed with NBT/BCIP chromogenic substrate. A photograph of the 
developed blot is shown in Figure 5:7. The acrA knockout strain showed a band of 
comparable intensity to the wild-type strain, while the band for the complemented 
strain was of considerably greater intensity. Of the mutants, only the GS-tip, Δhelices 
and Δhairpin variants were analysed by this method, given that these showed a 
significant difference compared to the complemented strain in other methods. The 
GS-tip mutant showed what appears to be two bands, one for the same size as the 
wild-type protein and one of a smaller size. These bands were approximately the 
same intensity as the complemented strain, indicating the same overexpression as 
seen in the complement. Both the Δhelices and Δhairpin mutants showed lower band 
intensity, although bands were still clearly visible. Each of these mutants showed two 
bands, one corresponding in size to the wild-type protein and the other being 
smaller. For each of these three mutants, the smaller protein corresponds to the 
mutant protein: the mature wild-type AcrA protein is 39.7 kDa, the GS-tip is 38.9 kDa, 
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Δhelices is 34.6 kDa and Δhairpin 32.9 kDa. Although the amounts of each protein are 
not necessarily the same for each mutant, the protein is present. 
Given that all of the strains, including the knockout, show a band corresponding to 
the wild-type AcrA protein, the strains were re-tested by colony PCR to ensure that 
the chromosomal acrA gene was indeed deleted in these mutants, and that there had 
been no error of strain selection during transformation. During the process of cell 
disruption and membrane purification, some cells pass through the disruptor intact 
and are removed by a relatively low-speed centrifugation step. The pellet from this 
step was used as material for colony PCR. The acrA-upst-F and acrA-dnst-R primer 
pair were used for amplification, which would generate a PCR product only from 
chromosomal copy of acrA, and of a different size depending upon whether the 
strain is acrA+, acrA::aph or ΔacrA, as the primers anneal up- and down-stream of the 
recombination sites used for gene deletion. All of the strains generated a PCR 
product which was shown by agarose gel electrophoresis to be approximately 450 bp 
in size, corresponding to the ΔacrA fragment. This confirmed that the apparently 
wild-type AcrA band seen on the Western blot in the knockout strain, and in the 
mutants showing two distinct bands, was not caused by the presence of AcrA which 


























































Figure 5:7 - Western blot for AcrA protein in acrA mutants. 
Mutants of acrA were grown in the same conditions as in preparation for flow 
cytometry and the membranes harvested. The membrane protein sample volume 
loaded for SDS-PAGE was adjusted to load equal amounts of total membrane 
protein per sample. The 38 kDa (upper) and 28 kDa (lower) marker bands are visible. 
Multiple protein bands are visible from the various samples, corresponding to (a) 
full-length AcrA at 39.7 kDa after removal of the signal sequence; (b) the GS-tip 
variant of AcrA at 38.9 kDa; (c) AcrA lacking the hairpin helices (Δhelices) at 34.6 kDa 
and (d) AcrA in which the hairpin structure has been replaced with the BesA loop 








Having shown that the GS-tip, Δhelices and Δhairpin mutants of acrA cause a loss of 
function phenotype, it was necessary to show that this phenotype is not caused by a 
loss of protein, protein misfolding or mislocalisation. The results here suggest that 
AcrA may be present in the knockout strain, although genetic testing subsequently 
showed that the acrA gene was not present in the strain. Given the high similarity 
between AcrA and AcrE, it is likely that there is some cross-reactivity of the α-AcrA 
antibody with AcrE, which would explain the presence of the band in the knockout 
strain. The same band is also present in the GS-tip, Δhelices and Δhairpin mutants, 
although at lower band intensity. This indicates that although AcrE is likely to be 
present in these mutants, it is not expressed at the same levels as in the acrA 
knockout strain, presumably because the cells recognise that AcrA protein is present, 
even if it is not functional.  
All of the mutant proteins are expressed, and localise to the membrane. The GS-tip 
mutant appears to express at around the same level as the wild-type protein from 
the complemented strain, while both mutants lacking the hairpin structure  appear to 
be expressed at levels closer to the chromosomally-encoded AcrA from the wild-type 
strain. However, the site on AcrA to which the antibody binds is not known, and, 
being polyclonal, it is possible that different antibodies within the mixture recognise 
different parts of the protein. Due to the prominence of hairpin structure, it is likely 
that at least some of the antibodies recognise this site, which may explain why these 
two mutants appear to have a lower expression level – they are missing the 
recognition site of a portion of the antibodies.  
Ultimately, the results in this section show that all phenotypic differences between 
mutants are caused by differences in protein functionality, not by differences in the 
protein expression or by differences in localisation of the proteins to the membrane.  
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Work in all of Chapter 6 was assisted by Dr Martin Picard and Mr Dhenesh 
Puvanendran, and supported by FEMS Research Grant FEMS-RG-2015-0124. 
6.1 Analysis of protein-protein interaction by glycerol gradient fractionation 
Each of the AcrAB-TolC component proteins, with 6xHis tag, were expressed from 
the pET26 vector in the corresponding knockout strain of the C43 (DE3) high 
expression strain. To optimise protein yield, 1 l cultures were grown in multiple 
condition sets. In each condition, cultures were grown to an OD600 of 0.3 to 0.5, at 
which point IPTG was added to a final concentration of 0, 10 or 50 μM, and growth 
continued at 37°C for 16 h, 20°C for 16 h, or 37°C for 3 h, respectively.  
Upon cell disruption with a OneShot cell disruptor, it was evident that the majority of 
the target proteins in cultures with the higher concentration of IPTG had formed 
inclusion bodies, which was confirmed upon Coomassie staining of soluble, 
solubilised membrane and insoluble fractions. Cultures grown with induction by  
10 μM IPTG grew to a final OD600 in a range of 1.8 to 3.5, while uninduced cultures 
reached final OD600 in a range of 3.7 to 6.1; however, when the membrane fractions 
were analysed by Coomassie staining, the bands corresponding to target protein 
from uninduced cultures were of similar density to the other membrane proteins. 
Mutated versions of the proteins were therefore expressed by induction with 10 μM 
IPTG and growing for 16 h at 20°C post-induction. Each of the wild-type proteins, the 
GS-tip, Δhairpin and Δhelices variants of AcrA, and the D121N, N145L, R158D, Y344F, 
S350F, YFRS, K383E and RENT variants of TolC were expressed and subsequently 
purified by Ni-NTA affinity chromatography. Following concentration of the AcrB 
protein, it was observed that very little solution remained in the column, and dilution 
was required in order that the volume was workable. Despite this, the total amount 
of AcrB protein purified was calculated by nanodrop analysis to be 1.2 mg and 
analysis by SDS-PAGE indicated that the sample was of high purity. From any single 
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culture, the protein yield ranged from 0.8 mg (a WT TolC sample) to 2.4 mg (for a 
sample each of WT AcrA and TolC(D121N)).  
Each purified protein was incubated with BAPol to exchange the detergent hydration 
shell before mixing components in a 120:40:50 μg AcrB:AcrA:TolC ratio, 
approximately equivalent to a 1:1:1 molar ratio. The mixtures were then subjected to 
ultracentrifugation on a 10-28% glycerol gradient. As this part of the project was 
done as part of a research visit, time restraints meant that the only combinations 
tested were AcrB-AcrA-TolC, AcrB-AcrA-TolC(N145L), AcrB-AcrA(Δhp)-TolC and AcrB-
AcrA(Δhelices)-TolC. Fractions were aspirated and resolved by SDS-PAGE.  Coomassie 
staining of the resulting gels (Figure 6:1) showed protein at approximately 120, 100, 
90 and 45 kDa for samples from 12-20% glycerol. In the AcrB-AcrA-TolC and AcrB-
AcrA-TolC(N145L) samples, these bands were all between 14-20% glycerol, with 
maximum intensity at 16% glycerol for all the bands; very little protein was seen in 
these samples from fractions containing less than 14% glycerol, and most of the AcrA 
could be seen at 90 kDa rather than 45 kDa, indicating dimer formation. All of the 
same bands were visible for both of the AcrA mutants, although the majority of 
mutated AcrA was seen at 45 kDa rather than 90 kDa, indicating that it was 
monomeric. There was also a shift in which fractions yielded the fragments from the 
AcrA mutants - the higher weight bands were visible from 12-20% glycerol, with the 




Figure 6:1 - Coomassie staining of glycerol fractions to determine interaction 
of proteins 
After ultracentrifugation on a glycerol gradient, proteins which interact are 
present in the same glycerol fraction, and therefore appear within the same 
column on the gel image following SDS-PAGE. Solid boxes indicate where AcrA is 
found in the same glycerol fraction as AcrB and TolC, while dashed boxes indicate 






Glycerol gradients represent a simple yet effective means of testing for protein-
protein interactions, provided proteins of interest have different buoyancy. The use 
of in vitro techniques was time-limited in this study, by virtue of being part of a 
research visit, and therefore have not been utilised to their maximum. The time 
limitations also meant that vital controls – such as omission of TolC in the analysis of 
AcrA variants and omission of AcrB when testing TolC variants, were not included. It 
is also responsible for only having tested very few of the mutant proteins that were 
expressed. This work needs to be continued and expanded in order to determine 
whether or not the mutations included in this thesis cause loss of TolC-AcrA 
interaction, or if there is a different reason for the phenotypes observed using in vivo 
analyses. Alternatively, qualitative approaches such as surface plasmon resonance or 
thermophoresis could be used to analyse the interactions between each of the 
components when introducing mutant protein. Either of these approaches would 
allow binding affinities to be calculated, which would be more persuasive evidence 
than the binary detail obtained from glycerol gradients.  
In both the complete wild-type combination and in the combination with 
TolC(N145L), AcrA is present in the same fraction as both of the other partner 
proteins. Without testing potential bipartite combinations (AcrA-TolC, AcrA-AcrB and 
AcrB-TolC), it is not possible to determine whether or not the TolC(N145L) mutant is 
deficient or proficient in binding either or both of its partner proteins, although in 
vivo results indicate that this mutation only affects the MIC of nalidixic acid and the 
growth rate in the presence of novobiocin, and therefore it is likely that the entire 
complex forms normally in the presence of other substrates. Why any particular 
substrate would affect binding or functionality of this point mutant is unclear. 
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From this experiment, it appears that neither of the hairpin mutants can effectively 
bind to TolC or AcrB. However, it is unclear whether this is due to their decrease 
propensity to form dimers or because of an otherwise decreased affinity for the 
partner proteins. The laboratory of Helen Zgurskaya has previously reported that 
AcrA dimers bind AcrB with greater affinity than do AcrA monomers (Tikhonova et al., 
2011). As there is a small amount of dimeric AcrA(Δhelices) protein present in the 
higher glycerol concentration fraction, with TolC and AcrB, it is unclear whether the 
interaction that causes this mutant AcrA protein to co-fractionate with its partner 
proteins. It is possible that either the mutant AcrA shows lesser propensity to form 
dimers, and therefore has decreased affinity towards AcrB, or if the hairpin is 




CHAPTER 7: DISCUSSION 
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The overall aim of this project was to determine the interface between MFPs and 
OMCs in tripartite multidrug efflux complexes. A series of computational approaches 
were used in combination with available literature to determine a library of 
mutations to make in tolC and acrA. Mutations were designed with the hypothesis 
that they would affect either TolC channel closure or the TolC-AcrA interaction. The 
logic and hypotheses for each individual mutation are discussed within the 
preparatory work section (Sections 3.3 and 3.5). These mutations were subsequently 
assessed by a variety of in vivo techniques, and a research visit to the laboratory of Dr 
Martin Picard allowed preliminary assessment of the mutations using in vitro 
techniques.  
During these studies, the immediate field of multidrug efflux pump assembly 
progressed rapidly. Whilst some of the publications were reacted to in preparation of 
experiments for this thesis, important papers were also published too late during this 
study to take into consideration for experimental design. Despite the advances made 
in the last four years, the study presented here makes use of a wider range of 
techniques to assess the importance of individual residues on both the function of 
the pump as a whole and the inter-component interactions. Each of the experimental 
approaches used here provide slightly different insight as to the effect of the 
introduced mutations, and therefore this study represents the most thorough 
investigation of a set of efflux assembly component point mutations.  
 
7.1 Limitations to general experimental designs in this study 
Using a site-directed mutagenic approach in this study, there were two general 
options for expression of the mutated genes for in vivo studies: make site-directed 
mutations on the chromosome, or utilise a plasmid-borne expression system. Each of 
these options has its own advantages and limitations. Use of chromosomal 
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mutagenesis allows expression of the single-copy gene under control of its own 
native promoter and in its normal genetic context, although in the case of multidrug 
efflux pump components, this will mean that expression is upregulated as 
concentration of toxic substances increases, which could affect gene regulation in 
the case of a mutation decreasing efflux function. However, genome editing requires 
several processes, each of which can be slow and, in some cases, unreliable. Once the 
mutagenic process is completed, it is advisable to sequence the whole genome of the 
newly-created strain, to ensure that no recombination took place at other positions 
on the chromosome. Chromosomal mutagenesis can therefore be a slow and 
expensive process. In contrast, mutagenesis on a plasmid requires only PCR, 
transformation, extraction and sequencing of the plasmid, and the mutated plasmid 
can then be transformed to any desired strain. For reasons of practicality, the use of 
a plasmid-based expression system was chosen, despite the biological benefits to 
mutagenesis of the chromosome. 
A variety of expression systems are available on plasmids, each of which is suitable 
for different purposes. Several studies investigating MFP-OMC function have used 
the T7 expression system in the pET series of plasmids. However, as the T7 promoter 
causes very high levels of gene expression with minimal induction of T7 RNA 
polymerase expression (Hattab et al., 2015), and sufficient protein expression for 
structural studies (2 mg protein per g of wet cellular weight) even without induction 
(Walse et al., 2008), this was deemed unsuitable for in vivo investigations. Other 
common inducible gene regulation systems present on vectors include the lac and 
PBAD systems, but both of these are known to be titratable only at the culture level; at 
the cellular level, these systems are “all-or-nothing”, whereby the system is either 
completely repressed or completely activated (Novick & Weiner, 1957; Morgan-Kiss 
et al., 2002). Therefore, the tetracycline promoter was chosen for use in this study, as 
it has not been reported as “all-or-nothing” at the cellular level, and despite showing 
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basal expression in the absence of induction, expression from this promoter should 
be titratable and therefore can be controlled to ensure approximately equal levels of 
expression between mutants (Whetstine et al., 2009). Anhydrotetracycline is a 
derivative of tetracycline that displays no antibacterial activity but does induce 
expression from the tetracycline promoter. Although long known to impact 
metabolism of E. coli (Silverman & Atherly, 1978), this is not an issue at the 
concentrations used in this study (as shown in Section 5.1). It is currently unclear as to 
whether or not anhydrotetracycline is an efflux substrate of AcrB, as is tetracycline 
(de Cristobal et al., 2006). If anhydrotetracycline is a substrate of the efflux complex, 
then it will theoretically be removed from the cell at a lower rate in cells with a 
mutation that decreases efflux activity, thus allowing higher expression of the 
inactive or partially-active protein. In such a situation, minor defects in the efflux 
complex may be hidden by an increased expression level, as the extra complexes 
compensate for the decreased efficiency of each individual complex.   
Having chosen to use the tetracycline promoter for expression of the mutated 
proteins during in vivo assays, it was necessary to determine the concentration of 
inducer to use for these assays. As detailed in Section 4.1, this was done by means of 
MIC testing to erythromycin and novobiocin at a variety of 10-fold dilutions of 
anhydrotetracycline. This showed that anhydrotetracycline should be omitted 
entirely or used at 2 ng.ml-1 to give comparable results between the wild-type strain, 
expressing tolC from the chromosome, and the complemented strain expressing tolC 
from the pASK plasmid. Ideally a quantitative reverse-transcriptase PCR (q-PCR) 
approach would be used to determine the relative tolC transcript levels in each of 
these strains at a variety of anhydrotetracycline concentrations. This would give 
direct detail about the effect of anhydrotetracycline on promoter activity, rather 
than using a phenotype to indirectly derive this information. However, as the in vivo 
experiments used in this study primarily compared the knockout, complement, and 
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plasmid-encoded mutants, the absolute expression level should not be a major factor 
in the results, provided that there is sufficient protein expressed in each (except for 
the knockout) strain.  
 
7.2 A range of assay types is essential in studies of this type 
A significant proportion of papers detailing the effects of mutating efflux pump 
components use only a single susceptibility assay to determine functionality – usually 
either MIC or zone of inhibition studies. As the results in this thesis show, a mutation 
can give different results depending on the assay used, and even the parameters 
analysed within an assay. For example, the TolC N332L mutation appeared to have no 
effect in MIC assays, but shows a substrate-specific effect in growth kinetics and may 
show reduced efflux activity in dye efflux assays. Use of only a single assay type 
would therefore have led to this mutation being dismissed as having no effect which 
is not true, mainly because the effect is small. In particular, alternatives to MIC assays 
should be sought for similar projects, as these assays are designed only to attribute a 
“resistant” or “susceptible” phenotype to a strain – within two consecutive growth 
incubation periods (a total of 24 h for E. coli), they are capable of ascertaining 
whether or not therapeutic treatment with a particular drug is likely to be effective 
against a particular strain. Therefore, whilst MIC assays are of undoubted potential 
within the diagnostic environment, they are insufficiently sensitive for use in 
determining potentially small differences between mutations.   
It appears to be of equal importance to consider viable in vivo assays, as these report 
more accurately upon the natural state of the proteins than do in vitro assays which 
use artificial environments, and in vitro assays, which separate efflux activity from 
other possible contributing effects on the entire cell that are not present in isolated 
systems. In vitro assays therefore have a key advantage in that they are sensitive only 
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to the changes upon the system under investigation. Any defects that are 
compensated within the cell will not be compensated in vitro, thereby allowing 
greater focus of interpretation of results. However, it is not known what contribution 
to efflux pump activity other cellular components may have, such as peptidoglycan, 
or the exact composition of the periplasmic fluid. Use of artificial buffers may 
therefore force proteins into unnatural interactions, a possible explanation for the 
apparent MacA-MacA tip-to-tip interaction which is not in itself discussed as a 
possible physiologically relevant configuration, although 20% of AcrA is found 
associated with the outer membrane even in the absence of a cognate OMC 
(Tikhonova & Zgurskaya, 2004).  
 
 
Figure 7:1 - Peptidoglycan surrounds the periplasmic tip of TolC. 
Thicknesses and distances between the major components of the cell envelope are 
shown to scale based on measurements by Matias et al. (2003), with TolC shown also 
to scale. Based upon the distance between the peptidoglycan (PG) and outer 




Peptidoglycan is usually ignored in the study of Gram-negative bacterial multidrug 
efflux pumps, although drawing of the measured inter-membrane distances, 
membrane to peptidoglycan distances and thicknesses of each of these structures, 
and superimposition of TolC in the outer membrane of this drawing, indicates that 
the coiled-coil domain of TolC (the periplasmic tip and the α-helical barrel up to the 
equatorial domain) should lie embedded within the peptidoglycan, as shown in 
Figure 7:1. Only one paper has reported any interaction between peptidoglycan and 
either TolC or AcrA, indicating that both proteins have an intrinsic affinity for 
peptidoglycan which is increased by the partner protein (Xu et al., 2012). The role of 
peptidoglycan in the MFP-OMC interaction is entirely unknown, though it is possible 
that it assists in maintaining TolC and AcrAB in close proximity or affects the 
interaction between the components of the assembly. AcrB has been shown to form 
distinct foci in the presence of TolC but to be mobile within the membrane in the 
absence of TolC (Yamamoto et al., 2016). It is unclear whether this is entirely due to 
the lower fluidity of the outer membrane or if the complex is trapped in place by its 
penetration of the peptidoglycan matrix. If the latter is true, then it is entirely 
plausible that the local environment of the AcrA-TolC interaction is heavily 
influenced by the presence of the peptidoglycan, which is omitted from in vitro 
studies.  
Whilst structural studies are capable of providing convincing data, and indeed are 
vital for informing wider studies – this study would have been very different if 
structures of the components were not available – they are subject to the above 
limitations of in vitro studies. Unfortunately, they are also currently only capable of 
providing a snapshot view of the assembly, which does not give any indication as to 
the other stages of a dynamic process. The latest structural studies of multidrug 
efflux pumps, which show complete complex assembly, provide strong evidence that 
the tip-to-tip model is accurate, as redefined based upon the data provided by such 
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structural studies. The caveat, however, is that the accuracy is restricted to a single 
step within the dynamic process. Given that the complex is de-energised in these 
structural studies, the step represented by the structural studies is presumably the 
step at which energy is required for further progression.  
 
7.3 AcrA and TolC mutations can have a substrate-specific effect 
Some of the mutations in this study show a substrate-specific effect, particularly the 
TolC N145L and K383D and AcrA S139G mutations. The most simple explanation for 
this is that the mutations alter the substrate-exposed surface, which may be the case 
for N145L (in either model of interaction) and S139G in the tip-to-tip model, but is 
certainly not the case for K383D, which is on the external face of H8 and faces the 
periplasm. If the MFP is involved in selection and loading of the substrate to the 
transporter (Bagai et al., 2008; De Angelis et al., 2010; Mealman et al., 2012), then 
mutation on the MFP could alter the efflux profile of the complex in a similar fashion 
to mutation of the transporter binding pockets (Blair et al., 2015). Given the location 
on the structure of the AcrA S139G mutation, it is unclear how substrate selection 
could be affected by this mutation, and it is even less clear how TolC mutations 
would have this effect unless they induce conformational changes in AcrA that 
indirectly alter substrate specificity.  
This is particularly important when comparing data between studies. For example, 
the AcrA S139D mutation has previously been reported to abolish function, based 
only on resistance to erythromycin and novobiocin (Kim et al., 2010). Although the 
mutation made for this thesis essentially removed the side chain from this position, 
the substrate-specific effect of this mutation indicate that previous studies may 
make significant conclusions from insufficient evidence. The hydroxyl group of AcrA 
residue S139 has been proposed to form hydrogen bonds with either the side chain 
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of TolC T366 or the backbone of TolC G147 (Jeong et al., 2016; Wang et al., 2017). If 
this position is part of such a limited interface, and causes disruption of that 
interface, then loss of function should be observed with all substrates, and not only a 
subset of them. This aspect of the results is therefore incompatible with a purely 
tip-to-tip interaction between AcrA and TolC.   
Naturally substrate-specific MFP-OMC interactions have been observed, notably for 
MexJ (Chuanchuen et al., 2002). The MexJK MFP and pump utilises either OprM or 
OpmH in a substrate-specific manner (Chuanchuen et al., 2005). Substrate-specific 
effects of mutations on either the MFP or OMC should therefore not be completely 
surprising: had this study been done using MexJK-OprM and MexJK-OpmH rather 
than AcrAB-TolC, then certain mutations may make one channel more like the other, 
and alter the channel utilisation in a substrate-specific manner. Whilst it is unclear 
how the substrate determines which channel protein is used, it now appears that 
substrate-specific selection of a channel protein by an MFP is altered even by 
mutation of single residues.  
 
7.4 The choice of mutation at a position affects the change in phenotype 
Two positions on TolC were mutated to two different residues: Q352 (to both alanine 
and glutamate) and K383 (to both aspartate and glutamate). The results for 
mutations at these positions indicate the importance of the choice of mutation in a 
study such as this: Q352A showed a decreased MIC to vancomycin, which was not 
seen in Q352E, while K383D showed increased susceptibility to a variety of 
substrates, even though K383E appeared wild-type. Combined with the above factor 
of substrate-specific effects of mutations, this further indicates the robustness 
required in studies of this type – mutation to a single alternative amino acid may not 
provide sufficient evidence of the significance of a position; conversely, one mutation 
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at a position that causes a phenotypic difference may be over-interpreted and make 
the position seem more important for a certain aspect of the protein’s function than 
what it really is. This is particularly evident with the difference between K838D and 
K383E, which both involve the same reversal of charge and differ only by a single CH2 
group in the chain length. Such a minor difference in the mutation was not expected 
to have such a difference on functional impact.   
 
7.5 The helices of the AcrA hairpin are essential for interaction with TolC 
Upon deletion of the AcrA hairpin helices, either alone or with replacement of the tip 
as well, efflux function is completely abolished (Sections 5.1, 5.2 and 5.3). This loss of 
function appears to be due to loss of interaction with TolC (Section 6.1). This could be 
expected in vivo in either interaction model. In the helical bundling model, these 
helices are clearly required for the interaction with TolC, while in the tip-to-tip model 
they are required to bridge the distance between AcrB and TolC. However, even 
when any spatial requirements of the periplasm (such as the inter-membrane 
distance) are not present in the experiment due to use of BAPol, the interaction is 
lost. This suggests that the tip alone (as is present in the Δhelices mutant) is 
insufficient to recruit TolC, otherwise AcrA(Δhelices) should be able to maintain the 
TolC interaction but without substantial spatial separation between TolC and AcrB. 
The logical conclusion from this is that the helices of the MFP hairpin are required for 
direct interaction with the helices of the OMC, as was believed to be the case before 
the MacA structure was solved (Akama et al., 2004; Fernandez-Recio et al., 2004; 
Higgins et al., 2004a). Such a conclusion is supported by evidence in the literature 
that the entire AcrA hairpin is in close proximity (7 Å) of TolC, and that positions even 
as high up the α-barrel of TolC as the equatorial domain are with the same close 
proximity to AcrA (Lobedanz et al., 2007). It is also supported by the periplasmic tip 
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of TolC seemingly only being required for flexibility – to enable opening and closing 
of the channel – and not for interaction with any specific part of AcrA, as determined 
by mutagenesis and analysis of reversion mutants (Weeks et al., 2010). 
The results here are therefore incompatible with the electron microscopy data 
published in the past few years (Du et al., 2014; Daury et al., 2016; Jeong et al., 2016), 
which suggest that the helices are required only to form a conduit continuous with 
that of TolC. Although it is possible that the artificial conditions used in structural 
studies force unnatural configurations of the complex to form, it seems unlikely that 
data from such approaches are never true in vivo, and therefore are probably correct 
at some stage of complex assembly. 
 
7.6 The AcrA hairpin tip is essential for closing of the TolC channel 
Based upon the kinetics of growth in the presence of vancomycin, it appears that any 
acrA mutant lacking a natural hairpin tip sequence grows more slowly than those that 
have the natural hairpin tip sequence. Furthermore, the hairpin structure itself is not 
required for the phenotype to match that of the wild-type. This suggests that AcrA is 
as essential in closing of TolC as it is in efflux of substrates, and that this function is 
achieved by the hairpin tip. Although this is inconsistent with previously published 
data regarding the opening and closing of channel proteins by MFPs, it must be 
remembered that these results are based upon relatively small changes in growth 
kinetics. This study is therefore more sensitive to differences between mutants than 
previous studies, which assessed susceptibility by the less sensitive MIC and disc 
diffusion assays.  
This putative function of the hairpin tip could partly explain why the TolC tip mutants 
YFRS and YFRE were more susceptible to vancomycin in the previous studies. 
Although these mutations on TolC cause partial channel opening, based on the 
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crystal structures, the aperture remains too narrow for vancomycin to pass, shown in 
Figure 7:2. Without further opening, presumably induced by binding of a partner 
protein, it is therefore unclear how vancomycin uses the channel partially dilated by 
mutation to gain access to the cell. The vancomycin susceptibility of the partially-
opened mutant TolC had been tested in an acrA knockout, but it is possible that 
expression of other MFPs present in the cell, particularly AcrE, caused additional 
dilation of the channel. In such a scenario, it is reasonable to expect that the 
mutation of the TolC tips may prevent MFP-induced closing of the channel for the 
same reason as the AcrA(GS-tip) and AcrA(Δhairpin) mutants were unable to close the 




Figure 7:2 - Vancomycin is larger than the mutationally-opened TolC aperture. 
When docked into the crystal structure of a TolC protein that has been partially 






In the Δhelices mutant, the hairpin structure is shortened to just 15 Å, with the loop 
that forms the hairpin tip brought closer to the lipoyl domain by approximately 33 
Ångstroms. The dimensions of this mutated hairpin are incompatible with the helical 
bundling model of interaction, but a tip-to-tip type interaction remains possible, as 
shown in Figure 7:3. When combined with available  structural data of the entire 
complex, which as discussed in Section 7.2 is de-energised, and also combined with 
data indicating that energy is required for dissociation of the complex, this leads to 
the conclusion that the tip-to-tip model represents a stage of the dynamic process at 
which the channel is closing. The implication of this is that the sequence similarity 
between hairpin tips of MFPs with unique partners is due to a conserved mechanism 
of closing the channel aperture and dismantling the complex, but not for the MFP-
OMC interaction. This is also compatible with the results from Consurf, which 
indicate that the OMC tip regions are generally very well conserved between species, 
while the mid-section of the coiled-coil domain below the equatorial domain is less 
well conserved, as shown in Figure 7:4. A new hypothesis is therefore presented 
based on the results here and the available literature: the tip-to-tip model of 
interaction represents a pre-dissociation state, regardless of whether an efflux event 




Figure 7:3 - Potential interactions of AcrA(Δhelices) mutant. 
The AcrA(Δhelices) mutant, shown in brown with the relocated hairpin tip in yellow, is 
likely only conducive to a tip-to-tip interaction with TolC (green). In a subtle change, a 
direct TolC-AcrB (blue) interaction would probably cause incompatibility between the 
hairpin tip and the lower part of the TolC channel (left), while abolition of the TolC-
AcrB interaction would allow a shortened form of the prototypical tip-to-tip 





Figure 7:4 - Consurf results for TolC indicating conserved regions. 
Using the 1EK9 structure as the query, the Consurf results are mapped directly onto 
the same structure, to a single protomer. In pale yellow are adjacent helices of the 
other protomers. Each position is coloured on a scale from blue through white to 
purple, with blue being hypervariable, white being semi-variable and purple being 
most conserved. Positions in green are those lacking sufficient data in the alignment 
to calculate a conservation score.  
234 
 
7.7 An AcrA tip mutant shows a dominant effect over the wild-type protein 
Preliminary data (Section 5.1) indicate that when the acrA+ WT strain is transformed 
with the pASK-acrA(GS-tip)B  plasmid, and thus is expected to express both WT and 
mutant AcrA, the strain becomes more susceptible to novobiocin. This is explained by 
the dominant phenotype of the GS-tip mutation. There are three likely explanations 
for the observed effect.  
The first explanation involves formation of AcrA-AcrA(GS-tip) heterodimers, in which 
the mutant protein prevents the WT protein from functioning normally. However, 
the knockout strain expressing only the GS-tip variant is more like the knockout 
strain with empty vector, with a more severe phenotype than in the strain expressing 
both genes. Given that expression from the plasmid was shown to be higher than 
from the chromosome (if the wild-type and the complemented strains are compared 
in Section 5.4), it is reasonable to expect that there would be an excess of the GS-tip 
variant over the wild-type, and that therefore very little, if any, wild-type 
homodimeric AcrA would be able to form, and therefore that the phenotype of the 
strain expressing both variants in this way should be more like the knockout than the 
wild-type, which was not the case. It is therefore unlikely that this explanation alone 
is capable of explaining the observed results.   
The second explanation is that the mutant is capable of binding to TolC, but is non-
functional because it is unable to dissociate from or close the TolC channel, thus 
allowing a greater rate of drug influx. This is consistent with the apparent 
requirement of the AcrA hairpin tip in closing but not opening of the TolC channel as 
indicated in this study. It would also remove a proportion of the TolC channel protein 
from circulation for use by the wild-type AcrA protein. Such effective decrease of the 
available TolC protein would decrease the likelihood of complete wild-type 
complexes forming. Given the increased abundance of the mutant compared to wild-
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type protein, one might expect that sequestering of the TolC channel would give rise 
to a severe phenotype, but it has previously been shown that TolC abundance as low 
as 10% that of the BW25113 strain is sufficient to provide resistance at wild-type 
levels (Krishnamoorthy et al., 2013). However, the results in that paper were based 
on MIC testing, which only provide very limited information, as this thesis indicates. It 
would therefore be interesting to see if the growth kinetics of a strain with TolC 
levels at only 10% would be impacted, even though the effective MIC is not. This 
explanation could therefore a possibility, especially if there is also some contribution 
from the first explanation, which would mean that both TolC and AcrA are 
sequestered by the AcrA(GS-tip) protein.  
The third explanation is that the mutation causes effects in the membrane that are 
not TolC dependent. This could be due to either AcrA interaction with the outer 
membrane in a TolC-independent manner (Tikhonova & Zgurskaya, 2004), or 
differences in wider gene expression caused by differences in transcript levels of 
RND components (Webber et al., 2009; Buckner et al., 2016; Wang-Kan et al., 2017). 
From the available data, it is impossible to say whether these are likely effects or not, 
although a comparative transcriptomics approach could provide some insight as to 
the likelihood of the latter of these possibilities. 
To test each of the first two explanations, surface plasmon resonance or 
thermophoresis should be performed, to determine relative binding affinities in 
TolC-AcrA(WT), TolC-AcrA(GS-tip), AcrA(WT)-AcrA(WT) and AcrA(WT)-AcrA(GS-tip). 
This would indicate whether either of the interactions are impacted by mutation of 
the MFP tip, as has been reported in the ABC-type efflux pump DevBCA-HgdD from a 
species of Anabaena (Staron et al., 2014). 
If either of the first two of the above explanations, or a combination of both of them, 
are correct, then there may be some potential to use a truncated hairpin peptide 
236 
 
with the GS-tip sequence in a therapeutic approach. It is not at all clear how much of 
the hairpin is required in interaction with TolC, but the sequence of the mutation, 
GSGGSG, is 6 amino acids, thus allowing only up to 25 amino acids contributing to 
helices if the 31 amino acid limit for biotin-facilitated is conformed to (Walker & 
Altman, 2005). This makes it unlikely, though not impossible, that the dominant 
peptide could be provided externally.  
 
7.8 Loss of the lower ion-selectivity ring of TolC is detrimental to the cell 
The aspartate residues at TolC positions 371 and 374 form two rings of negative 
charge, which act as a cation trap and form the region of smallest diameter in the 
TolC lumen (Andersen et al., 2002c). The lower of these, D371, may be involved in 
stabilising the open state of TolC upon rearrangement of the ionic network at the 
periplasmic tip of TolC, namely by forming a new interaction with R367. This may 
partially explain why the R367A mutation causes hypersusceptibility to efflux 
substrates (Augustus et al., 2004), even though removal of the position charge at this 
position does not on its own cause constitutive dilation of the TolC channel (Pei et al., 
2011).  
Previous mutation of these aspartate rings was to alanine, which will not protrude 
very far into the TolC lumen and therefore contributes little to the overall 
electrophysical profile of the face of the lumen. Mutation of D371 to alanine was 
reported not to impact upon either deoxycholic acid resistance nor haemolysin 
export (Andersen et al., 2002c). Meanwhile, the mutation to valine, as done for this 
thesis, introduces a new hydrophobic ring at the narrowest part of the channel. This 
mutation was predicted to cause electrostatic incompatibility of the charge and 
H-bond network at the periplasmic tip, the new hydrophobic ring, and the existing 
negatively charged D374 ring one helical turn higher in the TolC lumen. Such 
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electrostatic incompatibility was expected to cause the tip to force apart, leading to 
a constitutively open TolC channel. However, from the data presented here, it 
appears that the introduced hydrophobic ring locks the aperture in the closed 
conformation, as the valine sidechains have no compatible hydrophobic 
environments into which to move upon channel opening. Flow cytometry data 
indicate that this increased energy barrier to TolC is overcome in a proportion of the 
cells, as the population is split between apparently efflux active and apparently 
efflux deficient cells. The lower fluorescence of the apparently efflux active 
population cannot be explained through decreased dye influx alone, as the knockout 
strain does not show the same split. Unfortunately, this strain grows slower than the 
wild-type strain even in the absence of antibiotic, and therefore growth kinetic data 
are not comparable for this strain. The normalised dye efflux results indicate that 
D371V mutant is entirely deficient in efflux activity of Nile Red, which does not 
match the likely ethidium bromide efflux profile as suggested by flow cytometry 
data. As Nile Red adsorbs to hydrophobic surfaces, and is fluorescent in hydrophobic 
environments, it may be that Nile Red is trapped by the valine ring in the same way as 
large cations are trapped by the aspartate ring, thereby inhibiting its own efflux. 
Although the fluorescence assays presented in this thesis suggest that there is a 
significant decrease in function, the OprN channel from Pseudomonas aeruginosa 
contains valine at this equivalent position (Yonehara et al., 2016), and with MexEF 
forms a functional efflux pump capable of providing resistance against several 
substrates, both hydrophilic and hydrophobic(Maseda et al., 2000). It therefore 
seems unlikely that a hydrophobic valine ring at position 371 introduces a 
hydrophobic barrier or trap.  
The overall effect of the D371V mutant on the cell is very clearly not simply a result 
of loss of TolC function. Deletion of tolC is well tolerated in laboratory conditions, 
while the D371V mutation is not. Therefore, there is either a difference in 
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compensatory changes made in response to loss of functional TolC, as are made in a 
tolC knockout (Webber et al., 2009),or the mutation causes the protein to be 
inherently detrimental to the cell. Given that the same detrimental effect is not seen 
in other efflux-deficient tolC point mutants, such as S350F, the differential gene 
expression hypothesis is unlikely, although it could be tested by comparative 
transcriptomics (RNA-seq). It would be interesting to perform a comparative 
metabolomics analysis of the wild-type, knockout and D371V point mutant, to 
determine what causes the growth deficiency. It is likely that the protein is incapable 
of fulfilling its normal role in removal of toxic metabolic products (Ruiz & Levy, 2014), 
a task presumably fulfilled by other proteins in the knockout (Rosner & Martin, 2009). 
This mutation also requires further analysis using in vitro techniques such as 
proteoliposome assays, to determine the effect on actual efflux activity.  
During mutagenesis, multiple attempts were made to generate a D371V/D374V 
double mutant. Several candidate plasmid preps were sequenced, and all of them 
contained secondary mutations within the PCR priming site. Unless the primers used 
for the double mutation were of very poor quality, these secondary mutations were 
not encoded within the primers – each sample sequenced contained different 
mutations. Initially, it was assumed that the sequence for the double mutant 
contained too much repeat sequence, which can result in errors during amplification, 
either during PCR or in vivo following transformation. However, the phenotype of the 
D371V single mutant led to consideration that the D371V/D374V double mutation 
could cause a more severe phenotype, even from background expression in the 
absence of the inducer, and that the secondary mutations, most of which were 
frameshift and result in a truncated protein, were required for the survival of the 
bacterial cells by preventing incorporation of the double mutant into the outer 
membrane. Testing of this hypothesis would require use of an expression system 




7.9 TolC S350F mutant loss-of-function is not caused by low protein levels 
The laboratory of Rajeev Misra have previously reported conflicting information 
about the TolC S350F mutation: the mutant protein is “surprisingly impervious to 
degradation” (Werner et al., 2003), and yet the same mutation “resulted in somewhat 
reduced protein levels” (Augustus et al., 2004). The figures associated with the 
statements did not indicate particularly low protein levels, although the Western blot 
shown in this thesis (Section 4.5) indicate that in this particular study, the S350F 
mutant is present in the membrane fraction at approximately the same level as the 
wild-type protein expressed from the same vector. Not only is a slight decrease in 
TolC expression unlikely to lead to the apparent loss of function that was reported 
(Krishnamoorthy et al., 2013), but the phenotype in the presence of vancomycin is 
also inconsistent with a decrease of TolC protein levels, both in this thesis and in the 
previous study (Augustus et al., 2004). Although the mutation does not appear to 
cause a change in MIC to vancomycin, the growth kinetics profile of this mutant in the 
presence of vancomycin are distinct from those of the knockout and complemented 
strains. The S350F mutation causes an extended lag phase duration, and the 
stationary phase OD600 is decreased in this mutant in the presence of vancomycin, 
even though the maximum growth rate does not change, indicating that the 
mutation has a mild effect on vancomycin susceptibility.  
Position 350 of TolC is on the external face of helix 7, with the side chain partially 
embedded in the space between this helix and H4 of the adjacent protomer. 
Mutation to phenylalanine was expected to either cause constitutive opening of the 
channel due to insertion of a bulky side chain between the helices, thus forcing a 
movement of H7 into the more open conformation, or to force a more closed 
conformation as one of the side chains of D162 or F350 is moved more towards the 
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channel lumen. The very mild effect on vancomycin susceptibility suggests that 
neither of these is likely to be entirely correct. The MFP-dependency of the 
vancomycin susceptibility of this mutation needs to be determined, probably using a 
proteoliposome approach to measure transfer of vancomycin through the channel. 
Based upon the lack of efflux activity and the very mild vancomycin susceptibility, the 
current hypothesis regarding this mutation is that it prevents normal closure of the 
channel by the MFP, which also prevents normal cycling of the pump activity.   
 
7.10 Future experiments to consider 
There is limited evidence that vancomycin gains entry to the cell through an open 
TolC channel, based upon vancomycin susceptibility of certain TolC point mutants 
beings similar to hlyCABD+ cells (Augustus et al., 2004). However, the TolC-
dependence of the vancomycin susceptibility of haemolytic E. coli cells was not 
reported, and it is possible that both HlyCABD and point mutants of TolC 
independently compromise the structural integrity of the outer membrane. Another 
research group has used vancomycin as a general indicator of outer membrane 
disruption in knockout mutants, irrespective of a possible entry route through TolC 
(Morris, 2014). To determine the extent to which vancomycin gains entry via TolC, 
TolC-proteoliposomes could be prepared loaded with vancomycin (similar to how 
OMC-proteoliposomes are prepared loaded with RNA), and the leakage of 
vancomycin from the proteoliposome to the buffer analysed either by HPLC or by 
sensitivity screening against a Gram-positive (monodermic) bacterial strain. As there 
are multiple MFPs in the cell that might induce TolC opening in vivo, this 
proteoliposome approach could also be used to test the MFP-dependence of 
vancomycin movement through TolC and its mutants.  
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To determine the exact positions on TolC with which the AcrA hairpin tip interacts, 
the photoreactive synthetic amino acid benzoyl-phenylalanine could be introduced to 
the AcrA hairpin tip, ideally replacing each of Y129, Y137 and Y143, independently. 
Following light-activated cross-linking of the proteins, they would be purified (via a 
hexahistidine tag on AcrA) and analysed by mass spectrometry. Given that this would 
generate a fragment unknown within protein databases, the data would require 
manual analysis, which would be quite time consuming. 
 Having obtained preliminary data indicating that the AcrA(GS-tip) mutation is 
partially dominant when co-expressed with the wild-type protein, it would be useful 
to determine the effect of this mutation on utilisation of TolC by other MFPs. For 
example, when expressed in a haemolytic strain of E. coli, does the AcrA(GS-tip) 
mutation prevent haemolysin export? This would be tested by a simple haemolytic 
activity assay on blood agar. Such information could assist in determining what 
potential there may be for this mutated hairpin structure in therapeutic use. 
It is not known from the experiments done so far whether the AcrA loss-of-function 
mutations are capable of forming dimers or oligomers. To give an indication as to the 
number of AcrA moieties bound to each other, 2D-PAGE could be used on purified 
AcrA and its mutants. If sufficiently diluted, it may be possible to determine self-
association binding affinities through thermophoresis or surface plasmon resonance.  
In light of the substrate-specific effect of some of the TolC mutations, and the 
available literature indicating that OMC selection by an MFP can be determined in a 
substrate-specific manner, it would good sense to determine if any of the TolC 
mutations gain function with non-cognate IMT/MFP pairs. Such an experiment would 
be similar to that reported by Bokma et al. (2006), except that the mutation is 
directed rather than random. It would also make good sense to test this cross-
reactivity with a variety of potential substrates, given the substrate-specific effect of 
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some of the mutations. This could also be tested by a proteoliposome system, to 
eliminate possible pleiotropic effects.   
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As alluded to in Sections 7.5 and 7.6, this particular study indicates that both the tip 
and the helical parts of the MFP hairpin are essential for normal efflux function. The 
hairpin tip is required for closing of the channel protein, and therefore probably also 
for dissociation of the complex, while the helices are required for stable interaction 
with the OMC during the efflux process. Neither part of the hairpin appears to be 
essential for dilating the aperture of the OMC.  
A new dynamic model of interaction is therefore proposed based on the results from 
this study and consideration of the available literature. This new dynamic model, 
including some speculation as to the mechanisms, is detailed below; the key steps 
are: 
1. A bipartite assembly of IMT-MFP or IMT-(closed)OMC forms. 
2. (a) The third protein joins the complex, forming a tripartite complex 
conforming to a helical bundling model of interaction and (b) the channel is 
opened. 
3. (a) An efflux event occurs, both passing the substrate directly to the lumen of 
the OMC and (b) inducing a second conformational change in the MFP. 
4. The MFP moves towards a tip-to-tip model of interaction with the OMC. 
5. In the tip-to-tip type interaction, the MFP closes the channel, with the 
substrate in the channel lumen. 
6. The MFP dissociates from the OMC and returns to its resting conformation 
ready to recycle.  
The interaction between MFP and IMT is prevented by the pre-formation of MFP-
OMC bipartite complexes, but either MFP-IMT or IMT-OMC bipartite complexes can 
form as the initial step towards tripartite assembly, and the channel is closed during 
formation of the tripartite complex (Tikhonova et al., 2011). For recycling of the 
complex, and to minimise unproductive cycling of the transporter upon its 
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interaction with the MFP (Verchère et al., 2014), it is likely that the IMT-OMC 
bipartite complex is the most relevant for productive assembly (STEP 1). This would 
also allow monomeric or, more likely, dimeric MFP to wrap around the pre-formed 
IMT-OMC complex, avoiding the large conformational changes that would be 
required to allow a claw-like closing of the IMT-bound MFP around the OMC that 
would slide over the top of the IMT-MFP complex (Figure 8:1). It is unclear how any of 
the proposed mechanisms take place through the peptidoglycan layer. To avoid 
opening of the channel in the absence of either of the other components, it may be 
that opening is only induced upon binding of both partner proteins.  
As the only place the IMT can bind the OMC is through interaction of the β-hairpins of 
the IMT with the periplasmic tip of the OMC, these proteins must interact in this 
manner, and so the MFP must interact with the OMC as in the helical bundling 
models, although the exact positions remain debatable (STEP 2a). Positions as high 
up the channel as N332 (a full 9 helical turns from the periplasmic tip) are involved in 
the interaction with the MFP, and are involved in the MFP-OMC interaction in a 
substrate-dependent manner. On TolC, D121 (7 helical turns from the periplasmic tip) 
is also involved in this interaction in a substrate-dependent manner, and mutation of 
this residue can switch MFP specificity of the channel in a single step. Due to these 
two positions being on different putative binding grooves – D121 is intra-protomer, 
while N332 is inter-protomer – it appears that during normal function both grooves 






Figure 8:1 - Possible bipartite routes to forming a tripartite RND assembly. 
Top: If TolC (1EK9, green) and AcrA (2F1M, brown) form a bipartite complex, AcrB 
cannot be recruited, possibly because of the bipartite complex being membrane-
bound at both ends. Middle: When AcrA binds AcrB (1IWG, blue), either the outer 
membrane must flex outwards to allow TolC to enter from above, or the AcrA hairpin 
must undergo a claw-like movement to open (1), allowing TolC to move onto the 
complex (2), and then reverse the initial claw-like opening to close around TolC. More 
likely (bottom), AcrB transiently recruits TolC, allowing AcrA to enter the complex 
without allosteric restrictions. 
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Upon binding of the MFP to the OMC as per the helical bundling model, the MFP and 
OMC each independently undergo a conformational change. The OMC moves into its 
open conformation in readiness for the efflux event, assisted also by its interaction 
with the IMT. Meanwhile, the MFP moves about its hinge regions into a conformation 
that would, on its own, be unable to bind the IMT, explaining the aforementioned 
observation that the MFP-OMC bipartite complex cannot bind the IMT (STEP 2b). 
Upon recruitment of the MFP to the complex, one of the transporter protomers 
transitions from its tight state to its open state, causing release of the substrate. As 
the substrate must traverse the docking domain of the transporter upon the 
conformational change of the transporter, the channel should have completed its 
own conformational change and be fully dilated by the time the substrate is free of 
the transporter. Therefore, the transporter is able to pass the substrate directly into 
the lumen of the channel, where there must presumably be a transient interaction 
between the OMC and the substrate, possibly also destabilising the interaction 
between the IMT and OMC (STEP 3a). The conformational change of the transporter 
(or, possibly, the destabilisation of the IMT-OMC interaction) induces a second 
conformational change in the MFP, causing the MFP to re-arrange its interaction with 
the OMC and transferring potential energy to the MFP (STEP 3b). Such 
re-arrangement essentially causes the OMC to slide away from the IMT and enter the 
tip-to-tip model of interaction (STEP 4). In this configuration, the complex 
presumably also causes a localised protrusion at the outer membrane, which logically 
would also lead a localised thinning of O-antigen around the channel exit, possibly 
facilitating faster exit of the substrate from the channel to the extracellular milieu.  
From the tip-to-tip type interaction, the potential energy stored with the MFP is 
transferred to the OMC, overcoming the energy barriers required to close the 
channel back into its coiled-coil state (STEP 5). As part of the closing mechanism and 
in order to return to its resting state in which it is capable of binding to both partner 
248 
 
proteins, the MFP must also undergo a further conformational change to dissociate 
from the complex (STEP 6). In order to completely recycle the complex, there may be 
an intermediate MFP conformation at this step, which causes the MFP to dissociate 
from both the IMT and OMC – logically it would be once dissociated from both 
partner proteins that the MFP would return to its resting state.   
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9.3 Appendix 1: PCR primers used in this study 





















TolC_WT_F CACGAACATATGAAGAAATTGCTCCCCATTCTTATC 63 Eurogentec 
TolC_WT_R GAGTCGCTCGAGGTTACGGAAAGGGTTATGACC 61 Eurogentec 
AcrA_WT_F GGTCAACATATGAACAAAAACAGAGGGTTTACG 61 Eurogentec 
AcrA_WT_R TGGTTGCTCGAGACTTGGACTGTTCAGGCTG 63 Eurogentec 
AcrB_WT_F TAGCTTCATATGCCTAATTTCTTTATCGATCGCCCGATTTTTG 69 Eurogentec 
AcrB_WT_R ATATTCCTCGAGATGATGATCGACAGTATGGCTGTGC 67 Eurogentec 
Salm_AcrB_F TAGCTTCATATGCCTAATTTCTTTATCGATCGCCCGATTTTTG 69 Eurogentec 

















TolC_Y344F_F TCAGTAGCATTAACGCCTTCAAACAAGCCGTAGTTTC 60 Eurogentec 
TolC_Y344F_R GAAACTACGGCTTGTTTGAAGGCGTTAATGCTACTGA 60 Eurogentec 
TolC_N145L_F ATTAGATCAAACCACCCAACGTTTTCTCGTGGGCCTGGTA 60 Eurogentec 
TolC_N145L_
R 
TACCAGGCCCACGAGAAAACGTTGGGTGGTTTGATCTAAT 60 Eurogentec 
TolC_R158E_F GACGTGCAGAACGCCGACGCACAGTACGATAC 60 Eurogentec 
TolC_R158E_
R 
GTATCGTACTGTGCGTCGGCGTTCTGCACGTC 60 Eurogentec 
TolC_Q346L_
F 
AGCATTAACGCCTACAAACTAGCCGTAGTTTCCGC 60 Eurogentec 
TolC_Q346L_
R 
GCGGAAACTACGGCTAGTTTGTAGGCGTTAATGCT 60 Eurogentec 
TolC_Q352E_
F 
AGCCGTAGTTTCCGCTGAAAGCTCATTAGACGC 60 Eurogentec 
TolC_Q352E_
R 
GCGTCTAATGAGCTTTCAGCGGAAACTACGGCT 60 Eurogentec 
TolC_Q352A_
F 
CAAGCCGTAGTTTCCGCTGCAAGCTCATTAGACGCGAT 60 Eurogentec 
TolC_Q352A_
R 













TolC_K383E_F CGTTGTACAACGCCGAGCAAGAGCTGGCG 60 Eurogentec 
TolC_K383E_
R 
CGCCAGCTCTTGCTCGGCGTTGTACAACG 60 Eurogentec 
TolC_K383D_
F 
CCACGTTGTACAACGCCGATCAAGAGCTGGCGAATGC 60 Eurogentec 
TolC_K383D_
R 
GCATTCGCCAGCTCTTGATCGGCGTTGTACAACGTGG 60 Eurogentec 
TolC_D371V/
D374V_F 
ACGCGTACCATTGTTGTTGTGTTGGTTGCGACCACCAC 60 Eurogentec 
TolC_D371V/
D374V_R 
GTGGTGGTCGCAACCAACACAACAACAATGGTACGCGT 60 Eurogentec 
TolC_D371V_
F 
ACGCGTACCATTGTTGTTGTGTTGGATGCGACC 60 Eurogentec 
TolC_D371V_
R 
GGTCGCATCCAACACAACAACAATGGTACGCGT 60 Eurogentec 
TolC_D374V_
F 
CATTGTTGATGTGTTGGTTGCGAACCACCACGTTGT 60 Eurogentec 
TolC_D374V_
R 
ACAACGTGGTGGTCGCAACCAACACATCAACAATG 60 Eurogentec 
TolC_Q129L_
F 
CTTTCCTATACACAGGCACTGAAAGAAGCGATCTACCGTC 60 Eurogentec 
TolC_Q129L_
R 
GACGGTAGATCGCTTCTTTCAGTGCCTGTGTATAGGAAAG 60 Eurogentec 
seq_tolC_upst CAATCAGCACAACTTCATCACGCAC 67 
Alta 
Bioscience 























tolC_int_F GCTGAAAGAAGCCGAAAAACGCAACC 70 
Alta 
Bioscience 
tolC_int_R GGTTGCGTTTTTCGGCTTCTTTCAGC 70 
Alta 
Bioscience 
acrA_int_R GACCGTTCTGTACCAATGC 61 
Alta 
Bioscience 





acrB_int_F CCAAGCTCCTTCTTGCCAG 64 
Alta 
Bioscience 
acrB_int_R CTGGCAAGAAGGAGCTTGG 64 
Alta 
Bioscience 
pASK_seq_F GAGTTATTTTACCACTCCCT 56 
Alta 
Bioscience 
pASK_seq_R CGCAGTAGCGGTAAACG 61 
Alta 
Bioscience 
pET_seq_F CGAAATTAATACGACTCACTATAGG 58 
Alta 
Bioscience 
pET_seq_R GCTAGTTATTGCTCAGCG 58 
Alta 
Bioscience 
pASK_Stop_F CGGGGATCCCTCGAGTGAGACCTGCAGGGGGAC 60 
Alta 
Bioscience 




































































S54P_F CGATGCCAGACGGTTTTCCAATCTGGCATCACCT 60 
Alta 
Bioscience 















H43A_R ATCGTTGTGCCTTGAGCAACGGCACGAATCGCCAG 60 
Alta 
Bioscience 

















R95A_F AAAAGCGGTCCTCGACGCAACATTGCCCCATGGC 60 
Alta 
Bioscience 
R95A_R GCCATGGGGCAATGTTGCGTCGAGGACCGCTTTT 60 
Alta 
Bioscience 
pBAD_seq_F ATGCCATAGCATTTTTATCC 55 
Alta 
Bioscience 
pBAD_seq_R GATTTAATCTGTATCAGG 48 
Alta 
Bioscience 
kan_seq_F GCATCAGAGCAGCCGATTGTC 67 
Alta 
Bioscience 
kan_seq_R CATCGCCTTCTATCGCCTTC 64 
Alta 
Bioscience 
pKT_seq_t25R GTTGACCAGGCGGAACATCAATGTG 69 
Alta 
Bioscience 











































pDOC-cure-5 GTATGTGAATTCTTAAGTTCTACGTGTTCCGCTTCC  
Alta 
Bioscience 












































acrA_TY-VF_F CTGCGACCTATCAGGCGGTATTCGACAGTGCGAAAGGTG 61 
Alta 
Bioscience 
acrA_TY-VF_R CACCTTTCGCACTGTCGAATACCGCCTGATAGGTCGCAG 63 
Alta 
Bioscience 
acrA_K-A_F GATCAATCTGGCTTACACCGCAGTCACCTCTCCGATTAGC  
Alta 
Bioscience 
















































K-FWD GACCGGTCAATTGGCTGGAG 67 
Alta 
Bioscience 
P-REV GGAACTAAGGAGGATATT 51 
Alta 
Bioscience 
pDOC-S1 TATGCTTCCGGCTCG 59 
Alta 
Bioscience 
pDOC-S2 GGATGTGCTGCAAGG 58 
Alta 
Bioscience 
pDOC-CC1F GCGGAACACGTAGAACTTAAG 61 
Alta 
Bioscience 
pDOC-CC2F CATGCTGGAGTTCTTGCGCCC 70 
Alta 
Bioscience 















ClaI-pask-f CCGCTACTGCGTCATCGATTTCCACGCGCC  
Alta 
Bioscience 
ClaI-pask-r GGCGCGTGGATATCGATGACGCAGTAGCGG  
Alta 
Bioscience 
acrAΔhpHup-f CTATCAGGCGACATACCTGCTCGGTACTCAGT  
Alta 
Bioscience 
acrAΔhpHup-r ACTGAGTACCGAGCAGGTATGTCGCCTGATAG  
Alta 
Bioscience 


















SacI-mzrA AATAATGAGCTCCAAATACCTCGCATGTCGCTTCGC 69 
Alta 
Bioscience 
XhoI-mzrAr AATAATCTCGAGTCCGAAGCGATGAGAGTTATCCCG 69 
Alta 
Bioscience 
NcoI-envZ AAAATACCATGGCAGGCGATTGCGCTTCTCGC 71 
Alta 
Bioscience 
SalI-envZr AATAATGTCGACCCTTCTTTTGTCGTGCCCTGC 67 
Alta 
Bioscience 



































































































































tolC-S350F-F CGCCTACAAACAAGCCGTAGTTTTCGCTCAAAGCTC  
Abingdon 
Health 















tolC-D162A-F CGCCAGCACGGTAGCGTACTGTGCGCG  
Abingdon 
Health 
tolC-D162A-R CGCGCACAGTACGCTACCGTGCTGGCG  
Alta 
Bioscience 
tolC-V198D-F ACTGGCTGCGCTGAATGACGAAAACTTTAAAACCGA  
Abingdon 
Health 

















tolC-YF1-F ATGGAAGCGGGCTTCTCGGTCGGTACG  
Abingdon 
Health 
tolC-YF1-R CGTACCGACCGAGAAGCCCGCTTCCAT  
Abingdon 
Health 
tolC-RS2-F GCTACTCGGTCGGTACGAGTACCATTGTTGATGTG  
Abingdon 
Health 










































XhoI-mtrE-R AAATCCCTCGAGTTTGCCGGTTTGGGTATCCCGTTTCAATC 72 
Abingdon 
Health 
NdeI-mtrC-F TCTTTACATATGGCTTTTTATGCTTCTAAGGCGATGCGTGC 72 
Abingdon 
Health 













NcoI-mtrC-F TTTTTTCCATGGCTTTTTATGCTTCTAAGGCGATGCGTG 67 
Abingdon 
Health 
HindIII-mtrC-R TATCTCAAGCTTATTTCGCTTCAGAAGCAGGTTTGGCTTC 70 
Abingdon 
Health 
ss-tolC-F AAGAAATTGCTCCCCATTC 58 
Abingdon 
Health 
pBAD-start-R CATGGTGAATTCCTCCTG 58 
Abingdon 
Health 
pASK-start-R CATATGTATATCTCCTTCTTAAAGTTAAAC 57 
Abingdon 
Health 
mtrC-TA-R GTTTCGCTTCAGAAGCAGGTTTGGCTTC 71 Invitrogen 
mtrE-TA-F TGAATACTACATTGAAAACTACCTTGACCTCTGTTGCAGC 72 Invitrogen 
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mtrE-TA-R GTTTGCCGGTTTGGGTATCCCGTTTCAATC 71 Invitrogen 




TTGATGCATCTATCAGTAGCATTAACGCCTACAAAC  Invitrogen 








TTGGTCGCGACCACCACGTTGTACAACG  Invitrogen 
mtrC-hp-F TCCTTCCACTTATGAAGCAGGTCTGG 69 Invitrogen 




CACTACAACAATGGTACGCGTACCGAC  Invitrogen 




GGTACGAGTACCATTGTTGATGTGTTGGATGCGA 68 Invitrogen 




GACCGAGAAGCCCGCTTCCATCGCGTC 72 Invitrogen 
pBAD-TA-R GGTGAATTCCTCCTGCTAGCCCA 70 Invitrogen 
acrB-D288G-F GGTCTTGGCATCAAACTGGCTACCG  Invitrogen 
acrB-D288G-R TGACGCTGGCTGACCGT  Invitrogen 
acrA-TA-F TGAACAAAAACAGAGGGTTTACGCCTCTGG 71 Invitrogen 
acrA-TA-R GAGACTTGGACTGTTCAGGCTGAGC 70 Invitrogen 
acrB-TA-R GATGATGATCGACAGTATGGCTGTGCTC 69 Invitrogen 
tolC-TA-F TGAAGAAATTGCTCCCCATTCTTATCGGCCTG 72 Invitrogen 
tolC-TA-R GGTTACGGAAAGGGTTATGACCGTTACTGG 71 Invitrogen 





















cftC-F TGAATATGAACAATCCATTAGAGGTTCTTGGGCATGTATC 70 
Alta 
Bioscience 



























AAAAAAGAATTCAGGAAAGTCAGGTGTGTAACGCTTC 67 Invitrogen 
LCR-tolCupst-
R 
TGCATTCCTTGTGGTGAAGCAGTATTTAGC 69 Invitrogen 
LCR-pDOC-
EcoRI-R 








CCCAGAGCTGAGCAAATATTCAGCTGATTAATCAGGTAG 58 Invitrogen 
LCR-pDOC-
NdeI-F 
ATGCTAGCGTCGACTAGTAGGGATAACAG 69 Invitrogen 
LCR-TolCdnst-
F 
TGATGACGACGACGGGGCTTCG 72 Invitrogen 
P-rev2 CTCGAGATATGAATATCCTCCTTAGTTCCTATTCC 67 Invitrogen 
pDOC-C-tolC-
upst 
ATAACAGGGTAATCGATGAATTCAGGAAAGTCAGGTGT  Invitrogen 
tolC-Kan-upst TCACCACAAGGAATGCAGACCGGTCAATTGGCT  Invitrogen 
mtrE-int-F GACTGGGTGCGGCATC 64 Invitrogen 
mtrE-int-R CAATTCGACAGAACCCGTACC 64 Invitrogen 
tolC-Kan-dnst AGGAGGATATTCATATCTCGAGTGATGACGACGACGG 58 Invitrogen 
rlS-rlG-F GGTAAGCAAGAGTACGATCAGGCTCTGGCT 72 Invitrogen 
rlS-rlG-R GATGTACTGAGTACCGAGCAGTTTCTGATAACGATTCAC 72 Invitrogen 
pDOC-C-tolC-
dnst 
TCAGTATTACCGAGCGTCGACTAGTAGGGATAACAGGG  Invitrogen 
EcoRI71-
acrAupst-F 
AAAAAAGAATTCCGGCGCTTCAGCGACT 71 Invitrogen 
LCR-acrAupst-
R 
ATGTAAACCTCGAGTGTCCGATTTCAAATTGGT 70 Invitrogen 
qeyD-qeyA-F GCTCAGGCTCTGGCTGATGCGC 71 Invitrogen 
qeyD-qeyA-R GTACTCTTGCTTACTGATGTACTGAGTACCGAGCAG 72 Invitrogen 
LCR-acrBdnst-
F 
TACAACGTGTAATCACTAAGGCCGCGTAAG 70 Invitrogen 
aaKaa-aaEaa-
F 
GAAGCTGCCGTTGAAACTGCG 67 Invitrogen 
aaKaa-aaMaa-
F 
ATGGCTGCCGTTGAAACTGCG 66 Invitrogen 
aaKaa-aaEaa-
R 
CGCCGCAGTTACCGCAGCATTC 72 Invitrogen 
pDOC-C-acrA-
upst 
ATAACAGGGTAATCGATGAATTCCGGCGCTTCAG  Invitrogen 
acrA-Kan-upst GACACTCGAGGTTTACATGACCGGTCAATTGGCT 56 Invitrogen 
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acrB-Kan-dnst TACAACGTGTAATCACTAAGTGATGACGACGACGG 51 Invitrogen 
aavE-aavA-F CAACTGCGCGGATCAATCTGGCTTACAC 72 Invitrogen 
aavE-aavA-R CAACGGCAGCTTTCGCCGC 72 Invitrogen 
pDOC-C-acrB-
dnst 
GTCAGTATTACCGAGCGTCGACTAGTAGGGATAACAGGG  Invitrogen 
TA-mtrE-Nlac-
F 
TGAATACTACATTGAAAACCACCTTAACTTCTGTTGCGGC 72 Invitrogen 
TA-mtrC-Nlac-
F 
TGGCTTTTTATGCTTCTAAGGCGATGCGT 71 Invitrogen 
TA-mtrD-
Nlac-F 
GGCTAAATTTTTTATCGACCGCCCCATTTTCGC 72 Invitrogen 
TA-mtrD-
Nlac-R 








CATGGACGAGCTGTACAAGTTAACTCGAGTGAGACCTG  Invitrogen 
pASK-acrA AAGAAGGAGATATACATATGAACAAAAACAGAGGGTTTAC 50 Invitrogen 
acrB-pBAD GCCATACTGTCGATCATCATTAAGCTTGGCTGTTTTGG 58 Invitrogen 
pBAD-tolC CAGGAGGAATTCACCATGAAGAAATTGCTCCCCATTC 58 Invitrogen 
tolC-pASK GTCATAACCCTTTCCGTAACTAACTCGAGTGAGACCTG 53 Invitrogen 
pASK-Start-R CATATGTATATCTCCTTCTTAAAGTTAAAC 57 Invitrogen 
pBAD-HindIII-
F 
TAAGCTTGGCTGTTTTGG 58 Invitrogen 
pBAD-Start-R CATGGTGAATTCCTCCTG 58 Invitrogen 
pASK-XhoI-F TAACTCGAGTGAGACCTG 58 Invitrogen 
mCherry-5-F GTGAGCAAGGGCGAG  Invitrogen 
NmCherry-R GTCCTCGGGGTACATCC  Invitrogen 
CmCherry-F GGCGCCCTGAAGG  Invitrogen 
mCherry-3-R ACTTGTACAGCTCGTCCA  Invitrogen 
pASK-
NmCherry 
AAGAAGGAGATATACATATGGTGAGCAAGGGCGAG  Invitrogen 
NmCherry-
mzrA 
AGCGGATGTACCCCGAGGACCAAATACCTCGCATGTCGC  Invitrogen 
mzrA-F CAAATACCTCGCATGTCGC 62 Invitrogen 
mzrA-R TCCGAAGCGATGAGAGTTATC 62 Invitrogen 
envZ-F AGGCGATTGCGCTTC 60 Invitrogen 
envZ-R CCCTTCTTTTGTCGTGC 59 Invitrogen 
tolC-F AAGAAATTGCTCCCCATTC  Invitrogen 
tolC-R CGGAAAGGGTTATGACC  Invitrogen 
acrA-F AACAAAAACAGAGGGTTTAC  Invitrogen 
acrB-R ATGATGATCGACAGTATGG  Invitrogen 
3-mzrA-pBAD ATAACTCTCATCGCTTCGGATAAGCTTGGCTGTTTTGG  Invitrogen 
pBAD-envZ AGCAGGAGGAATTCACCATGAGGCGATTGCGCTTCTCGC 63 Invitrogen 
ASK-tolC-
XhoI-F 
AAAAAACTCGAGTAAGAAGGAGATATACATATGAAGA  Invitrogen 
tolC-HindIII-R TTTTTTAAGCTTTTAGTTACGGAAAGGGTTATG  Invitrogen 
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pET-mCh-F GTTTCTAAAGGTGAAGAAGACAACATG 62 Invitrogen 
pET-CmCh-F GGTGCTCTGAAAGGTGAAATC 62 Invitrogen 
pET-NmCh-R GTCTTCCGGGTACATACGT 61 Invitrogen 
pET-mCh-R TACAGTTCGTCCATACCGTTG 62 Invitrogen 
pASK-
NmCherry 
AGAAGGAGATATACATATGGTTTCTAAAGGTGAAGAAGAC  Invitrogen 
NmCherry-
mzrA 
ACGTATGTACCCGGAAGACGTGAGCAAGGGCGAG  Invitrogen 
pBAD-
CmCherry 
GCAGGAGGAATTCACCATGGGTGCTCTGAAAGGTGAAATC 59 Invitrogen 
CmCherry-
mzrA 
CAACGGTATGGACGAACTGTAGTGAGCAAGGGCGAG  Invitrogen 
LCR-pKD13-F GACCGGTCAATTGGCTTGTAGGCTGGAGCTGCTTC  Invitrogen 
LCR-pKD13-R CTCGAGATATGAATATCCTCCTTTCCGGGGATCCGTCG  Invitrogen 
Kan-acrB-
dnst-F 
GAGGATATTCATATCTCGAGTACAACGTGTAATCACTAAG  Invitrogen 
pASK-
mCherry 
AAGAAGGAGATATACATATGGTTTCTAAAGGTGAAGA 49 Invitrogen 
NmCherry-
mzrA 
ACGTATGTACCCGGAAGACCAAATACCTCGCATGTCGC 61 Invitrogen 
mCherry-
mzrA 
CAACGGTATGGACGAACTGTACAAATACCTCGCATGTCGC 62 Invitrogen 
envZ-
CmCherry 
GGCACGACAAAAGAAGGGGGTGCTCTGAAAGGTGAAATC 62 Invitrogen 
mzrA-pASK ATAACTCTCATCGCTTCGGATAACTCGAGTGAGACCTG 58 Invitrogen 
mCherry-
pBAD 
CAACGGTATGGACGAACTGTATAAGCTTGGCTGTTTTGG 58 Invitrogen 
pUC18-seq-f CCAGTCACGACGTTGTAAAACG 64 Invitrogen 
pUC18-seq-R AGCGGATAACAATTTCACACAGG 63 Invitrogen 
XhoI-
MF(pT2SC) 
CAACCTCGAGTAATCTCAAGAGTGGCAGC 62 
Alta 
Bioscience 
NdeI-
MR(pT2SC) 
CATTCATATGTTACGCCCCGCCCTGC 73 
Alta 
Bioscience 
pASK_NdeI-F 
TAACTTTAAGAAGGAGATATACATATGAAGAAATTGCTCCC
CATTCT 
60 Eurogentec 
 
